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Abstract 
 
For centuries, mankind has turned to natural sources for cures, remedies, and ways to improve its 
quality of life.  It was not until the discovery of the antibiotic penicillin in 1928, however, that 
natural products – small molecule secondary metabolites produced by a variety of organisms for 
a variety of purposes – were truly appreciated as the source of these beneficial properties.  In the 
ensuing decades, research in the field of natural products boomed, and a number of discoveries 
were made that revolutionized global health.  In the 1970s and 1980s, however, these discoveries 
started to become fewer and farther between, prompting pharmaceutical companies to turn away 
from natural products research in favor of synthetic chemistry approaches to drug discovery.  
Nevertheless, despite diminishing returns from traditional natural product discovery methods, 
modern genomics has in fact revealed that vast numbers of natural product gene clusters exist 
across all domains of life, far in excess of the number of known natural products and far 
surpassing any previous predictions.  Thus, natural product discovery efforts to date have only 
scratched the surface of Nature’s true capabilities. 
 
In this work, we sought to leverage modern techniques for natural product discovery at the 
protein, pathway, and genome scales to tap into this biosynthetic potential.  The past several 
years have seen the development of many tools for the manipulation of DNA with ease and 
precision far exceeding the standards set by traditional methods.  These methods, combined with 
the ever-increasing number of putative natural product pathways revealed by genome sequencing 
efforts, open the door for new platforms of natural product discovery and engineering.  At the 
protein level, we demonstrate the synthesis of novel derivatives of the antimalarial natural 
product FR-900098 by leveraging the substrate promiscuity of the native biosynthetic machinery.  
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Through structural and biochemical characterization of the N-acetyltransferase FrbF and the 
corresponding target for FR-900098 inhibition, Dxr from Plasmodium falciparum, we show that 
the novel FR-900098 derivatives can serve as more potent inhibitors.  A platform for their 
biosynthesis is also established in Escherichia coli. 
 
We additionally demonstrate a genome-mining platform for fungal polyketide synthases via the 
one-step assembly of expression-ready plasmids by homologous recombination in yeast.  
Through the evaluation of previously uncharacterized endogenous promoters from 
Saccharomyces cerevisiae, we demonstrate the heterologous production of polyketides from the 
dimorphic fungus Talaromyces marneffei.  Extension of this approach to the pathway level is 
also demonstrated to assemble both a 6-gene resorcylic acid lactone cluster and a 13-gene 
phosphonic acid biosynthetic cluster.  The latter case, in which all 13-genes from a phosphonic 
acid non-producing strain were placed under individual strong promoters, enabled the production 
of novel phosphonic acid compounds when heterologously expressed in Streptomyces lividans. 
 
At the genome scale, we developed a versatile system from genome engineering in a broad range 
of Streptomyces species.  As the genus Streptomyces is by far the most important producer of 
pharmaceutical natural products to date, tools to facilitate their genetic engineering are of 
significant interest to aid discovery and improve production.  Here, we show that the 
CRISPR/Cas9 system of S. pyogenes can be reconstituted in S. lividans for high-efficiency, 
multiplex editing of genomic loci.  We show that deletions ranging from 20 bp to 31 kb can be 
successfully introduced in one step, and extend this approach to additional Streptomyces strains.  
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CHAPTER 1. Natural product discovery and engineering
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1.1 Natural Products: Invaluable Natural Resources 
For centuries, mankind has turned to Nature for the means by which to improve quality of life.  
Microbial fermentation, for example, has been extensively utilized for the production of beer, 
bread, and wine, with the oldest known fermentations occurring at least 9000 years ago [1].  In 
the area of human health, natural sources have long been known to possess therapeutic 
properties.  Plants such as Artemisia annua (sweet wormwood) and Salix alba (white willow) are 
referenced in texts from thousands of years ago for their healing potential.  It was not, however, 
until Alexander Fleming’s 1928 discovery of the antibacterial penicillin that small molecule 
secondary metabolites, known simply as natural products, were fully appreciated as the effectors 
of these beneficial properties [2].  In the years that followed, natural products saw intense 
research interest as scientists searched and screened to find the next “miracle drug.”  Evidencing 
this prodigious effort is the CRC Dictionary of Natural Products, which currently lists 170,000 
unique natural products [3]. 
 
At present, natural products continue to see extensive pharmaceutical use.  In the period from 
1981–2010, approximately half of all small molecule NCEs (new chemical entities) were natural 
products, natural product derivatives, natural product mimics, or synthetic analogues of natural 
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product pharmacophores [4].  Despite this success, pharmaceutical companies in the 1990s began 
to turn away from natural product discovery, which required significant investments of time and 
resources, toward synthetic chemical libraries, which could be synthesized in large numbers 
through combinatorial approaches [5].  While such libraries can be more easily prepared and 
screened, they tend to feature limited chemical complexity compared to the diversity of natural 
products. 
 
For pharmaceutical companies, a significant liability in natural product discovery efforts was the 
increasing rate of rediscovery of known compounds.  This finding raised concerns over the 
overall diversity of compounds found in Nature, and whether this supply was reaching 
exhaustion.  In the academic field, however, these fears were abated as genome sequencing 
began to take off.  Across all domains of life, a major finding in sequenced genomes was the 
presence of a large number of putative secondary metabolite pathways for which the 
corresponding natural product was not known [6].  Amazingly, such “cryptic” clusters were 
found even in well-studied microbial species, suggesting a silent majority of natural products 
waiting to be discovered with the right tools or the right conditions.  When this observation is 
coupled with the notion that the vast majority (> 99 %) of microorganisms remain uncultivable 
in the laboratory setting [7], it becomes apparent that there still exists a great wealth of as yet 
undiscovered natural products for the treatment of any number of human diseases.  The grand 
challenge, then, is to develop the tools and methodologies needed to find these compounds and 
develop them into the next generation of pharmaceuticals. 
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1.2 Methods for Natural Product Discovery 
1.2.1 Pathway-independent approaches 
1.2.1.1 Environmental sampling 
Life is manifested in many unique and varied forms to suit a broad range of physical and 
ecological environments.  This diversity can be traced down to the chemical level as organisms 
have grown and evolved to maximize their own fitness in the face of varied stresses and 
competitors.  It follows, then, that diverse sampling in ecological space will also lead to diverse 
sampling in chemical space. 
 
Early on, soil sampling was the most common means to access microbial diversity, and many 
notable successes were achieved.  The antibiotic kanamycin, for example, was identified from a 
Streptomyces kanamyceticus strain isolated from a Japanese flower bed in 1957 (Figure 1.1) [8].  
Remarkably, development of the compound into a widely available commercial drug took less 
than a year– a feat irreproducible with modern regulatory standards.  In the soil outside of an 
Italian castle, another Streptomyces strain was identified that produced the anthracycline 
chemotherapeutic daunorubicin [9].  The antibiotic chloramphenicol (originally chloromycetin) 
was discovered in 1947 from a Venezuelan soil isolate [10].  Notably, the same compound was 
concomitantly discovered in a soil isolate from Urbana, Illinois [11], highlighting the (now 
common) observation that physical distance is no guarantee of uniqueness.  In fact, identical 
natural product gene clusters can be found from strains all over the world [12], making 
rediscovery of known compounds a significant concern. 
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Figure 1.1: Representative natural products from global sampling efforts. 
 
Outside of “traditional” soil sampling, a more recent trend has been to explore more extreme 
environments in search of greater chemical diversity.  For example, sampling from a salt field 
led the discovery of a halophilic actinomycete that produces three novel polyketides with 
anticancer properties [13].  In the acidic, metal-contaminated Berkeley Pit copper mine, a fungus 
was identified that produced the novel anticancer spiroketal berkelic acid [14].  Recently, 
sampling from a microbial mat in an iron-rich spring led to the characterization of six novel 
fungal natural products: clearanols A-E and disulochrin [15].  While the native biological 
functions of compounds isolated from extremophiles are generally unknown, they likely play a 
role in helping the native producers cope with harsh environmental stresses. 
 
To access even greater natural product diversity, sampling from marine environments has 
become a popular approach.  Compared to natural products of terrestrial origin, marine natural 
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products exhibit a greater diversity of molecular scaffolds and have shown a higher incidence of 
clinically relevant bioactivity [16].  The jamaicamides, discovered from marine cyanobacterium 
Lyngbya majuscula, provide an excellent example of this rich chemical diversity; jamaicamide 
A, for example, features such uncommon moieties as a vinyl chloride, an alkynyl bromide, a β-
methoxy eneone system, and a pyrrolinone ring (Figure 1.2) [17].  Recently, anthracimycin was 
discovered from a marine actinomycete and found to possess activity against the significant 
human pathogens Bacillus anthracis and methicillin-resistant Staphylococcus aureus (MRSA) 
[18]. 
 
 
Figure 1.2: Structure of jamaicamide A. 
 
The great diversity of life in marine environments has also led to particularly unique interspecies 
relationships.  Endosymbiotic bacteria, for example, represent a rich source of natural products 
[19], as many higher organisms rely on them to supplement their own defense systems.  In a 
family of bivalve mollusks known as shipworms, boronated natural products with antibiotic 
activity were recently discovered from the cultivated symbiotic bacterium Teredinibacter 
turnerae [20].  Similarly, diverse pyrone polyketides have been discovered from Nocardiopsis 
alba CR167, an actinomycete endosymbiont of the cone snails Conus rolani and Conus tribblei 
[20].  Of course, symbiosis is not a unique property of marine environments.  For example, 
several agriculturally relevant insects have also proven to be sources of antibiotic natural 
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products [21].  Nevertheless, marine environments currently seem to be the most promising for 
natural product discovery overall, with discovery rates increasing every year.  In 2012 alone, 
over 1200 new chemical entities were discovered from marine environments [22]. 
 
1.2.1.2 Culture manipulation 
While laboratory cultivation of microorganisms is typically conducted under well-defined 
conditions (often with an abundance of nutrients), in Nature growing conditions vary widely in 
time and space.  As a result, an organism must be able to adapt to survive.  At the metabolic 
level, this entails dynamic regulation of anabolic and catabolic pathways to maximize efficiency 
and competitive advantage.  To culture an organism under a single set of conditions, then, is to 
observe only one dimension of its full biosynthetic potential. 
 
To mimic in a laboratory setting the diverse environmental stresses an organism may experience 
in nature, screening of different growth conditions is often employed.  This process is generally 
termed the “one strain-many compounds” (OSMAC) approach [23].  As an early example, the 
fungus Aspergillus ochraceus DSM7428 was initially known to produce only one secondary 
metabolite.  However, by varying the culture conditions and culture vessels, 15 additional 
compounds were discovered.  A recent example of this approach is the utilization of chemostat 
fermentation of Aspergillus nidulans to manipulate specific growth rate as well as carbon, 
nitrogen, and phosphorous levels [24].  Transcriptomic and metabolomic analyses revealed 
production of many polyketides under different conditions, including one novel compound. 
 Besides systematic control of nutrient levels, more unorthodox culture techniques have also 
been employed for natural product discovery.  For example, fermentation medium containing 
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Cheerios breakfast cereal was found to promote growth and secondary metabolism of several 
isolated fungal strains, including the production of a novel diarylcyclopentendione metabolite 
and a novel biphenyl metabolite from Preussia typharum (Sacc.) Cain [25].  Also, an in vivo 
culture method to elicit the production of typically silent glidobactin/luminmycin metabolites 
from Photorhabdus asymbiotica was demonstrated by injecting the bacterium into live crickets 
and extracting the carcasses [26].  It should be noted, however, that the four compounds 
observed, including two new derivatives, were first identified in defined liquid medium culture. 
 
An alternate technique to introduce external stresses in laboratory culture is to challenge a target 
organism with other co-cultured species.  This method has been demonstrated for many 
biotechnological applications [27,28].  For example, cultivation of the marine fungus Emericella 
sp. with the actinomycete Salinispora arenicola activated production of the antibiotic 
emericellamides by the fungus [29].  As a recent example, a novel prenylated polyketide was 
discovered from the fungal pathogen Aspergillus fumigatus only when cultured with the 
actinomycete bacterium Streptomyces rapamycinicus [30].  A particularly interesting example is 
the co-culture of the bacteria Rhodococcus fascians, not known to produce antibiotics, and 
Streptomyces padanus, an actinomycin producer [31].  Following co-culture, a surviving R. 
fascians mutant was discovered that produced novel aminoglycoside antibiotics 
rhodostreptomycin A and B.  Interestingly, antibiotic production was correlated with the 
acquisition of DNA from the S. padanus strain, but the compounds produced did not match 
known Streptomyces metabolites. 
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1.2.1.3 Global genetic and epigenetic manipulation 
While the approaches described in the previous section manipulate an organism’s external cues 
to elicit a desired response, a complimentary approach would be to manipulate an organism’s 
internal cues.  A proven means by which to accomplish this goal is to introduce mutations to 
housekeeping genes.  In actinomycetes, RNA polymerase and ribosomal protein S12 have been 
popular targets through the isolation of mutant strains resistant to the antibiotics rifampicin and 
streptomycin, respectively [32-34].  For example, the Ochi group screened 1068 soil-isolated 
actinomycetes, and found that 6 % of non-Streptomyces strains and 43 % of Streptomyces strains 
produced antibiotics only after isolation of spontaneous resistance mutations in rpoB (RNA 
polymerase β-subunit) and/or rpsL (ribosomal protein S12).  Other targets for this so-called 
“ribosome engineering” approach include rsmG, encoding 16S ribosomal RNA 
methyltransferase, the mutation of which activated the transcription of several cryptic secondary 
metabolite genes [35].  Notably, this approach is not limited to actinomycetes.  In Bacillus 
subtilis, an RNA polymerase mutation activated production of an aminosugar antibiotic [36]. 
 
Regulatory proteins can also serve as targets for the induction of secondary metabolism.  For 
example, over-expression of the Crp transcription factor, a cyclic AMP receptor protein, was 
found to activate production of known and unknown antibiotics in multiple Streptomyces species 
[37].  In fungi, nuclear protein LaeA has been found to be a global regulator of secondary 
metabolism [38].  While many secondary metabolite clusters have been found to be positively 
regulated by LaeA, discovery of a novel compound via LaeA overexpression has not yet been 
achieved [39].  An alternative global strategy in fungi has been the knockout of kinases, known 
to play important roles in regulation and signal transduction. In Aspergillus nidulans, screening 
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of a genome-wide kinase knockout library led to identification of the novel prenylated 
isoindolinone aspernidine A, along with its corresponding gene cluster [40]. 
 
Outside of genetic modification, epigenetic modification has been demonstrated as a means to 
induce the expression of otherwise silent gene clusters in eukaryotes [41].  In a pioneering study 
in this area, the Cichewicz group treated fungi with the histone deacetylase (HDAC) inhibitor 
suberoylanilide hydroxamic acid (SAHA) and the DNA methyltransferase inhibitor 5-
azacytidine, eliciting the production of novel oxylipins, perylenequinones, and polyketides.  This 
technique has similarly been applied to discover novel meroterpenes from Penicillium 
citreonigrum [42], novel fusaric acid derivatives from plant endophytic fungi [43], and a novel 
coumarin from Pestalotiopsis crassiuscula [44], among other examples.  Curiously, treatment 
with HDAC inhibitors has also been evaluated in Streptomyces strains [45].  Though lacking 
histones, Streptomyces species do possess HDAC-like proteins.  Treatment with various HDAC 
inhibitors was found to stimulate some known antibiotic pathways in Streptomyces coelicolor, 
though no novel compounds were discovered. 
 
1.2.2 Pathway-specific approaches 
1.2.2.1 Bioinformatic tools to identify natural product gene clusters 
Remarkable advances in DNA sequencing technologies have made available the complete 
genome sequences for thousands of organisms [46].  Encoded in this data are the templates for 
countless proteins which catalyze a myriad of chemical transformations, many of which are 
involved in secondary metabolic pathways.  The ability to identify these genetic blueprints for 
natural product biosynthesis has inspired a paradigm shift in natural product discovery, in which 
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identification of an interesting gene cluster precedes discovery of its cognate natural product.  
Given the sheer volume of data that has been generated, in silico tools are absolutely necessary 
to identify, annotate, and prioritize potentially interesting genes and pathways. 
 
The earliest gene identification algorithms were developed mainly for the analysis of shorter 
DNA sequences in which the exact coding sequence of a protein was ambiguous.  These methods 
were reasonably simplistic, but provided fairly accurate predictions of “coding” versus “non-
coding” sequences [47].  Subsequent prediction algorithms employed more sophisticated 
approaches to achieve better results.  For example, the GeneMark (initially GENMARK) 
program of Borodovsky and McIninch combined non-homogeneous Markov chain models with 
Bayesian decision making for coding sequence prediction [48].  This program also introduced 
simultaneous analysis of both DNA strands as a method to improve accuracy.  As the sequencing 
of entire genomes became realized, the need for reliable gene prediction was underscored.  To 
improve the GeneMark program for entire bacterial genomes, a hidden Markov model 
framework was implemented, as well as recognition of ribosome binding site sequences [49].  
Further improvements came with the implication of self training for new prokaryotic genome 
sequences [50] and expansion to eukaryotic and viral systems [51,52].  GLIMMER represents a 
complementary tool for gene identification that was built on interpolated Markov models 
[53,54].  This tool has similarly been adapted to eukaryotic DNA [55,56] as well as 
endosymbiont and metagenome DNA [57,58]. 
 
Identification of coding sequences is an important first step, but sequence information alone is 
not enough to describe a protein’s utility.  Bench-top experiments both in vitro and in vivo are, of 
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course, the best way to determine protein function.  However, the vast success in DNA 
sequencing and coding sequence identification has provided such a wealth of putative protein 
targets that laboratory characterization of them all is simply not feasible.  Fortunately, if two 
proteins have similar primary sequences, it is quite likely that they will also share similar 
functions.  As a result, sequence alignment and homology analysis based on proteins of known 
function has proved vital to the accurate prediction of protein function from sequence data alone. 
 
The earliest exercises in protein homology comparisons were carried out to evaluate evolutionary 
relationships rather than to predict function [59-61].  Nevertheless, these algorithms provided the 
groundwork upon which subsequent protein alignment tools would be built.  In 1985, Lipman 
and Pearson noted the increasing number of protein sequences made available at the time, and 
that functions could be inferred by comparison to other characterized proteins.  As a result, they 
developed the FASTP algorithm for rapid in silico comparison of a query sequence to a protein 
sequence database [62].  This was followed by FASTA, which featured improved sensitivity, and 
LFASTA, which allowed for analyses of local similarity [63,64].  Other tools followed, such as 
MSA and CLUSTAL W, for the high sensitivity alignment of smaller sets of proteins [65,66]. 
 
Currently, state-of-the-art sequence database search tools employ more sophisticated algorithms 
to reduce computation time and increase sensitivity to weak similarities.  For example, tools such 
as SAM [67] and HMMER [68] employ hidden Markov models to identify sequence homology.  
Perhaps the most widely used search tool is the Basic Local Alignment Search Tool, or BLAST, 
first presented by Altschul and coworkers in 1990 [69].  At its inception, BLAST offered high 
sensitivity database searching at speeds much faster than any previous algorithm, and proved 
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amenable to mathematical and statistical analysis.  Subsequent versions, such as gapped BLAST 
and position-specific iterative (PSI) BLAST, have further improved computation time and 
sensitivity to weak, but still biologically relevant, similarity [70].  Functional prediction via 
BLAST is further enhanced through coupling with the Conserved Domain Database (CDD) [71], 
which integrates data from sources such as Pfam [72] and SMART [73] to identify regions of the 
query sequence with evolutionarily conserved functions, such as binding a metal ion or cofactor.  
BLAST results can also be coupled to tools such as GCView [74], which enable analysis of the 
genomic context of search results to facilitate more accurate functional prediction. 
 
Predictive algorithms have also expanded beyond individual coding sequence queries to a variety 
of other targets.  For example, IsoRankN enables the alignment of entire protein-protein 
interaction networks for the prediction of functional orthologs across species [75].  Tools such as 
PromPredict [76], ConTra [77], and RSAT [78], among others, focus not on protein sequences, 
but on the sequences of regulatory regions such as promoters and transcription factor binding 
sites. 
 
With accurate prediction of the functions of encoded proteins, it has become possible to identify 
gene clusters for particular classes of natural products based upon the presence of characteristic 
enzymes.  In particular, large, multi-domain polyketide synthases (PKSs) and non-ribosomal 
peptide synthetases (NRPSs) have been especially amenable to this approach.  In the past two 
decades, a number of computational tools have been developed not only for the identification of 
natural product gene clusters from DNA sequence data, but also the prediction of their 
corresponding products.  Some of the earliest efforts toward in silico prediction of NRPS 
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products focused on the specificity of adenylation domains.  In 1997, de Crécy-Lagard and 
coworkers examined 55 adenylation domain sequences to devise rules for specificity prediction, 
but found that they could only come up with good predictions in 43 % of cases [79].  Two years 
later, however, analysis of the crystal structure of the adenylation domain PheA involved in 
gramicidin S biosynthesis enabled two groups to provide much more accurate specificity 
predictions.  Stachelhaus and coworkers identified 10 specificity-conferring residues, allowing 
86 % accuracy in specificity prediction [80].  Challis and coworkers took a very similar 
approach, identifying an 8 residue signature sequence [81].  More recently, a sophisticated 
prediction algorithm based on transductive support vector machines have been devised that also 
incorporates the physico-chemical properties of the residues lining the active site to narrow down 
its predictions [82].  This tool is available online via NRPSpredictor2 [83].  For the analysis and 
comparison of the nonribosomal peptide products themselves, the database NORINE was 
established, which currently contains over 1100 compounds [84]. 
 
For the analysis of PKSs, the earliest computational tools focused on the identification of their 
constituent domains [85,86], as well as of the linker regions between them [87].  The purpose 
here was not only to aid product prediction, but also facilitate the reconstitution of individual 
domains and the combinatorial biosynthesis of “unnatural” natural products via domain 
swapping.  Identification of the specificity-determining residues of acyltransferase domains was 
again enabled by crystallographic data, allowing prediction of malonyl-CoA or methylmalonyl-
CoA specificity [85,86].  More recent tools have afforded more accurate predictions and 
increased functionality.  For example, ASMPKS allows the input of entire genome sequences for 
analysis [88].  As with NRPSs, support vector machines have been applied to type III PKSs to 
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afford improved prediction accuracy [89].  Finally, SBSPKS allows PKS domains and modules 
to be modeled and docked to better predict and engineer inter-subunit contacts, as well as to 
predict the order of substrate channeling in gene clusters with multiple PKS open reading frames 
[90]. 
 
Currently, the bulk of the state-of-the-art computational tools for analysis of secondary 
metabolites focus on concomitant analysis of both PKS and NRPS genes.  These tools, such as 
NRPS-PKS [91], ClustScan [92], CLUSEAN [93], NP.Searcher [94], and the PKS-NRPS 
Analysis Web-site [95] continue to improve upon the accuracy and functionality of their 
predecessors while providing user-friendly interfaces and increased computational power.  
Nevertheless, other classes of secondary metabolites have seen increased attention in recent 
years as well.  For example, the genome mining tool BAGEL2 focuses exclusively on 
bacteriocins, which are ribosomally-synthesized antimicrobial peptides from bacteria [96].  
BAGEL2 considers conserved domains, physical properties and genomic context to identify 
putative bacteriocins, which can easily be missed by other genome annotation tools due to their 
short size (<100 amino acids).  Another example is the SMURF program, which can be used not 
only to scan fungal genome sequences for gene clusters producing polyketides and nonribosomal 
peptides, but also for indole alkaloids and terpenes by identifying prenyltransferases and terpene 
cyclases, respectively [97].  Finally, a new program called antiSMASH promises the greatest 
versatility of any program to date, expanding beyond just polyketides and nonribosomal peptides 
to include such classes of compounds as β-lactams, lantibiotics, and siderophores among others 
[98].  The identification and analysis of such diverse secondary metabolism genes will surely be 
of great benefit to the synthetic biologist for the design and engineering of new pathways.  Of 
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course, it must be stated that despite their increasing utility, in silico tools will never completely 
replace laboratory experiments for the analysis and understanding of secondary metabolite genes.  
Nevertheless, such tools clearly provide valuable support to natural products research. 
 
1.2.2.2 Manipulation of native strains 
The modern bioinformatic tools described above have made trivial the transformation of 
genomic sequence data to a set of putative natural product gene clusters.  The rate limiting step, 
then, lies in drawing a connection between a putative gene cluster and its corresponding natural 
product.  Unfortunately, direct in vitro demonstration of catalytic function for every step in a 
putative pathway, though possible [99], is inherently difficult.  Identifying suitable hosts and 
conditions for the expression and purification of every enzyme in a pathway is a non-trivial 
problem, even with the most advanced expression optimization algorithms.  Further, many gene 
clusters of interest are very large and/or include complex, multi-domain megasynthases that are 
particularly difficult to express and purify in a non-native host.  Coupling these facts with 
insufficient means for predicting substrate and cofactor identity a priori, in vitro characterization 
is rendered an impractical first-pass approach for identifying the product of an uncharacterized 
gene cluster.  As a result, genetic manipulation of the native strain to elicit expression of a target 
pathway is a much more viable approach. 
 
Any target pathway with unknown product(s) identified via genome mining falls into one of two 
categories: 1) the product has already been discovered, but the link between the cluster and the 
product has not been established; or 2) the product has not yet been discovered.  For any pathway 
falling into the first category and some falling into the second, deletion of key genes coupled 
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with metabolomic profiling can be a successful approach to pair pathways with products (Figure 
1.3).  For example, PKS deletion in S. coelicolor led to the discovery of germicidins produced by 
this strain [100].  In fungi, systematic deletion of all PKS genes was performed in Aspergillus 
nidulans, identifying the gene responsible for synthesis of the previously identified austinol 
family of meroterpenoids [101].  Similarly, single deletion of several NRPS genes in A. nidulans 
was performed, leading to the discovery of novel emericellamide products [102].  In the latter 
example, several of the NRPS deletion mutants did not exhibit any differences in their metabolite 
profiles, highlighting the limits of this approach. 
 
Despite some successes in deletion-based pathway characterization, the fact remains that this 
method is ineffective for natural product pathways that are functionally “silent”– i.e., those that 
yield no product under laboratory cultivation conditions, or those whose products are generated 
at levels below the practical limit of detection.  In these cases, activation of the gene cluster of 
interest is necessary to elucidate the corresponding product.  Conceptually, the simplest way to 
accomplish this goal is perhaps to locate and over-express a pathway-specific regulatory protein, 
which could activate all of the genes in the pathway of interest (Figure 1.3).  This has been 
demonstrated very successfully in A. nidulans, where cloning of pathway-specific regulators 
under the inducible alcohol dehydrogenase alcA promoter has led to the discovery of the 
polyketide asperfuranone [103,104] and the aspyridones [105].  Similarly, expression of a 
pathway-specific regulator under the ermE* promoter activated production of a family of 
glycosylated macrolides in Streptomyces ambofaciens [106].  Notably, this approach necessitates 
only supplementation of the regulatory gene in trans, and thus is generally applicable to any 
strain for which rudimentary genetic tools are available.   
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Figure 1.3: Coupled with gene deletion (left) or promoter insertion (right), metabolomic profiling enables 
identification of the product of a target gene cluster. 
 
Besides regulators, strong promoters can also be introduced in front of pathway genes of interest 
for a more direct activation strategy.  For example, knock-in of the ermE* promoter in front of 
key genes in Streptomyces albus activated production of the blue pigment indigoidine as well as 
the two novel polycyclic tetramic acid macrolactams [107].  In Streptomyces avermitilis, cloning 
of a terpene synthase under an endogenous strong promoter and re-introduction to a genome-
minimized strain led to discovery of a novel sesquiterpene, avermitilol [108]. 
 
1.2.2.3 Heterologous expression 
While the methods described above have enabled discovery of many novel natural products, they 
all entail attempts to mitigate, manipulate, or override native regulatory mechanisms, which at 
best behave like a black box (defined input/unpredictable output), and at worst like a black hole 
(defined input/no output).  An alternative approach is to remove the pathway from its native 
context completely via heterologous expression, and thus liberate it from intrinsic regulation 
[109-111].  Heterologous expression has been demonstrated for many native natural product 
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gene clusters [112-115] as a means of confirming their boundaries and necessary elements.  
However, by and large a wild-type cryptic natural product gene cluster will remain cryptic in a 
heterologous host either via similarly strict regulation (if the heterologous host is closely related 
to the native strain) or an inability to recognize the native promoters (if the heterologous host and 
the native strain are more distant). 
 
To rectify a cryptic natural product gene cluster with its heterologous host, replacement of native 
promoters with well-characterized constitutive or inducible promoters is a common approach.  
On the single gene level, for example, expression of a cryptic terpene cyclase from Arabidopsis 
thaliana in S. cerevisiae resulted in discovery of a novel triterpenoid, thalianol [116].  Similarly, 
a silent myxobacterial type III PKS was found to produce flaviolin when expressed in various 
Pseudomonas hosts [117].  This approach has also been extended to multi-gene clusters.  For 
example, two natural product gene clusters from Photorhabdus luminescens were cloned under 
the tetracycline-inducible tetO promoter in E. coli to enable discovery of luminmycin and 
luminmide natural products [118].  Similarly, the 56 kb epothilone cluster from Sorangium 
cellulosum was cloned under the actI promoter to achieve heterologous expression in S. 
coelicolor [119].  Notably, the latter example was not the purpose of discovery, but to transfer 
the cluster to a more suitable host for fermentation.  Pushing this approach to its limit, 
replacement of every promoter in a cryptic five-gene polycyclic tetramic acid macrolactam 
pathway from Streptomyces griseus led to the discovery of multiple novel compounds when 
expressed in Streptomyces lividans [120]. 
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Reconstruction of pathways for heterologous expression also enables the beneficial manipulation 
of native regulatory elements.  For example, heterologous expression of the thiocoraline pathway 
from marine Micromonospora strains in S. lividans or S. albus was only possible after replacing 
the native promoter of the activator tioA with the strong ermE promoter [121].  On the other end 
of the spectrum, discovery of the daptomycin-like lipopeptide taromycin via heterologous 
expression in S. coelicolor required deletion of pathway repressor tar20 [122], while activation 
of a silent spectinabilin cluster from Streptomyces orinoci required deletion of repressor norD 
[123].  Here, replacement of all promoters in the pathway further improved heterologous 
production levels. 
 
Heterologous expression in a well-studied host further enables metabolic fine-tuning to optimize 
product titer by increasing flux into the pathway of interest and eliminating competing reactions.  
In E. coli, engineering of precursor pathways enabled expression of the polyketide 6-
deoxyerythronolide B [124].  Streptomyces strains have also been significantly engineered for 
heterologous expression.  In S. coelicolor, native antibiotic clusters have been deleted or 
inactivated to create a host strain with a cleaner metabolite background [125].  With additional 
activating mutations in rpoB and rpsL, such a strain has been shown to improve titers of 
heterologous natural products [126].  In S. avermitilis, a large-scale deletion approach was 
employed to remove over 1.4 Mb of the chromosome, eliminating endogenous natural product 
clusters [127].  The resulting host was shown to produce higher titers of some heterologous 
natural product pathways [128,129].  As a result, such hosts should benefit natural product 
discovery efforts. 
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1.3 Enabling Technologies for Natural Product Engineering 
Current and future efforts in natural product discovery and engineering will depend upon new 
technologies to enable sophisticated manipulation of natural product gene clusters, the proteins 
they encode, and the organisms that produce them.  At the DNA level, modern assembly 
methods allow flexible, reliable, high-throughput construction of natural product gene clusters.  
At the protein level, direction evolution represents a powerful tool to engineer new pathways and 
new products.  At the organism level, genome-scale engineering techniques enable engineering 
of native and heterologous strains to optimize natural product biosynthesis. 
 
1.3.1 Modern DNA assembly methods 
In the mid-1970s, cloning methods based on restriction digestion and ligation revolutionized 
biology by enabling unprecedented manipulation of the very building blocks that define 
biological systems [130].  While the contributions of such techniques to the field cannot be 
overestimated, the fact remains that for the manipulation of large numbers of DNA sequences of 
interest (i.e., multi-gene pathways or even entire chromosomes or genomes), traditional methods 
are tedious, time-consuming, and too sequence-specific to generalize.  As a result, a lengthy 
series of sub-cloning steps is typically required en route to the desired pathway constructs, and 
even then assemblies of significant size and complexity can be prone to failure.  In recent years, 
however, a number of revolutionary DNA manipulation techniques have been developed, 
transforming arduous constructions into relatively routine tasks. 
 
Modern DNA assembly techniques can broadly be classified into two groups: those based on 
homology and those based on digestion/ligation (Figure 1.4).  Homology-based methods require 
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neighboring DNA fragments to share identical sequences, such that splicing can occur either by 
annealing and extension of the homologous ends in vitro or by homologous recombination in 
vivo.  Perhaps the most prominent in vitro technique is the one-pot isothermal assembly 
pioneered by Gibson and coworkers, colloquially known as “Gibson assembly” [131].  In this 
process, DNA fragments with homologous termini are spliced via three enzymatic reactions.  
First, T5 exonuclease catalyzes “chew-back” (single strand degradation) of the 5’ ends of each 
fragment.  This exposes their complementary single-stranded 3’ ends, which anneal to each other 
in the desired order to form the target construct with single-stranded gaps.  Phusion polymerase 
then fills in the gaps, and Taq ligase seals the nicks to produce the intact final product, which can 
subsequently be used to transform a host of choice.  A variety of previously developed in vitro 
assembly techniques present variations on this theme, including sequence and ligase independent 
cloning (SLIC), which utilizes T4 DNA polymerase for both 3’ chew-back and partial gap-
filling, but requires addition of a single deoxynucleotide to switch between the two functions 
[132]; polymerase incomplete primer extension (PIPE) cloning, which relies on incomplete 
primer extension during PCR of each fragment to leave single-stranded 3’ ends [133]; and uracil-
specific excision reagent (USER) cloning, which utilizes uracil-containing primers and a uracil-
specific glycosylase and endonuclease to generate defined single-stranded 3’ ends [134].  Note 
that besides Gibson assembly, none of the above methods employ a ligase enzyme, instead 
requiring nick-sealing to occur in vivo following transformation into the desired host.  Further, 
both SLIC and PIPE cloning also require additional gap-filling in vivo to generate the nicked 
target construct. 
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Figure 1.4: Representative schematics of a three-piece DNA assembly protocol via digestion/ligation-based (left) or 
homology-based (right) methods. 
 
Published shortly after Gibson assembly, circular polymerase extension cloning (CPEC) presents 
an alternative to the “chew back and anneal” strategy.  Starting from a set of DNA fragments 
with homologous ends, this method instead relies on cycles of heating to denature the duplex 
fragments, cooling to anneal neighboring strands at their overlapping ends, and polymerase-
mediated extension to generate the concatenated duplex.  After several cycles, the nicked target 
construct is formed, which can be sealed in vivo [135].  Site-specific recombination-based 
tandem assembly (SSRTA), on the other hand, employs the Streptomyces phage φBT1 integrase 
to splice neighboring fragments in vitro [136].  This method requires each fragment to be flanked 
by a set of orthogonal recombination sites, and consequently leaves interstitial scar sequences.  
While this is a clear disadvantage compared to the other techniques described, the absence of a 
polymerase extension step and the high specificity of the φBT1 integrase for its cognate 
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recognition sequences make this method attractive by avoiding the introduction of mutations or 
off-target recombination events. 
 
An alternative to in vitro assembly is to allow fragment splicing by native cellular homologous 
recombination machinery.  A key example of this is the DNA Assembler method, which relies 
on Saccharomyces cerevisiae to assemble DNA fragments with terminal overlap sequences 
[137].  In this approach, the assembly host is simultaneously transformed with individual 
fragments containing homologous ends.  The target construct generated in vivo via homologous 
recombination can then be selected via an incorporated selection marker.  Additional in vivo 
assembly methods include the Red recombination system, in which homologous recombination 
in E. coli is enhanced through expression of the Redαβ proteins from the lambda prophage or 
RecET proteins from the Rac prophage [138]; mating-assisted genetically integrated cloning 
(MAGIC), which employs bacterial conjugation to transfer a donor plasmid to the assembly host 
strain containing a receiver plasmid, a homing endonuclease (to generate linear fragments), and 
inducible lambda recombinases (to facilitate homologous recombination) [139]; transformation-
associated recombination (TAR) cloning, which can be used to clone large portions of genomic 
DNA via simultaneous transformation of S. cerevisiae with genomic DNA containing the target 
sequence and a receiver vector [140]; and RecET-mediated “direct” cloning, which is similar to 
TAR cloning but carried out in E. coli with inducible expression of the RecET recombinases and 
requires prior digestion of the genomic DNA to liberate the target sequence as a linear fragment 
[118].  An ex vivo recombination-based method named for its seamless ligation cloning extract 
(SLiCE) has also been recently described, which utilizes E. coli extracts rather than whole cells 
to catalyze fragment assembly [141]. 
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Although numerous powerful homology-based assembly methods have been developed, there are 
still non-trivial limitations to their general utility.  Among these is the necessity to avoid multiple 
fragments with similar homologous ends in the assembly design, as this can lead to incorrect 
pairing of fragments not intended to be neighbors.  Such concerns become significant in clusters 
containing repeated similar elements, such as the domains of a modular PKS or NRPS or the 
exogenous promoters and terminators used in pathway refactoring.  Thus, there still exists a need 
for assembly techniques that do not rely on homologous recombination.  Of course, the classic 
restriction digestion/ligation method is one such technique which generates only short single-
stranded overhangs at specific sites.  As noted above, however, this method has limited 
applicability for rapid combinatorial assembly.  To facilitate and streamline its application, the 
concept of BioBricks (and subsequent variants, including BglBricks) has been proposed [142].  
BioBrick assembly can be seen as the standardization of traditional cloning techniques.  The 
BioBrick assembly standard dictates the restriction enzyme recognition sequences that should be 
positioned at the 5’ and 3’ ends of the assembly fragments.  Utilization of two restriction 
enzymes with different recognition sequences but identical single-stranded overhangs (e.g., XbaI 
and SpeI) renders the assembly of two fragments an idempotent operation.  In other words, 
correct ligation of two fragments abolishes the recognition sites between them while retaining 
those at the 5’ and 3’ termini of the product fragment.  Thus, the product fragment can be 
employed in subsequent assemblies under the same standardized conditions, eliminating the need 
to identify new restriction enzymes for each fragment in the target construct.  Nevertheless, this 
restriction enzyme-recycling approach necessitates a stepwise rather than simultaneous assembly 
scheme as only two fragments can be joined per round of assembly.  As a result, construction of 
large secondary metabolite gene clusters by this approach can still be time-consuming. 
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To reconcile the assembly of several fragments with a convenient enzyme-recycling 
methodology, a restriction enzyme that can recognize only a single defined sequence but 
generate many different single-stranded overhangs is needed.  Fortuitously, both of these 
properties are manifested in Type IIS restriction endonucleases, which can bind only to a specific 
recognition site but cut indiscriminately at a prescribed distance from this site.  Thus, by 
incorporating Type IIS restriction sites at the termini of each fragment, user-defined overhangs 
can be generated such that simultaneous assembly of multiple fragments in the desired 
configuration can be achieved.  This technique, initially proposed by Engler and coworkers in 
2008, is termed Golden Gate assembly [143]. 
 
Note that modern digestion/ligation-based cloning techniques still carry with them a major 
limitation of traditional cloning; namely, the necessity to remove all DNA recognition sites of 
the selected restriction endonuclease within the fragments to be assembled.  To obviate this 
requirement, Chen and coworkers recently presented a method to limit restriction endonuclease 
digestion only to the desired terminal sequences [144].  Their method, methylation-assisted 
tailorable ends rational (MASTER) ligation, expands the utility of Golden Gate assembly via 
utilization of MspJI, a Type IIS restriction endonuclease containing 5-methylcytosine in its 
recognition sequence.  Through incorporation of 5-methylcytosine in the primers used to amplify 
each fragment for assembly, digestion only occurs at the desired terminal locations and not 
within the fragments where only unmodified cytosines are present. 
 
Along with the development of more advanced DNA manipulation techniques, more advanced in 
silico tools for the design of assembly schemes have been created.  When given a list of parts to 
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assemble, for example, the j5 program of Hillson and colleagues can output a set of PCR primers 
to amplify each of the parts with suitable overhangs (i.e., restriction sites or homologous 
overhangs) for any of a variety of popular assembly methods [145].  This program can also 
recommend direct synthesis or PCR amplification of parts based on cost analysis, and will 
suggest a hierarchical assembly scheme in cases where there are apparent barriers to one-step 
assembly (e.g., repeated use of a single part).  Using a suitable language such as PR-PR 
[146,147], assembly protocols can then be sent to a liquid handling device for automation 
purposes.  Moving a step further, the Raven software suite applies multiple design algorithms to 
optimize assembly strategies for human or robotic implementation [148].  Notably, it can also 
learn from past assembly results to improve future predictions. 
 
1.3.2 Directed evolution 
Directed evolution is a versatile laboratory process for the creation of biological entities with 
desired properties.  Though the term had been occasionally applied in past decades to describe 
adaptive evolution experiments, directed evolution in the modern sense began to take root in the 
1990s.  In broad terms, directed evolution can be defined as an iterative two-step process 
involving first the generation of a library of variants of a biological entity of interest, and second 
the screening of this library in a high-throughput fashion to identify those mutants that exhibit 
better properties, such as higher activity or selectivity.  The best mutants from each round then 
serve as the templates for the subsequent rounds of diversification and selection, and the process 
is repeated until the desired level of improvement is attained (Figure 1.5).  As compared to 
rational design, which had been pioneered several years prior [149], directed evolution on the 
protein level provides the distinct advantage of requiring no knowledge of the protein structure 
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or of the effects of specific amino acid substitutions, which are very difficult to predict a priori 
[150].  
 
 
Figure 1.5: Direct evolution involves iterative cycles of diversity generation (1) and screening or selection (2), with 
the top hits of the previous round serving as the basis of the next round (3). 
 
As modular biopolymers build from twenty canonical building blocks, proteins are highly 
evolvable through mutations in their amino acid sequences, which are directly encoded via their 
cognate genes.  Because of this, proteins have by far been the most common targets for directed 
evolution experiments, where a host of techniques have been developed to manipulate individual 
gene sequences for the creation of diverse protein libraries.  From the reductionist perspective 
that has dominated much of the biological sciences in the modern era, proteins provide defined, 
discrete elements that can readily be isolated and studied under highly controlled conditions, 
making them ideal experimental subjects.  In the context of natural products research, the 
evolution of pathway enzymes can serve not only as a way to de-bottleneck rate-limiting steps 
28 
 
for improved overall productivity, but also as a means to generate “unnatural” derivatives by 
manipulating substrate specificity. 
 
1.3.2.1 Random evolution strategies 
Given the aforementioned properties of proteins, it is no wonder that the earliest modern directed 
evolution experiments focused almost exclusively on protein targets.  As the a priori prediction 
of the effect of mutations on a given protein is often difficult, the earliest techniques focused 
simply on random mutagenesis.  A landmark example in this field is the evolution of subtilisin E, 
a serine protease useful in several industrial applications, for increased activity in 
dimethylformamide [151].  In this pioneering study, random mutations were introduced to the 
subtilisin E gene using an error-prone PCR amplification strategy.  After three sequential rounds 
of mutagenesis and screening, a mutant was identified with six additional point mutations that 
exhibited 256-fold higher activity in 60 % dimethylformamide.  This effort clearly demonstrated 
the power of a sequential, evolutionary protein engineering strategy to identify multiple 
cooperative mutations for vast protein improvement.  In contrast, previous protein engineering 
efforts typically employed parallel single rounds of selection, identifying individual mutations 
that were by no means guaranteed to combine beneficially. 
 
While error-prone mutagenesis is an effective means to introduce gradual changes to a protein, in 
natural evolution this is supplemented by an additional mechanism: recombination.  
Recombination allows larger pieces of similar genes to be exchanged, significantly diversifying 
the resultant pool of variants.  Thus, to harness this power for directed evolution experiments, 
techniques were developed to mimic natural recombination in vitro. A key example of this is the 
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DNA shuffling method developed in 1994 by Willem Stemmer of the Affymax Research 
Institute.  In this method, a library of similar genes (e.g., homologs from different organisms or 
mutants identified from previous engineering efforts) is PCR amplified and digested into smaller 
fragments with DNase I.  Following subsequent isolation of these fragments, a primer-free PCR-
like assembly step recombines the fragments from diverse parent genes into new chimeric 
hybrids, which can then be cloned into an expression vector and screened [152].  As an example 
of the power of this approach, a β-lactamase was evolved to improve the resistance of its host 
Escherichia coli strain to the antibiotic cefotaxime [153].  After three cycles of shuffling and two 
cycles of backcrossing (to remove non-essential mutations), a mutant was identified that 
increased the minimum inhibitory concentration (MIC) of the host by 32,000-fold, compared to 
the 16-fold increase observed when non-recombinogenic methods were employed. 
 
In subsequent years, numerous refined recombination-based directed evolution strategies were 
developed [154].  One such example is the staggered extension process (StEP) for in vitro 
recombination [155].  Similar to DNA shuffling, this approach generates chimeric progenies 
from a set of parent genes.  However, in StEP, the full-length recombined genes are synthesized 
in the presence of the parent genes without the intermediate step of generating and purifying 
short fragments.  This is accomplished by sequential annealing of the nascent polynucleotide to 
different templates with abbreviated extension times, allowing only a small portion of the gene to 
be filled in before dissociating and annealing to a new template.  Using a StEP-based approach, 
subtilisin E was evolved to exhibit thermostability equal to that of thermitase, a thermophilic 
homolog from the extremophile Thermoactinomyces vulgaris [156].   
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While error-prone mutagenesis and recombination approaches both seek to develop improved 
protein functionalities via random variation of existing scaffolds, a more extreme approach to 
random evolution of proteins is to start from completely random sequences.  This tactic has been 
employed by Keefe and Szostak to identify novel ATP-binding proteins from a library of 
completely random 80-mer polypeptides [157].  From a library of 6 x 10
12
 proteins, each 
covalently bound to its cognate mRNA, they employed 18 rounds of selection on ATP-agarose to 
identify four with ATP-binding functionality.  Of course, such a system is dependent upon both 
the ability to synthesize very large libraries and, most importantly, screen them in a high-
throughput manner, which may be difficult for certain target properties.  Nevertheless, this work 
serves as an impressive example of the power of a random evolutionary approach. 
 
1.3.2.2 Targeted evolution strategies 
While random evolution strategies have a proven record of success, the solution space they 
explore for any given protein is large – too large, in fact, for many screening methods to feasibly 
allow sufficient library coverage.  However, it is apparent that with any random mutagenesis 
strategy, the vast majority of the mutants generated will exhibit no improvement or even inferior 
performance relative to the parent protein.  As a result, a number of techniques have been 
developed to leverage the substantial amount of protein structural data available for the design of 
smaller, targeted libraries enriched in variants most likely to exhibit improved properties.  Two 
examples of this are structure-based combinatorial protein engineering (SCOPE) and the 
SCHEMA algorithm, both presented in 2002 [158,159].  These strategies employ protein 
structural data to first identify discrete units of protein secondary structure.  By biasing a 
recombination-based evolution strategy such that recombination occurs only between these units 
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and not within them, the chances of the resulting chimeric proteins maintaining a correct folding 
pattern, and thus functionality, increase.  Additionally, SCHEMA and SCOPE carry the benefit 
of enabling shuffling of parent proteins with low sequence identity, provided that they share 
similar folds.  Besides these techniques, a number of such methods have been developed 
[160,161]. 
 
While SCHEMA and SCOPE focus on structural elements of a target protein, other approaches 
focus instead on the functional elements.  To evolve a nuclear hormone receptor to bind a new 
ligand, for example, Chockalingam and coworkers employed stepwise saturation mutagenesis of 
active site residues to target only those that are expected to play a role in contacting the ligand 
[162].  Similarly, Reetz and coworkers utilized an iterative saturation mutagenesis approach to 
increase the thermostability of a lipase from Bacillus subtilis by targeting those residues that 
showcased the highest degrees of thermal motion based on X-ray data [163].  In multi-domain 
proteins, each domain can be independently evolved in the context of the holoenzyme.  As an 
example of this approach, each domain of cytochrome P450BM3 from Bacillus megaterium was 
separately evolved using a combination of random, saturation, and site-directed mutagenesis.  
When the beneficial mutations in each domain were combined, the resulting protein was able to 
hydroxylate propane, a nonnative substrate, with native-like coupling efficiency of cofactor 
utilization [164]. 
 
When structural information for a particular target protein is unavailable, computational 
modeling can be employed to guide directed evolution experiments.  A particularly impressive 
example of this is the evolution of a transaminase for the industrial synthesis of the antidiabetic 
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drug sitagliptin by researchers at Codexis and Merck [165].  Motivated by the desire to replace a 
rhodium-catalyzed enamine hydrogenation (necessitating high pressure and extra purification 
steps) with a more efficient enzymatic process, they first sought a transaminase with activity 
towards the prositagliptin ketone.  While a particular enzyme with the desired stereospecificity 
was identified, it had no activity toward the desired substrate.  As a result, a homology model of 
the transaminase was built in silico to guide reconstruction of the active site.  Applying multiple 
rounds of targeted mutagenesis, detectable activity toward the prositagliptin ketone was detected.  
Subsequently, the enzyme was evolved to function under process conditions, yielding a practical 
biocatalyst for the industrial process. 
 
Beyond evolving a given protein scaffold for activity with a new substrate, multiple directed 
evolution efforts in recent years have set the ambitious goal of evolving the scaffold for 
completely novel activities.  In 2006, Park and coworkers presented a method to do so called 
simultaneous incorporation and adjustment of functional elements (SIAFE) [166].  In this 
approach, functional elements (including active site loops involved in catalysis and in substrate 
binding) are systematically and combinatorially incorporated into a chosen template sequence.  
As proof of concept, they evolved β-lactamase activity from an αβ/βα metallohydrolase scaffold 
through deletion, insertion and remodeling of active site functional elements.  At the end of the 
process, although the kinetic properties of the new β-lactamase protein were inferior to those of 
natural β-lactamases, it no longer exhibited its former metallohydrolase activity.  For this 
experiment, the choice of functional elements was guided by the structural and mechanistic data 
available for known β-lactamases of the αβ/βα superfamily; it would likely be significantly more 
difficult, therefore, to evolve a completely novel function using this approach.  Nevertheless, this 
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has been achieved by Röthlisberger and coworkers to create an enzyme capable of catalyzing the 
Kemp elimination reaction, for which no known natural enzymes exist [167].  To accomplish this 
goal, a computational design strategy was employed, coupled with directed evolution.  First, an 
ideal active site for the desired Kemp elimination enzyme was designed in silico based on 
quantum mechanical transition state calculations.  Next, further computational analysis was used 
to identify the protein scaffolds that could best support the designed active site.  Eventually, 59 
different designs were experimentally characterized, of which eight exhibited the desired 
function at a detectable level.  After seven rounds of directed evolution, comprising both random 
mutagenesis and shuffling, an increase of greater than 200-fold was observed in kcat/Km for the 
best mutant, yielding an overall rate enhancement of 1.18 x 10
6
 relative to the uncatalyzed 
reaction.  Another example of coupled in silico design and directed evolution was recently 
provided by Karanicolas and coworkers, who engineered a heterodimerization interface between 
two unrelated proteins [168].  While the in silico design alone yielded a pair with a measured Kd 
of 130 nM, subsequent directed evolution decreased this value almost 1000-fold to 180 pM.  
These two examples clearly illustrate the synergistic relationship between computational tools 
and directed evolution, a trend that is likely to continue to develop in the years to come. 
 
1.3.3 Genome engineering 
1.3.3.1 Genome evolution 
Natural product biosynthesis is most often thought of in terms of either biosynthetic pathways or 
their constituent enzymes, as these elements directly participate in the conversion of substrates to 
products.  Nevertheless, it is important to remember that natural product biosynthesis occurs in 
the context of the cellular milieu, and thus cannot be truly decoupled from the rest of cellular 
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metabolism.  As a result, techniques that focus on engineering of microorganisms at the genome 
scale can be particularly useful for natural products research to create ideal production strains.   
 
Classic strain development processes involve the random introduction of mutations to an 
organism in a stressed environment, relying either on intrinsic mutation rate or supplementation 
of mutagenizing chemicals or radiation to generate an improvement genotype (and thus 
phenotype) [169].  Modern processes employ new methods to exploit the diversity generated or 
define the specific changes introduced.  One such technique  is genome shuffling, a process that 
takes advantage of whole-genome recombination between members of a diverse population to 
create complex, multi-parent progeny with significantly improved fitness in every successive 
generation [170].  This technique has been applied to increase production of (2S,3R)-
hydroxycitric acid (HCA) in the native producer Streptomyces sp. U121, the biosynthetic 
pathway of which is not well characterized [171].  Typically, genome shuffling experiments 
proceed in two major steps: creation/identification of the parent strains to be shuffled, and 
subsequent recombination (via protoplast fusion) and selection to identify the desired progeny.  
In this study, the parent strains were created through random mutagenesis using nitrosoguanidine 
(NTG).  From this initial round of mutagenesis, four strains were identified with increased HCA 
production and used for genome shuffling.  Multiple rounds of shuffling led to a five- to six-fold 
improvement in product titer. 
 
Genome shuffling can be applied in a variety of different hosts.  For example, application in the 
strict anaerobe Clostridium diolis DSM 15410 led to improved 1,3-propanediol (1,3-PD) 
production [172].  In this study, NTG-based chemical mutagenesis was employed to generate 
35 
 
two sets of parental strains: those improved in glycerol (substrate) tolerance, and those improved 
in 1,3-PD (product) tolerance.  Four rounds of genome shuffling in the presence of 1,3-PD and 
the side products acetic and butyric acid were carried out, yielding a strain with 80% greater 
volumetric production of 1,3-PD.  Further application of genome shuffling in Propionibacterium 
shermanii and Penicillium decumbens JU-A10 have been explored as well, resulting in mutants 
with increased production of vitamin B12 and cellulase, respectively [173,174]. 
 
As a complement to genome engineering approaches based on random mutagenesis, the Church 
group developed a method for large-scale, parallel modification of a genome at many targeted 
sites [175].  Termed multiplex automated genome engineering, or MAGE, this technique makes 
use of the bacteriophage λ-Red ssDNA-binding protein β to achieve allelic replacement of 
desired gene loci with synthetic oligos.  One cycle of MAGE includes transformation of cells 
with the synthetic oligos, recovery and growth to mid-log phase, and heat shock to induce β 
protein expression and recombination.  With successive cycles, increasing variation can be 
introduced into the host genome (Figure 1.6).  Depending on the oligo design, this technique can 
be used to introduce mutations, insertions, or deletions, all in a simultaneous fashion.  As proof 
of concept, 24 different genes were simultaneously targeted to induce a lycopene overproduction 
phenotype in E. coli.  Twenty of these genes had been reported to increase lycopene production, 
and so oligos with degenerate RBS sequences were designed to enhance translation efficiency.  
The remaining four genes came from alternate pathways and were targeted for inactivation via 
oligos containing nonsense mutations.  After 5-35 cycles of MAGE, up to five-fold greater 
lycopene production was observed when compared to the ancestral strain, yielding titers of 
~9000 ppm. 
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Figure 1.6: MAGE consists of iterative cycles of oligo-mediated mutagenesis. 
 
The decreasing cost of DNA oligomer synthesis has been an important factor driving genome 
engineering efforts.  Microarray technology has enabled parallel synthesis of oligos to target 
every gene in the genome of E. coli, for example, facilitating rapid and comprehensive library 
assembly.  When coupled with the MAGE process, microarray technology enabled construction 
of a genome-wide T7 promoter insertion library [176].  The trackable multiplex recombineering 
(TRMR) method similarly utilizes microarray-derived oligos to target the full genome of E. coli, 
and has been applied to introduce both up- and down-regulation [177].   
 
While such techniques are primarily limited to E. coli, expansion to other hosts could greatly 
accelerate industrial strain development.  For example, the MAGE approach was recently 
expanded to S. cerevisiae strains through a similar process called yeast oligo-mediated genome 
engineering, or YOGE [178].  Additionally, to evolve complex phenotypes in S. cerevisiae, 
genome-wide reduction-of-function libraries can be created by leveraging a heterologous RNA-
interference (RNAi) system [179].  This RNAi-assisted genome evolution method, known as 
RAGE, entails iterative cycles of RNAi-mediated gene knockdown with a genome-wide library 
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and screening or selection for a desired phenotype.  Beneficial knockdown cassettes can then be 
integrated to the genome to generate improved basis strains for the next round of screening or 
selection.  This approach has been successfully applied to increase S. cerevisiae tolerance to 
fermentation inhibitors acetic acid [179] and furfural [180], underscoring its potential as an 
industrial strain development platform. 
 
1.3.3.2 Genome tailoring 
As opposed to the broad-scale evolutionary approaches describe above, precise and rapid 
manipulation of specific loci in a genome of interest can also be highly beneficial from a strain 
engineering perspective.  Such manipulations can include gene deletions, for example to remove 
competing pathways; site-specific mutagenesis, to introduce beneficial mutations in situ; or gene 
replacement, to diversify pathways or evaluate homologs.  While recombination between the 
intact genome and a supplied DNA “editing template” can be harnessed to make such changes in 
a variety of organisms, the fact remains that even in the most proficient organisms, 
recombination rates are quite low.  As a result, laborious screening for the desired mutation is 
often required. 
 
In the cell, DNA damage is known to activate repair machinery.  As a result, introduction of a 
double-strand break (DSB) at a genomic locus of interest can be used stimulate the homologous 
recombination machinery, facilitating exchange between the chromosome and the editing 
template.  Site-specific introduction of a DSB, however, requires a highly-specific nuclease that 
will not cleave similar sites present at other locations in the genome.  To meet these demands, 
researchers have looked to exploit native DNA-binding proteins.  The most obvious first choices 
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in this area were homing endonucleases, restriction enzymes with large recognition sequences 
[181].  While some successes were achieved in the engineering of such enzymes [182,183], it 
became apparent that their recognition and cleavage domains did not exhibit the requisite 
modularity for facile recognition site alteration. 
 
Moving forward, greater modularity was achieved by creating artificial endonucleases with 
programmable DNA binding domains fused to non-specific nuclease domains [181].  The first 
wave of these chimeric endonucleases utilized zinc finger (ZF) DNA recognition domains, each 
of which can recognize a specific 3 nucleotide sequence [184].  By combining multiple ZF 
domains in a single polypeptide, longer recognition sequences could be built.  Further, fusion of 
the ZF domains to a nuclease domain that cleaves only upon dimerization, such as FokI, enables 
creation of ZF nucleases (ZFNs) that introduce a DSB only when two ZFNs are present, 
increasing specificity and decreasing off-target effects.  However, over time it was realized that 
design of functional ZFNs can be difficult, as a de novo designed ZFN pairs often fail to perform 
as expected [185]. 
 
The second wave of chimeric endonucleases replaced the ZF domains with transcription 
activator-like effector (TALE) DNA binding domains.  TALE domains recognize nucleic acids 
on a 1:1 basis based on a two amino acid specificity code [186], offering greater overall 
modularity to facilitate customization.  As a result, TALE nucleases (TALENs) have been 
applied for genome editing purposes in a number of different hosts [187].  Notably, the highly 
repetitive architecture of a TALE binding domain complicates their assembly by traditional 
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cloning methods, though modern cloning techniques can circumvent these difficulties given an 
appropriate library of building blocks [188,189]. 
 
Though TALENs offer great versatility in single-locus genome editing, multi-locus targeting can 
become cumbersome as a new pair of TALEN genes must be synthesized and introduced to the 
desired host for every site of interest.  Recently, an alternative approach based on the clustered 
regularly interspaced repeats (CRISPR)/CRISPR-associated (Cas) proteins of Streptococcus 
pyogenes has been pioneered [190].  In the native host, the CRISPR/Cas system serves as an 
immune system against foreign nucleic acids.  Short fragments of the invading DNA are 
integrated into the genome of the host in CRISPR array, which can then be transcribed to 
facilitate cleavage of the foreign DNA by Cas9, an RNA-guided endonuclease, upon subsequent 
invasion [191].  For genome editing purposes, Cas9 and a guide RNA sequence can be 
heterologously expressed in any host of interest to induce site-specific cleavage.  As DNA 
recognition is determined only by the short RNA sequence, adapting Cas9 to any desired locus 
simply requires the expression of a new guide sequence.  As a result, this system offers 
unprecedented flexibility for multiplexing [192,193] and library creation [194]. 
 
1.4 Project Overview 
Now more than ever, the raw materials for natural product pathway assembly (i.e., genes from 
sequenced genomes) are plentiful.  Couple this with an abundance of new techniques for DNA 
manipulation and the field appears poised for a new age of natural product discovery.  Gene 
clusters can be constructed, de-constructed, rearranged, repurposed, and repackaged with 
unprecedented ease, opening the door to rapid, facile platforms for natural product discovery, 
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characterization, and engineering.  Throughout my graduate career, I have sought to leverage 
these new technologies for the discovery and engineering of natural products at the protein, 
pathway, and genome scales. 
 
Chapter 2 describes the synthesis of new analogs of the natural product FR-900098 by 
discovering and exploiting the promiscuity of the native biosynthetic machinery.  Previous 
studies have shown that FR-900098, a phosphonic acid produced by Streptomyces 
rubellomurinus, can serve as a potent anti-malarial by inhibiting the 1-deoxy-D-xylulose-5-
phosphate reductoisomerase (Dxr) enzyme of malaria parasite Plasmodium falciparum.  Here we 
characterized the N-acetyltransferase FrbF from the FR-900098 biosynthetic pathway, 
determining its catalytic mechanism and scope of acyl-coenzyme A substrates.  Guided by our 
co-crystal structure of Dxr with phosphonic acid inhibitors, we enzymatically synthesized a 
novel N-propionyl derivative, FR-900098P, and demonstrated its superior Dxr inhibition in vitro.  
Further, we developed an in vivo platform for FR-900098P biosynthesis by leveraging the 
previously established E. coli expression system with metabolic engineering and mutasynthetic 
approaches. 
 
Chapter 3 outlines efforts towards the discovery of fungal polyketides via heterologous 
expression in S. cerevisiae.  The pathogenic, thermal dimorphic fungus Talaromyces marneffei 
was selected as a source of uncharacterized PKS genes, as a total of 25 were identified in its 
sequenced genome.  Yeast homologous recombination was demonstrated as a means to assemble 
entire pathways from individual gene expression cassettes, leading to the discovery of a 
resorcylic acid lactone halogenase.  Additionally, a helper plasmid was designed for expression, 
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detection, and purification of PKSs from yeast culture.  Following one-step assembly of 11 PKS 
expression cassettes, soluble protein expression was detected by Western blot.  We then 
characterized novel strong endogenous promoters to improve protein expression in S. cerevisiae 
and demonstrated their superior performance in the expression of a PKS responsible for 
production of fungal pigments YWA1 and citreoisocoumarin. 
 
Chapter 4 details the discovery of novel phosphonic acid compounds from a cryptic gene cluster 
discovered in a Streptomyces sp. soil isolate.  Bioinformatic analysis showed that the cluster 
contained three genes related to the FR-900098 biosynthetic pathway along with several other 
genes that diverge from this pathway.  Functionality of the early steps in the cryptic pathway was 
demonstrated via complementation of FR-900098 biosynthesis in E. coli, although no 
phosphonic acids were detected from the native strain.  Utilizing a two-step assembly strategy 
based on yeast homologous recombination, each of thirteen genes in the pathway was placed 
under a strong promoter on a single plasmid for heterologous expression in S. lividans.  As a 
result, several phosphonic acids were detected, and NMR-characterization revealed novel 
structures not previously reported in the literature.  Additionally, by expressing a 
phosphoenolpyruvate phosphomutase alone, we shed new light on the native metabolism of 
phosphonates in S. lividans, revealing an endogenous pathway to form 2-aminoethyl 
phosphonate from phosphonopyruvate. 
 
Chapter 5 presents a high-efficiency genome editing method for Streptomyces species using an 
engineered CRISPR/Cas system.  In the past two years, CRISPR/Cas systems have been one of 
the hottest topics in biological research, with impressive results demonstrated in a great variety 
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of organisms.  In Streptomyces species, a reconstituted CRISPR/Cas technology would enable 
manipulation of natural product gene clusters– such as site-specific mutation, gene deletion, 
promoter knock-in, or full cluster deletion– with unprecedented ease.  To accomplish this goal, a 
versatile base plasmid was designed and assembled with a codon-optimized cas9 gene and the 
necessary RNA components under the control of strong actinomycete promoters.  By targeting 
different loci in the genome of S. lividans 66, we were able to show high efficiency, multiplexed 
introduction of defined deletions ranging from 20 bp to 31 kb.  Further, we demonstrated high 
efficiency genome editing in two additional species, S. albus J1074 and Streptomyces 
viridochromogenes DSM40736, using the same base plasmid.  Thus, our designed system 
represents a powerful new tool for the manipulation of natural product gene clusters in a broad 
range of Streptomyces strains. 
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CHAPTER 2. Characterization and engineering of FrbF for the 
synthesis of novel FR-900098 analogs 
 
2.1 Introduction 
2.1.1 The ongoing malaria threat 
With 207 million cases and 627,000 deaths estimated in 2012 alone, malaria remains one of the 
most significant threats to global health today [1].  Despite past and current control efforts, 
nearly half of the world’s population still remains at risk.  The disease is caused by any of four 
different species of Plasmodia – Plasmodium falciparum, Plasmodium vivax, Plasmodium 
malariae, and Plasmodium ovale – all of which are transmitted to human hosts through 
mosquitoes of the genus Anopheles.  Of these four parasite species, Plasmodium falciparum and 
Plasmodium vivax are the most common [1].  Children under five years of age are particularly 
susceptible to the disease, accounting for 76 % of the reported deaths in 2012. 
 
Artemisinin, a sesquiterpene lactone derived from the plant Artemisia annua (Figure 2.1), 
currently serves as the basis for frontline malaria treatments.  Known as qing hao in China, the 
plant has a long history of therapeutic application [2].  Artemisinin itself was first isolated from 
Artemisia annua in 1972, and subsequent assays against Plasmodium falciparum demonstrated 
significant potency relative to established antimalarials chloroquine and mefloquine.  Trials in 
mice also showed good efficacy in treating Plasmodium berghei, and a 1979 human trial cured 
2099 patients, although moderate recrudescence was observed [3]. 
 
68 
 
 
Figure 2.1: Artemisinin and representative clinically-relevant derivatives. 
 
Although the native producer has served as the primary source of artemisinin, cultivation is time 
and resource intensive and cannot keep up with the significant demand [4].  To solve this 
problem, total synthesis of the compound was attempted by several research groups in the 1980s 
and 1990s.  Although multiple total syntheses were achieved, none was suitable for 
commercialization [5-8].  As vast improvements were made in recombinant DNA technology 
around the turn of the century, biosynthesis became a much more attractive alternative.  Efforts 
toward the biosynthesis of artemisinin were spearheaded by researchers at UC Berkeley, and 
further developed by the start-up company Amyris.  In 2003, synthesis of the artemisinin 
precursor amorphadiene was achieved in Escherichia coli via an engineered mevalonate pathway 
from Saccharomyces cerevisiae and a synthetic amorpha-4,11-diene synthase gene [9].  In 2006, 
artemisinic acid titers of up to 100 mg L
-1
 were achieved in an engineered strain of S. cerevisiae, 
paving the way to commercially relevant biosynthesis in this organism [10].  In 2013, titers of 25 
g L
-1
 were achieved in an engineered S. cerevisiae strain, which was subsequently licensed to 
pharmaceutical company Sanofi [11].  An efficient chemical conversion of artemisinic acid to 
artemisinin was also demonstrated, allowing further derivatization to more pharmacologically 
favorable forms of the drug (such as artesunate or artemether) through established chemical 
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processes.  Industrial-scale production of 50 to 60 tons of artemisinin per year is expected in 
2014, which is equivalent to between 80 and 150 million malaria treatments [12]. 
 
Despite these great successes in the biosynthetic production of artemisinin, artemisinin itself 
does not present a complete solution to the ongoing malaria problem.  The World Health 
Organization strongly discourages the use of artemisinin or its derivatives as solo therapeutics, as 
this can provide selective pressure for the development of resistance in the Plasmodium parasite.  
Evidence of artemisinin resistance has already been observed in field isolates from Cambodia, 
Myanmar, Thailand, and Vietnam, calling for urgent containment measures to stop its spread 
[1,13-15].  Rather, artemisinin-based drugs are to be used only in combination with 
complementary antimalarial drugs as artemisinin combination therapies (ACTs).  However, as 
many other antimalarials have seen decades of monotherapeutic application already, resistance 
can be a significant concern with their usage as well.  Thus, there is still a need for new 
antimalarial drugs, not only to replace the old but to supplement each other in novel combination 
therapies as the fight against malaria continues. 
 
2.1.2 Antimalarial phosphonic acids fosmidomycin and FR-900098 
2.1.2.1 Initial discovery and studies 
Two natural products of particular interest in the antimalarial field are the phosphonic acids 
fosmidomycin (originally called FR-31564) and FR-900098 (Figure 2.2).  These compounds 
were first isolated in the late 1970s by the Fujisawa Pharmaceutical Co., Ltd. from Streptomyces 
lavendulae and Streptomyces rubellomurinus sp. nov., respectively [16,17].  They were 
discovered in a screening program of soil isolates against the nocardicin C-supersensitive mutant 
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of Pseudomonas aeruginosa NCTC 10490, designed to identify novel inhibitors of cell wall 
biosynthesis.  The chemical structures of both compounds were solved at the time of isolation.  
They were found to differ only in their N-acyl groups, with fosmidomycin containing a formyl 
group and FR-900098 containing an acetyl moiety.  Antibiotic spectra for these compounds were 
determined against a variety of microorganisms in a serial dilution agar plate assay, and both 
were found to be much more effective against Gram-negative bacteria than Gram-positive.  In all 
cases tested, fosmidomycin was found to be at least as effective as FR-900098, often exhibiting a 
significantly lower MIC.  As a result, further development efforts and clinical trials proceeded 
with fosmidomycin in the 1980s [18-22].  It was found to have good pharmacokinetic properties 
and was initially targeted as a treatment of urinary tract infections.  Though initial results showed 
promise, the drug was found to be poorly effective against recurrent infections, and so further 
development was halted [23]. 
 
 
Figure 2.2: Phosphonic acids fosmidomycin and FR-900098. 
 
2.1.2.2 Renewed interest and clinical trials 
Following its initial discovery, little subsequent research interest was expressed in FR-900098, as 
it was thought to be the inferior of the two compounds from an antibiotic standpoint.  However, 
interest in both compounds was rekindled in 1993 with the elucidation of the non-mevalonate 
pathway for the biosynthesis of isoprenoid precursors [24].  As isoprenoid synthesis was 
previously thought to proceed solely through the mevalonate pathway, the discovery of this 
71 
 
alternate pathway shed light on novel targets for herbicides and antibiotics.  In 1989, it had 
already been demonstrated that fosmidomycin derived its antibiotic activity through inhibition of 
isoprenoid synthesis [25].  Kuzuyama and co-workers demonstrated this inhibition in vitro with 
purified deoxyxylulose-5-phosphate reductoisomerase (Dxr) from the non-mevalonate pathway 
in E. coli, observing mixed-mode inhibition with a Ki value of 38 nM for fosmidomycin [26].  
The full resurgence of fosmidomycin and FR-900098 was not underway until 1999, however, 
when the Jomaa research group first identified the two compounds as potential antimalarials 
[27].  In this study, bioinformatic analysis was employed to identify a possible Dxr enzyme in 
the recently sequenced genome of Plasmodium falciparum.  Fosmidomycin and FR-900098 were 
both assayed against three strains of P. falciparum.  While both compounds exhibited low IC50 
values (≤370 nM), FR-900098 proved to be roughly twice as effective as fosmidomycin.  This 
also proved true in in vitro inhibition assays against the purified recombinant target enzyme.  
Finally, animal studies were conducted in a mouse model with P. vinckei.  Again, FR-900098 
proved to be the most effective antimalarial drug, exhibiting <1 % parasitemia with a 2 mg/kg 
dosage. 
 
Likely owing to the difficulty in preparing large quantities of FR-900098, antimalarial clinical 
trials in humans instead proceeded with fosmidomycin.  Two initial trials evaluated the efficacy 
of fosmidomycin: first in 27 adults in Gabon, and then in 10 adults each from Gabon and 
Thailand [28,29].  In both trials, rapid initial clearance of the parasite was observed; however, 
recrudescence was found to be a significant concern, as several subjects had re-acquired the 
disease when evaluated at two or four weeks after starting treatment.  These results highlight the 
limits of fosmidomycin monotherapy, again pointing to the benefits of combination therapies for 
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malaria treatment.  Subsequently, fosmidomycin-clindamycin was evaluated in children of 
various age groups [30-32].  Initial studies focused on children aged 7 – 14 and found no 
evidence of recrudescence on day 14 when a multi-day treatment regimen was applied.  Further, 
comparison with 5-day regimens of either fosmidomycin alone or clindamycin alone clearly 
demonstrated the advantage of the combination therapy.  Extension of the subject age range 
showed similar cure rates in children as young as 3, but a significant decrease in children aged 1 
– 2.  An ACT consisting of fosmidomycin and the artemisinin derivative artesunate was also 
evaluated in children aged 6 – 15, revealing 100 % 14-day cure rates with dosing regimens of ≥2 
days.  Follow-up at 28 days revealed ≥90 % cure rates with dosing regimens of ≥3 days [33]. 
 
2.1.2.3 Chemical synthesis of analogs and derivatives 
Although fosmidomycin and FR-900098 were demonstrated to be potent antibiotic and 
antimalarial compounds, the fact remains that they are not optimized for use as human 
therapeutics.  As a result, several efforts have been directed toward the synthesis of a variety of 
analogs and derivatives, both in a search for greater efficacy and to facilitate structure-activity 
relationship (SAR) studies.  The earliest of these was carried out in an effort to develop 
improved antibiotics by researchers at the Fujisawa Chemical Co., Ltd. [34].  Through their 
synthetic efforts, they were able to generate four different types of compounds: fosmidomycin 
and FR-900098 with an additional hydroxyl group on the β-carbon; 1-trans-propenyl analogs of 
both compounds; ethylene analogs of both compounds, containing only a two-carbon spacer; and 
methylphosphinic acids of both compounds.  These derivatives were assayed against a broad 
spectrum of microbes for antibiotic behavior.  Although some of the derivatives showed minor 
improvements against particular species, fosmidomycin was again found to be the most potent 
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overall antibiotic.  As a result, interest in synthesis of derivatives and analogs remained minimal 
for the next several years.  One exception, however, is the work of Öhler and Kanzler, who in 
1995 published an alternate synthetic route to the 1-trans-propenyl analogs [35].  Through 
subsequent hydrogenation, the corresponding propylphosphonates could be generated for further 
derivatization.  Nevertheless, the authors’ were interested in these compounds solely from a 
synthetic perspective, and as a result biological assays were not pursued. 
 
Following the discovery of fosmidomycin and FR-900098 as potent antimalarials and subsequent 
clinical trials, interest in derivative synthesis boomed.  Among the goals of these efforts was 
improvement of the 20 – 40 % bioavailability observed for fosmidomycin [36].  To this end, 
multiple syntheses of ester prodrugs were reported (Figure 2.3).  These derivatives were 
designed to increase uptake by masking the charged phosphonate moiety until the compounds 
enter the bloodstream, at which point ubiquitous esterases release the active drug.  In 2001, 
Reichenberg and co-workers synthesized three diaryl ester prodrugs of FR-900098: the diphenyl 
ester, the bis-(2-methyl-phenyl) ester, and the bis-(4-methoxy-phenyl) ester [37].  Of these, oral 
administration of the diphenyl ester was found to be more effective than oral FR-900098 in the 
P. vinckei mouse model, while oral administration of the bis-(4-methoxy-phenyl) ester was most 
effective, performing comparably to intraperitoneally dosed FR-900098.  However, concern over 
the toxicity of the phenol product of ester bond cleavage led to the exploration of alternate alkyl 
masking groups.  Synthesis of a variety of acyloxyalkyl prodrugs and evaluation in the P. vinckei 
mouse model revealed the pivaloyloxymethyl, acetyloxyethyl, and propionyloxyethyl esters to be 
more effective than FR-900098.  Additionally, evaluation of plasma concentrations of FR-
900098 after dosage confirmed the improved bioavailability of the acetyloxyethyl ester [38].  In 
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a follow-up study, alkoxycarbonyloxy esters were also synthesized and evaluated [39].  Both the 
methoxycarbonyloxyethyl and ethoxycarbonyloxyethyl esters were found to be more effective 
than FR-900098.  Single ester prodrugs were also synthesized and evaluated, as these crystalline 
compounds would lend themselves more easily to capsule formulation than the oily diester 
compounds.  However, no improvement in efficacy over FR-900098 was observed with these 
compounds. 
 
 
Figure 2.3: Ester protecting groups found to increase the antimalarial efficacy of FR-900098. 
 
The next area of derivatization to be explored in depth was substitution on the α-carbon (Figure 
2.4), with several examples published within the last decade [40-45].  The van Calenbergh group, 
for example, explored a variety of substituted phenyl groups in the α-position and assayed them 
both against purified E. coli Dxr and two P. falciparum strains.  Curiously, none of the 
derivatives proved to be better inhibitors of E. coli Dxr than fosmidomycin or FR-900098, but 
three of the compounds (one fosmidomycin derivative and two FR-900098 derivatives, each 
featuring chlorine substituents on the phenyl moiety) did show significant improvement in IC50 
against one or both of the P. falciparum strains.  The Kurz group similarly tested a series of 
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arylmethyl fosmidomycin and FR-900098 derivatives against P. falciparum, also including 
pivaloyloxymethyl ester protecting groups on the phosphonate.  Although they were able to 
identify one compound (containing a 3,4-dichlorobenzyl substituent) with improved activity 
when compared to the fosmidomycin prodrug, none of their analogs could outperform the FR-
900098 prodrug.  Finally, a different study by Kurz and co-workers looked at various alkyl 
substitutions at the α-position of the pivaloyloxymethyl ester prodrugs.  It was found that ethyl, 
propyl, isopropyl, and dimethyl substitutions significantly decreased antimalarial efficacy, while 
methyl substitution produced a compound of comparable antimalarial activity to the FR-900098 
prodrug.  Some substituted phenyl derivatives were also included in this study, with results 
similar to those described above.  More recently, the van Calenbergh group examined 
heteroatom derivatization at the α-position.  Halogenation of the FR-900098 α-carbon with 
fluorine or chlorine was analyzed by growth inhibition of P. falciparum and in the P. berghei 
mouse model.  Both compounds performed comparably to FR-900098 in P. falciparum 
inhibition, and the fluorinated derivative performed better in the in vivo trial.  Addition of an 
amine or hydroxyl group to the α-carbon of FR-900098 was also explored to introduce ether, 
amide, urea, and 1,4-triazole functionalities.  However, none of these derivatives outperformed 
FR-900098 in vitro or in vivo. 
 
 
Figure 2.4: Substitutions at the α position with significantly improved antimalarial activity compared to FR-900098. 
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Beyond just α-substituted carbon spacers, cyclized and unsaturated derivatives have also been 
synthesized and analyzed for antimalarial efficacy.  Another study from the van Calenbergh 
group looked at cyclopropyl fosmidomycin and FR-900098 derivatives, restricting rotational 
freedom of the spacer by bridging the α- and β-carbons [46].  Unfortunately, none of the 
derivatives synthesized could outperform FR-900098 in inhibition of E. coli Dxr or P. 
falciparum growth.  Similarly, incorporation of the three-carbon spacer into a cyclopentane ring 
failed to match the inhibition levels of fosmidomycin and FR-900098 toward E. coli Dxr [47].  
Finally, synthesis of α,β-unsaturated derivatives with a variety of α-aryl substitutions was carried 
out, but the resulting compounds were all significantly worse inhibitors of E. coli Dxr [48]. 
 
Among the most recent attempts at the synthesis of novel derivatives are the β- and γ-oxa 
isosteres and the so-called “reverse analogs,” replacing the N-terminal moiety with a reversed 
hydroxamic acid group (Figure 2.5).  Of the β- and γ-oxa isosteres synthesized, γ-oxa 
substitution was found to significantly reduce activity, while β-oxa substitution of FR-900098 or 
the N-methyl hydroxamate reverse analog yielded slightly better inhibitors of P. falciparum 
growth [49].  Alternatively, the Kurz group synthesized the α-phenyl-substituted hydroxamate 
and N-methyl hydroxamate FR-900098 reverse analogs, revealing the latter to be a particularly 
potent inhibitor of P. falciparum and its recombinant Dxr enzyme [50].  In a follow-up study, the 
3,4-difluorophenyl α- substituted hydroxamate and N-methyl hydroxamate FR-900098 reverse 
analogs were synthesized, yielding further improvement in IC50 measured against P. falciparum 
[51].  The α-fluorinated N-methyl hydroxamate reverse analog has also been found to have high 
antimalarial activity when assayed in the P. berghei mouse model, further illustrating the 
promise of reverse analogs as more potent antimalarials [44]. 
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Figure 2.5: Potent reverse analogs of FR-900098, including the β-oxa reverse analog with pivaloyloxymethyl ester 
protecting groups and three α-substituted compounds. 
 
2.1.2.4 Heterologous expression and characterization 
With renewed interest in FR-900098 came renewed interest in its biosynthesis, both to elucidate 
the potentially unique biochemical transformations involved and to facilitate industrially relevant 
production through protein and metabolic engineering efforts.  Although few phosphonic acid 
gene clusters had previously been characterized, a common initial step in their biosyntheses was 
noted to be conversion of phosphoenolpyruvate (PEP) to phosphonopyruvate through the activity 
of a PEP mutase (PEPM) gene [52].  As a result, identification of the FR-900098 biosynthetic 
cluster from the native producer S. rubellomurinus began with PCR-amplification of the PEPM 
gene from a genomic DNA fosmid library using degenerate primers.  One hit from this screening 
process was subsequently integrated into the chromosome of the heterologous host Streptomyces 
lividans, enabling production of FR-900098.  Sequencing and deletion analysis led to the 
identification of eight open reading frames (ORFs), designated frbA – frbH, which were found to 
be necessary for FR-900098 production; two additional ORFs, frbI and frbJ, immediately 
downstream of the minimal cluster but not necessary for FR-900098 production; and one final 
ORF, dxrB, which appeared to be encode a Dxr homolog.  Of the eight requisite ORFs, frbD was 
found to encode the PEPM originally identified in the fosmid library screening, catalyzing the 
first step of FR-900098 biosynthesis (Figure 2.6).  As no phosphonopyruvate decarboxylase gene 
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was identified to catalyze the typical second step of known phosphonic acid biosyntheses, it was 
proposed that the early steps of FR-900098 biosynthesis parallel the TCA cycle, catalyzed by 
FrbA, FrbB, FrbC, and FrbE.  In vitro assays with purified FrbD and FrbC clearly demonstrated 
the formation of 2-phosphonomethylmalate, confirming FrbC to be phosphonomethylmalate 
synthase.  FrbA and either FrbB or FrbE (or both) were predicted to catalyze the subsequent 
TCA-analogous steps, yielding 2-oxo-4-phosphonobutyrate.   
 
To decipher the downstream steps in FR-900098 biosynthesis (Figure 2.6), the entire gene 
cluster was transferred to E. coli.  The eight requisite ORFs and dxrB, necessary for self-
resistance, were placed on three compatible plasmids, each under the control of an IPTG-
inducible T7 promoter.  The result was a strain capable of reaching FR-900098 titers of 6.3 mg/L 
in shake-flask cultures in LB media [53].  Through feeding studies, in silico analysis and in vitro 
enzymatic assays, it was determined that FrbH catalyzed both the PLP-dependent 
decarboxylation of 2-amino-4-phosphonobutyrate (derived from 2-oxo-4-phosphonobutyrate via 
endogenous transamination) and nucleotide transfer to yield CMP-5’-3-aminopropylphosphonate 
(CMP-5’-3APn).  Further in vitro studies showed that CMP-5’-FR-900098 was formed via 
hydroxylation and subsequent acetylation of CMP-5’-3APn, catalyzed by FrbG and FrbF, 
respectively.  Formation of the final product FR-900098 could be achieved through hydrolysis of 
the nucleotide catalyzed by FrbI, or by ubiquitous nucleotide hydrolases within the host.  Finally, 
a possible function for FrbJ was demonstrated in vitro in the conversion of FR-900098 to FR-
33289, a derivative first reported by Okuhara and co-workers at the same time that FR-900098 
was originally identified [17,54].  However, in vivo production of this compound was not 
detected. 
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Figure 2.6: The FR-900098 biosynthetic pathway, adapted from ref. 53. 
 
2.1.2.5 Biosynthetic derivatization 
To complement the chemical derivatization efforts outlined above, the focus of the work 
described here is to apply a biosynthetic approach to the synthesis of novel FR-900098 
derivatives.  To this end, the N-acetyltransferase FrbF was selected as the target for kinetic and 
structural characterization as well as directed evolution for multiple reasons.  First of all, FrbF 
catalyzes the penultimate step of FR-900098 biosynthesis, followed only by nucleotide cleavage 
to give the final product.  As a result, none of the upstream pathway intermediates will be altered 
in the context of a mutated FrbF, indicating that all of the upstream enzymes will still be able to 
function normally.  Mutating an enzyme further upstream in the pathway, in contrast, would 
yield a series of altered pathway intermediates.  Given the high substrate specificity observed for 
some of the pathway enzymes, such as the bifunctional nucleotide transferase/decarboxylase 
FrbH, this could significantly slow or completely halt the biosynthesis of any novel derivatives.  
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The only enzyme downstream of FrbF, the nucleotide hydrolase FrbI, exhibits very broad 
substrate specificity, and thus would likely be unaffected by the introduction of any FrbF mutant.  
Further, even in the absence of FrbI, ubiquitous nucleotide hydrolases within the cell can also 
serve to catalyze the final step.  Second, with the exception of a study by Gießmann and 
coworkers in which several bulky aromatic moieties were examined [55], variation in the N-acyl 
substituent remains largely unexplored.  Moreover, it has already been shown that variation at 
this end of the molecule is tolerated and can lead to more potent Dxr inhibitors, as exemplified 
by the N-methyl hydroxamate “reverse analogs” described above.  Third, although FrbF 
demonstrates activity analogous to enzymes of the well-studied GCN5-like N-acetyltransferase 
(GNAT) superfamily, FrbF shares no sequence similarity with any members thereof.  Rather, 
FrbF shares sequence similarity with a number of uncharacterized, putative aminoglycoside 
N(3’)-acetyltransferases.  As a result, characterization of FrbF could grant useful biochemical 
insights into a new class of N-acetyltransferases, and could facilitate further studies of new 
uncharacterized secondary metabolite pathways. 
 
Here, it is our goal to characterize the catalytic activity of FrbF with its native substrates.  
Additionally, thorough analysis of the active site will be applied to elucidate the catalytic 
mechanism of this enzyme.  Substrate specificity of the wild type enzyme will be then explored 
with respect to its acyl-donor to synthesize novel FR-900098 derivatives in vitro and in vivo.  To 
evaluate new FR-900098 derivatives as antimalarials, in vitro inhibition assays will be conducted 
against the heterologously expressed and purified Dxr enzyme from P. falciparum. 
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2.2 Results and Discussion 
2.2.1 Elucidation of the FrbF catalytic mechanism 
In order to elucidate the catalytic mechanism of FrbF, the residues located within 6 Å of the acyl 
moiety of the bound acetyl-CoA were analyzed in the x-ray crystal structure solved by Dr. Brian 
Bae of Prof. Satish Nair’s group at the University of Illinois, Urbana-Champaign.  Based on 
literature precedent, one could expect the reaction mechanism to proceed either via direct attack 
of the amine or hydroxylamine substrate on the carbonyl group of acetyl-CoA, as has been 
observed for the majority of GNAT superfamily members, or via an acyl-enzyme intermediate, 
as demonstrated in the yeast histone acetyltransferase Esa1 and in multiple mycobacterial 
enzymes [56,57].  Of the residues present in the active site, Glu-187, Ser-188, Thr-190, and Glu-
231 were identified as possible general acids, while only His-193 was identified as a potential 
general base.  Alanine mutants at each of these five positions were created, and their relative 
activities were measured in comparison to the wild type enzyme (Figure 2.7).   
 
The results indicate that the Glu-187Ala and Glu231Ala mutants demonstrate activities 
similar to the wild-type enzyme, confirming that these two residues do not play a role in catalysis 
and ruling out their participation in a mechanism that requires formation of a covalent acyl 
intermediate with an active site carboxylate.  The Ser-188Ala mutant exhibited a modest 
decrease in activity, as anticipated based on its interaction with the phosphopantetheine arm of 
the acetyl-CoA substrate.  In contrast, the activity of the His-193Ala mutant was less than 1 % 
of that of the wild-type, and no activity could be observed for the Thr-190Ala mutant.  These 
results strongly suggest the involvement of Thr-190 and His-193 in acid/base chemistry during 
acetyl-group transfer.  These results are consistent with the mechanistic route proposed in Figure 
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2.8.  Following the binding of the phosphonic acid substrate acetyl-CoA at the active site, His-
193 functions as a general base to facilitate the attack of the amine or hydroxylamine on the 
electrophilic carbonyl of the acetyl group.  Protonation of the resultant tetrahedral intermediate 
results in its collapse to yield the hydroxamate and CoA.  Alternatively, it is worth noting that 
His-193 could instead serve to stabilize the tetrahedral intermediate, as the N-O distance varies 
from 2.9 Å to 4.2 Å between the two pairs of FrbF dimers. 
 
 
Figure 2.7: Mechanistic characterization of FrbF.  (a) FrbF residues near the bound acetyl-CoA substrate.  
(b) Relative activities of FrbF active site mutants. 
 
Further analysis was carried out at the Thr-190 position through mutations to both Ser and Cys, 
as well as mutation of His-45 to Ala.  His-45 is the nearest residue to Thr-190, and so we 
speculated that this residue might serve to activate Thr-190 for a novel reaction mechanism 
involving attack of Thr-190 on the carbonyl of the acetyl group to form an acyl-enzyme 
intermediate.  The His-45Ala mutation reduced the relative activity of FrbF to 1.5% of the 
wild type, supporting the catalytic relevance of this residue.  However, high-resolution mass 
spectrometry provided no evidence of an acyl-enzyme intermediate (data not shown).  Further 
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analysis of the crystal structure suggests that His-45 can participate in hydrogen bonding 
interactions both with a carbonyl group of the acetyl-CoA phosphopantetheine arm and with the 
backbone amide nitrogen of either Thr-190 or Ser-191, suggesting that this residue is critical for 
the positioning of acetyl-CoA and the catalytically requisite Thr-190 residue.  Further, the Thr-
190Cys mutation, which would more closely reflect the active site of NAT enzymes that 
utilize an acyl-enzyme intermediate, lowered the activity dramatically, discrediting the prospect 
of a novel, Thr-mediated ping pong mechanism.  Finally, the Thr-190Ser mutation had no 
detectable effect on the relative activity. 
 
 
Figure 2.8: The proposed mechanism for the N-acetylation of CMP-5’-H3APn catalyzed by FrbF. 
 
 
2.2.2 Kinetics characterization with phosphonate substrates 
2.2.2.1 CMP-5’-3APn synthesis and kinetics 
Although the FR-900098 biosynthetic pathway has been definitively demonstrated to proceed via 
N-hydroxylation followed by N-acetylation [53], FrbF is nevertheless able to acetylate both the 
primary amine substrate CMP-5’-3APn and the hydroxylamine substrate CMP-5’-H3APn 
(compounds VII and VIII, respectively, in Figure 2.6).  As a result, CMP-5’-3APn was 
enzymatically synthesized using FrbH and purified for kinetic assays.  Kinetic parameters with 
CMP-5’-3APn have previously been reported using a continuous assay with 5,5’-dithiobis-(2-
84 
 
nitrobenzoic acid) (DTNB), but numerous efforts to replicate these results under identical 
conditions proved unsuccessful.  This is most likely due to the limited sensitivity of DTNB-
based quantitation, especially given the low activity level of FrbF.  Further, DTNB can react with 
the protein itself, increasing the noise level. 
 
As a result, an HPLC-based assay, in which the CMP-conjugated product can be directly assayed 
at a UV absorbance wavelength of 254 nm, was instead employed.  Surprisingly, linear 
dependence on substrate concentration was observed far beyond the Km value of 35 µM 
previously reported, ultimately yielding a Km value of 391 µM with a kcat value of 2.042 min
-1
.  
Given that CMP-5’-3APn is not the native substrate for FrbF, it is not surprising to see this 
relatively low level of activity.  Further evaluation of the enzyme with the His6 tag at the C-
terminal position or with the N-terminal His6 tag removed via thrombin cleavage did not show 
significantly altered activity (data not shown). 
 
2.2.2.2 CMP-5’-H3APn assays 
The native substrate for FR-900098 synthesis, CMP-5’-H3APn, can be synthesized in vitro using 
the purified FrbH and FrbG enzymes.  However, numerous efforts to observe FrbF catalysis with 
the purified reaction product revealed no reproducible activity.  Subsequent LC-MS analysis of 
the purified substrate revealed a dominant signal corresponding to a parent ion m/z of 457 in 
negative mode, corresponding to the nitroso derivative CMP-5’-NO3APn. 
 
Two schemes were proposed for the oxidation of the hydroxylamine to the nitroso.  First, the 
hydroxylamine could become a surrogate substrate for FrbG and pass through a second catalytic 
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cycle, yielding the nitroso after spontaneous dehydration.  Second, the hydroxylamine could 
simply undergo a non-enzymatic oxidation, either through reaction with oxygen or through a 
disproportionation reaction with another hydroxylamine molecule.  To study the first possibility, 
the FrbG reaction was monitored over time by LC-MS, and the signals for the substrate and both 
products were followed with time.  In this case, we would expect to see an initial formation of 
the hydroxylamine, followed by consumption of this compound and a lagging increase in 
formation of the nitroso.  However, concomitant formation of both compounds was observed, 
even at the earliest time points assayed, indicating that the second possibility may be at play. 
 
To further study the second possibility, two methods were pursued.  First, the FrbG reaction was 
run for a specified amount of time, after which the enzyme was removed by diafiltration.  
Subsequently, the filtered reaction mixture was incubated at a constant temperature and 
periodically analyzed by LC-MS.  At 30 °C, rapid loss of the hydroxylamine compound was 
observed, with half of the sample depleted in ~90 min.  Even at 5 °C, the m/z = 459 signal was 
completely lost from the LC-MS trace following overnight incubation.  To corroborate this 
observation, attempts were made to purify the hydroxylamine from FrbG reaction mixtures, but 
this could not be achieved.  Instead, the nitroso compound was purified and subsequently 
reduced back to the hydroxylamine under anaerobic conditions using samarium diiodide.  
Following anaerobic incubation for several hours, little reformation of the nitroso was observed 
by LC-MS.  Once exposed to air, however, rapid reformation occurred, with the hydroxylamine 
signal almost completely lost after 30 min.  Thus, it can be concluded that the conversion of the 
hydroxylamine to the nitroso is a rapid non-enzymatic process, as has been observed previously 
for other hydroxylamine compounds [58]. 
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To assess the kinetic behavior of FrbF with this substrate, in situ generation via concomitant 
FrbG catalysis was attempted.  Interestingly, incubation of equimolar amounts of FrbF and FrbG 
showed no significant difference in FrbF activity, both via HPLC analysis and DTNB endpoint 
assay.  This is likely due to the fact that even though FrbG can supply the true hydroxylamine 
substrate for FrbF, both enzymes can also compete for the primary amine substrate, and some of 
the hydroxylamine can be lost to the non-reactive nitroso.  Increasing the FrbG concentration, 
however, led to an increase in observed FrbF activity, up to a 10:1 molar ratio of FrbG to FrbF.  
Beyond this ratio, FrbF activity did not increase further.  Given the same initial concentration of 
FrbF, the observed activity level of FrbF increased 6.7-fold when supplemented with a 10-fold 
molar excess of FrbG.  This indicates that FrbF does in fact show greater activity with CMP-5’-
H3APn than CMP-5’-3APn, which correlates with its understood role in FR-900098 
biosynthesis.  
 
2.2.3 Kinetics characterization with coenzyme A substrates 
2.2.3.1 Acetyl-CoA kinetic characterization 
For the biosynthesis of FR-900098, FrbF installs an acetyl moiety on the hydroxylamine 
substrate by transferring the respective functional group from acetyl-CoA.  To determine the 
kinetic parameters with respect to this substrate, we employed the HPLC-based assay described 
above.  In this case, the CMP-5’-3APn surrogate substrate was used to ensure that the 
concentration of this substrate remained constant from trial to trial.  Kinetic characterization with 
acetyl-CoA revealed a 20-fold lower Km value than that observed for the CMP-5’-3APn 
substrate.  This is likely due to the significant number of favorable contacts that the enzyme can 
form with this rather large substrate molecule in its binding cleft.  The kobs with acetyl-CoA is 
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approximately 55 % of the kcat observed for CMP-5’-3APn.  This is a reasonable observation 
given that the acetyl-CoA kinetic parameters were measured with the CMP-5’-3APn 
concentration near its Km value, at which point half of the maximum rate would be expected. 
 
2.2.3.2 Evaluation of alternate acyl-CoAs 
Here our goal was to determine the scope of acyl-donor substrates that FrbF will accept for the 
synthesis of novel N-acylated FR-900098 derivatives.  As a result, seven alternate acyl-CoAs 
were selected for relative activity assays, including propionyl-, isobutyryl-, β-hydroxybutyryl-, 
acetoacetyl-, malonyl-, succinyl-, and glutaryl-CoA (Figure 2.9).  These substrates were selected 
to gradually expand the size of the acyl substituent, such that only small changes to the FR-
900098 scaffold will be made.  Additionally, these acyl-CoA substrates are biologically relevant, 
and their overproduction could potentially be engineered in future host strains for the 
overproduction of specific FR-900098 derivatives. 
 
 
Figure 2.9: Side chains of alternate acyl-CoA substrates. 
 
Activities with alternate acyl-CoA substrates were measured via an HPLC-MS assay (Table 2.1).  
Initial analyses showed no detectable activity by UV absorbance or MS for glutaryl-CoA, which 
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is not surprising given that this was the largest acyl substituent evaluated.  Surprising, however, 
was the absence of detectable activity for β-hydroxybutyryl-CoA, given that activity could be 
detected for the similar acetoacetyl- and malonyl-CoA substrates.  This suggests that the second 
carbonyl moiety not present in β-hydroxybutyryl-CoA may be necessary for favorable 
interactions with the active site to support catalysis.  Of the other substrates evaluated, both 
isobutyryl- and succinyl-CoA showed activity by MS analysis, as indicated by the presence of 
the expected m/z parent ion with the corresponding m/z = 322 daughter ion due to loss of CMP.  
However, no detectable UV peak was observed for either of these two products, preventing 
accurate quantitation of relative activity toward these novel substrates.  Propionyl-, malonyl-, 
and acetoacetyl-CoA all showed activity both by UV absorbance and MS analysis, and so 
activity levels were measured for each of these substrates relative to acetyl-CoA.  Additionally, 
kinetic parameters were determined for propionyl-CoA, which exhibited the highest relative 
activity.  This is not surprising, given that the propionyl moiety is the most similar to the acetyl 
moiety. 
 
Interestingly, the Km value obtained for propionyl-CoA is approximately the same as that 
obtained for acetyl-CoA.  This likely indicates that binding of the acyl-CoA substrate relies 
predominantly on interactions with the CoA backbone itself, and not with the acyl functionality.  
The ~12-fold drop in kobs for this substrate relative to acetyl-CoA, then, is most likely caused by 
the increased steric hindrance introduced by the bulkier acyl chain, which could potentially block 
the amine or hydroxylamine of the substrate from attacking the thioester carbonyl.  This is 
further evinced by the decreasing activity observed with the bulkier malonyl-CoA (2.7 % relative 
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activity) and acetoacetyl-CoA (0.4 % relative activity), and the lack of quantifiable activity 
observed when the isobutyryl-CoA or succinyl-CoA substrates are utilized. 
 
Table 2.1: Acyl-CoA activity assays (mean ± standard deviation of three replicates) 
substrate Km (µM) kcat (min
-1
) relative activity 
acetyl-CoA 19.5 ± 0.4 1.12 ± 0.03
a
 1.0 
propionyl-CoA 23.6 ± 4.2 0.089 ± 0.024
a
 0.080 ± 0.022 
malonyl-CoA ND ND 0.027 ± 0.006 
acetoacetyl-CoA ND ND 0.0044 ± 0.0013 
isobutyryl-CoA ND ND MS 
succinyl-CoA ND ND MS 
a
: measured at 400µM CMP-5’-3APn 
ND: not determined 
MS: below UV detection limit; product observed by MS/MS only 
 
2.2.4 In vitro synthesis of FR-900098 derivatives 
To demonstrate in vitro synthesis of FR-900098 derivatives, the non-native propionyl-CoA 
substrate was chosen, as it showed the highest relative activity among all acyl-CoAs evaluated.  
Synthesis of the propionyl-FR-900098 derivative (named FR-900098P) was attempted through 
sequential reactions with the purified FrbH, FrbG, and FrbF enzymes.  After each step, the 
enzyme was removed via diafiltration and products were isolated via HPLC fractionation.  
However, this procedure resulted in almost undetectable amounts of the desired CMP-conjugated 
FR-900098 derivative, again due to the non-enzymatic oxidation of the hydroxylamine 
intermediate, CMP-5’-H3APn, to its nitroso derivative.  In an attempt to prevent this undesired 
side reaction, the FrbG and FrbF reactions were instead performed simultaneously, such that the 
hydroxylamine product of FrbG could immediately be acylated by FrbF.  This was found to 
increase the amount of CMP-FR-900098P generated, such that it became easily detectable by 
HPLC (Figure 2.10a).  Following purification of this product, CMP cleavage was performed by 
addition of FrbI.  The FrbI reaction was performed separately to avoid non-specific cleavage of 
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CMP from other pathway intermediates [53].  The identity of the newly synthesized product was 
confirmed by tandem MS/MS (Figure 2.10b).  In positive mode, FR-900098 undergoes a 
characteristic 198138 fragmentation, indicating loss of both the N-acetyl and N-hydroxyl 
moieties.  As expected, we observed the same characteristic fragmentation (212138) for FR-
900098P. 
 
 
Figure 2.10: Enzymatic synthesis of FR-900098P.  (a) Co-incubation of FrbG and FrbF following the FrbH reaction 
yields a mix of UV active compounds, including: a, CDP; b, CMP; c, CMP-5’-NO3APn; d, CMP-5’-3APn; e, 
CMP-5’-P3APn; f, NADP+; and g, CMP-5’-FR-900098P.  (b) MS trace showing synthesized FR-900098P (m/z = 
212
+
) with the expected m/z = 138
+
 daughter ion. 
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To extend the scope of FR-900098 analogs synthesized, analogous enzymatic syntheses were 
performed with malonyl-, acetoacetyl, and n-butyryl-CoA.  The resulting CMP-conjugated FR-
900098 derivatives were all observable by HPLC-MS (Figure 2.11), and could be cleaved by 
FrbI to yield the corresponding FR-900098 derivative.  However, low activity of FrbF with the 
non-native substrates relative to the rapid non-enzymatic oxidation of CMP-5’-H3APn led to 
very poor estimated yields, preventing further analysis with these compounds. 
 
 
 
Figure 2.11: Synthesis of FR-900098 analogs.  Feeding of malonyl-CoA, acetoacetyl-CoA, and n-butyryl-CoA to 
FrbF enables synthesis of the corresponding CMP-conjugated FR-900098 analogs.  Extracted ion chromatograms 
are shown for the malonyl (black, top trace), acetoacetyl (red, middle trace), and n-butyryl (blue, bottom trace) 
products. 
 
2.2.5 PfDxr expression and characterization 
2.2.5.1 Recombinant expression in E. coli 
To develop a means to evaluate the antimalarial potential of novel FR-900098 derivatives, we 
elected to heterologously express and purify the PfDxr target enzyme in E. coli.  Expression of 
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the full-length protein (including the coding sequence for a 72 amino acid leader peptide) proved 
unsuccessful, and the tag was removed to express only the core enzyme [27].  Following 
optimization of expression conditions, including expression temperature, IPTG concentration, 
and total culture volume, the pure PfDxr protein was successfully purified, as confirmed by SDS-
PAGE (Figure 2.12a).  To demonstrate activity of the pure protein, an assay with the native 
substrates NADPH and DXP was carried out, demonstrating reduction in absorbance at 340 nm 
indicative of NADPH oxidation (Figure 2.12b).  To prove that this activity was due to the PfDxr 
enzyme itself and not a contaminating protein, the assay was repeated in the presence of 
fosmidomycin, demonstrating nearly complete inhibition. 
 
 
Figure 2.12: (a) Purity of the recombinant PfDxr enzyme was confirmed via SDS-PAGE (expected MW = 47 kDa), 
while (b) activity was confirmed by tracking NADPH oxidation in the presence or absence of fosmidomycin. 
 
2.2.5.2 Kinetic characterization 
Based on the literature precedent in the study of Dxr enzymes from other organisms, we elected 
to measure the kinetics of PfDxr in the presence of Mn
2+
, as the greatest or near-greatest 
activities have typically been observed with this divalent cation [59-61].  Only NADPH was 
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evaluated as the co-factor, as no Dxr protein has been identified with preference toward NADH.  
Activity measurements by cuvette in a total volume of 300 µL proved to be reproducible, but it 
was found that kcat values measured with the same PfDxr stock decreased with time.  In contrast, 
the calculated Km values did not change significantly with time, indicating that the enzyme loses 
activity in solution, even when kept on ice.  As a result, a fresh aliquot of PfDxr (stored at -80 °C 
in 15 % glycerol) was used for all subsequently performed assays to try to minimize loss of 
activity. 
 
Kinetic analysis of PfDxr revealed a Km value of 52 ± 13 µM and a kcat value of 2.0 ± 0.5 s
-1
.  
Interestingly, the Km value obtained for PfDxr is significantly lower than the value reported for 
DXP reductoisomerases from E. coli Dxr or Zymomonas mobilis in the presence of the same 
divalent cation.  This suggests that the PfDxr enzyme is particularly well suited to bind DXP, 
which may have implications for the binding of inhibitors as well.  The observed kcat value is 
approximately twice that of EcDxr, but not as great as those obtained for Z. mobilis (13 s
-1
) or 
Pseudomonas aeruginosa (8 s
-1
) [60,62].  Overall, these kinetic parameters are most similar to 
those obtained for Mycobacterium tuberculosis Dxr with Mg
2+
 (Km = 42 µM, kcat = 2.1 s
-1
) [61]. 
 
2.2.5.3 Structure elucidation with fosmidomycin and FR-900098 
The X-ray crystal structure of PfDxr in complex with fosmidomycin or FR-900098, along with 
the co-factor NADPH and the divalent cation Mn
2+
, was solved by Dr. Brian Bae and Dr. Zhi Li 
of Prof. Satish Nair’s group at the University of Illinois, Urbana-Champaign.  In both structures, 
the hydroxamate moiety of the inhibitor coordinates to the Mn
2+
 ion via its two oxygen atoms.  
Notably, the N-acyl moiety inserts into a hydrophobic binding pocket formed by Trp-296, Met-
94 
 
298, Met-360, and the nicotinamide ring of the cofactor.  The presence of this pocket justifies the 
increased potency of FR-900098 relative to fosmidomycin as a PfDxr inhibitor, and suggests that 
further hydrophobic extension of the N-acyl side chain could provide even better binding to the 
active site. 
 
Comparison of our PfDxr structure to the EcDxr co-crystal structure with the co-factor and 
fosmidomycin reveals key differences that suggest increased potency of the inhibitor toward 
PfDxr.  For example, PfDxr possesses a narrower substrate-binding cavity, with movement of 
Met-298 toward the N-acyl moiety to form the aforementioned hydrophobic pocket.  
Concomitantly, H-293 moves into a position in which it can hydrogen bond with the 
phosphonate end of the inhibitor.  The equivalent residues in EcDxr (His-208 and Met-213) are 
not positioned well for either of these interactions.  An additional difference is seen at the 
position of Ser-269 in the PfDxr structure, which can also hydrogen bond with the phosphonate.  
In EcDxr, Gly-184 occupies this space and thus cannot hydrogen bond. 
 
To evaluate these interactions biochemically, the Ser-269Ala and Met-298Ala mutants were 
constructed.  Following purification, both mutants were assayed for activity.  While the S269A 
mutant was capable of turning over NADPH and was inhibited by fosmidomycin, the M298A 
mutant was inactive.  A repeated attempt at purification of the M298A mutant again yielded the 
inactive enzyme.  This likely indicates that this active site residue is catalytically requisite, and 
might be involved in maintaining structural integrity of the active site or positioning the substrate 
for catalysis.  Inhibition assays were carried out with the active S269A mutant, and an increase in 
the Ki value for fosmidomycin from 7.5 nM to 9.8 nM was observed.  This demonstrates that this 
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residue’s interaction with the inhibitor is partly responsible for the superior inhibition of PfDxr 
by fosmidomycin relative to EcDxr. 
 
2.2.6 PfDxr inhibition studies 
Having demonstrated synthesis of FR-900098P in vitro, it was our goal to determine the 
potential of this compound as an antimalarial drug candidate.  Thus, we carried out inhibition 
studies with the purified PfDxr target enzyme.  For comparison, inhibition constants for both 
fosmidomycin and FR-900098 were first determined (Table 2.2).  To calculate these values, rate 
measurements were made for multiple substrate concentrations at multiple concentrations of 
each inhibitor.  Double-reciprocal plots for each inhibitor showed intersection at the vertical axis, 
indicating competitive inhibition made manifest by an increase in Km only.  From the measured 
Km values, the inhibition constants for fosmidomycin and FR-900098 were determined to be 7.5 
nM and 3.7 nM, respectively.  These values correlate very well with the in vivo IC50 values 
measured against both the HB3 strain (350 nM for fosmidomycin, 170 nM for FR-900098) and 
A2 strain (370 nM for fosmidomycin, 170 nM for FR-900098) of P. falciparum [27].  Both 
values are significantly lower than the 38 nM inhibition constant reported for EcDxr, and are 
more comparable to the values reported for Synechocystis sp. PCC6803 (4 nM for 
fosmidomycin, 0.9 nM for FR-900098) [63,64].  After we had carried out these measurements, 
Behrendt and co-workers published very similar PfDxr inhibition constants of 8.4 nM for 
fosmidomycin and 2.6 nM for FR-900098, which further justify the validity of our inhibition 
assay and the results derived therefrom [50]. 
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Preparation of pure FR-900098P for inhibition studies was performed from the in vitro reactions.  
The amount of product generated was quantified by weighing the lyophilized product, and was 
further checked via measurement of the LC-MS extracted ion peak area and by comparison to 
the concentration of the CMP-conjugated intermediate prior to treatment with the nucleotide 
hydrolase FrbI, which could be quantified via measurement of the UV absorbance peak area at 
254 nm.  Kinetic measurements at multiple inhibitor concentrations yielded a sub-nanomolar 
inhibition constant of 0.92 nM, indicating a significantly more potent inhibitor than 
fosmidomycin and FR-900098.  This result correlates very well with the observation of a 
hydrophobic binding pocket in the PfDxr crystal structures. 
 
Table 2.2: PfDxr inhibition constants (mean ± standard deviation of three replicates) 
Inhibitor fosmidomycin FR-900098 FR-900098P 
Ki, nM 7.5 ± 2.0 3.7 ± 0.9 0.92 ± 0.19 
 
2.2.7 An in vivo platform for FR-900098P biosynthesis 
Given the improved potency of FR-900098P as a PfDxr inhibitor, we sought to develop an in 
vivo biosynthetic platform, as in vitro enzymatic synthesis with purified enzymes is not suitable 
for large-scale production given the cost of protein purification and of the substrate materials.  
Similarly, chemical synthesis often requires expensive, hazardous, or non-renewable raw 
materials, and can also require harsh operating conditions.  Microbial biosyntheses, in contrast, 
can be performed using renewable biomass as a primary feedstock, and require only very mild 
operating conditions.  Additionally, biosynthetic machinery can access complicated reactions and 
specific stereochemistry that would otherwise be very difficult or even impossible to achieve by 
synthetic means [65].   
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To develop a biosynthetic chassis for FR-900098P production, we built upon an E. coli FR-
900098 production platform previously developed in the Zhao lab [53].  We first attempted to 
identify FR-900098P from the FR-900098 producing strain directly, given that E. coli can 
naturally produce propionyl-CoA and that the wild type FrbF enzyme can accept propionyl-CoA 
as a substrate.  However, no FR-900098P was detected, likely indicating that intracellular 
propionyl-CoA concentrations are too low to compete with acetyl-CoA in FrbF-catalyzed acyl 
transfer.  To overcome this problem, we investigated a mutasynthetic approach by which sodium 
propionate was fed to the culture at the time of induction.  Once taken up by the cell, propionate 
can be converted to propionyl-CoA via the propionyl-CoA synthetase gene prpE, which can then 
be utilized by FrbF.  As shown in Figure 2.13a, this approach proved to be successful, and FR-
900098P was detected in the cell culture broth by MS/MS.  FR-900098, however, was still the 
dominant phosphonate product, and FR-900098P represented only ~5 – 8 % of the total 
phosphonate yield. 
 
In an attempt to further increase FR-900098P production in vivo using the native FR-900098 
biosynthetic machinery, a metabolically engineered E. coli host was investigated.  In general, to 
increase flux through a secondary metabolite pathway, a driving force needs to be created.  One 
method by which to accomplish this goal is to engineer the host’s metabolism to over-produce a 
key substrate for a rate-limiting step.  In the case of FR-900098P, it is likely that the FrbF-
catalyzed acylation is slow, given the relatively low activity observed with the non-native 
substrate.  To overcome this, then, propionyl-CoA concentrations in the cell can be increased via 
two modifications.  First, over-expression of prpE can increase the rate at which propionyl-CoA 
is synthesized.  Second, deletion of the prpRBCD operon prevents propionyl-CoA from being 
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consumed in primary metabolism via conversion to succinate and pyruvate.  Both of these 
modifications have been reported in the literature and successfully utilized in the heterologous 
production of secondary metabolites [66].  As a result, we obtained this engineered strain, called 
BAP1, from the Blaine Pfeifer lab at Tufts University.  To engineer the BAP1 strain for FR-
900098P production, it was simultaneously transformed with the three compatible plasmids 
containing the FR-900098 pathway via electroporation.  Following selection on LB media with 
three antibiotics, a colony was isolated containing all three plasmids.  Production of FR-900098P 
in this host was analyzed under identical growth conditions as the BL21 host.  Relative to cell 
culture density, the FR-900098P titer increased 3.5-fold in the BAP1 strain as compared to the 
BL21 strain (Figure 2.13b).  However, it was observed that the BAP1 strain did not reach as high 
a density as the BL21 strain, resulting in an overall increase in endpoint FR-900098P 
concentration of only ~50 %.  This is likely due to the increased metabolic burden placed on the 
BAP1 strain by over-expressing prpE under a T7 promoter while simultaneously limiting its 
ability to utilize the exogenous propionate for central metabolism.  As observed in the BL21 
strain, the BAP1 strain also produced FR-900098 as its primary phosphonate product.  However, 
the relative amount of FR-900098P was significantly greater in BAP1, comprising ~22 – 25 % of 
the total phosphonate yield. 
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Figure 2.13: In vivo biosynthesis of FR-900098P.  (a) MS trace showing phosphonates produced (FR-900098 = 
198
+
, FR-900098P = 212
+
) in the presence (blue, lower trace) or absence (red, upper trace) of exogenous sodium 
propionate.  (b) Comparison of relative FR-900098P concentrations produced in BL21 and BAP1. 
 
2.2.8 Directed evolution of FrbF 
2.2.8.1 Screening method 
While we were able to demonstrate FR-900098P synthesis in vitro and in vivo, it is clear that 
wild type FrbF is not optimized for utilization of non-native acyl-donors.  As a result, in vitro 
synthetic yields are poor, and in vivo the native acetyl-CoA substrate out-competes the desired 
non-native substrate.  As a result, it would be desirable to identify mutants of FrbF that 
demonstrate increased activity toward non-native acyl-CoA substrates. 
 
To achieve this goal, we developed a screening method to detect FrbF activity in cell lysates in a 
high-throughput manner.  This method relies on 5,5’-dithiobis-(2-nitrobenzoic acid), known as 
DTNB or Ellman’s reagent, to detect the free coenzyme A product of the acyltransfer reaction 
[67].  Following a FrbF catalytic cycle, coenzyme A is generated, which possesses a free 
sulfhydryl terminus.  DTNB can participate in a rapid, non-enzymatic disulfide exchange with 
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this product, liberating 2-nitro-5-thiobenzoic acid (TNB).  TNB has a large extinction coefficient 
at a wavelength of 412 nm, and as a result its formation can readily be measured.  The overall 
flowchart of the FrbF screening procedure is outlined in Figure 2.14. 
 
To quantify FrbF activity, cells were grown and lysed in microtiter plates, and lysate was 
subsequently split into two assay plates for initial and final quantification with DTNB.  To 
maximize signal-to-noise ratio, a 60 minute assay was developed in which the native 
hydroxylamine substrate CMP-5’-H3APn was generated in situ via addition of FrbG to the assay 
mixture.  With this method, variation in output signal was found to be very low for wild type 
FrbF with acetyl-CoA or propionyl-CoA (~6 % relative to the mean), with a sufficient signal-to-
noise level of ~4 – 7 depending on the substrate. 
 
 
Figure 2.14: Flowchart of screening method for detection of FrbF activity toward novel substrates.  A library of 
FrbF mutant constructs is used to transform E. coli BL21(DE3).  Individual colonies are grown, induced, and lysed 
in a microtiter plate.  Following addition of lysate to the FrbF assay mixture, TNB formation is monitored at λ = 412 
nm to detect FrbF activity. 
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2.2.8.2 Library creation by saturation mutagenesis 
To limit the size of the library of FrbF mutants that would need to be screened, we first selected a 
site-directed mutagenesis approach to target only those residues that might be actively involved 
in blocking the incorporation of a larger acyl-CoA substrate.  Having determined the crystal 
structure of FrbF in complex with acetyl-CoA, we selected for saturation mutagenesis those 
residues located within 6 Å of the substrate acetyl group, with the exception of Thr-190 and His-
193, which were found to be catalytically requisite.  The resulting sites targeted for saturation 
mutagenesis were Phe-80, Glu-187, Ser-188, Asn-189, Glu-231, and Phe-234.  Degenerate 
primers were designed at each of these sites such that a saturation mutagenesis library could be 
constructed via megaprimer PCR.  Following library transformation, multiple colonies from the 
Phe-80, Glu-231, and Phe-234 libraries were chosen and sequenced to confirm mutation only at 
the desired site.  The results of the sequencing indicated a different codon in each construct 
successfully sequenced with no off-target mutations. 
 
For each of the saturation mutagenesis libraries generated, one microtiter plate was screened, 
representing ~5-fold coverage of the sequence space.  In all of the six libraries, few colonies 
significantly exceeded the signal output of the control strain expressing wild type FrbF.  Re-
screening of top hits showed at best modest improvement relative to the wild type control.  
However, sequencing revealed all of the top hits to contain the wild type frbF sequence.  SDS-
PAGE analysis revealed that the best hits produced a greater output signal not due to mutation of 
the protein, but due to higher protein expression levels. 
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2.2.8.3 Library creation by error-prone PCR 
To expand the sequence space of FrbF mutants available for screening, error-prone PCR was 
employed.  Using Taq polymerase, a biased nucleotide mixture, and various concentrations of 
MnCl2, mutation rates ranging from 1.7 amino acids per protein to 3.4 amino acids per protein 
were achieved, as determined by sequencing ten clones each from three different libraries.  A 
library with an average mutation rate of 2.0 amino acids per protein was chosen for screening.  
From this library, ~1000 mutants were screened.  Interestingly, many mutants in this library were 
found to generate only background-level signal.  Of the few hits obtained, the best contained 
single amino acid changes of Asp-98Gly and Arg-250Glu, but the improvement in activity 
was found to be minimal (< 15 %) when rescreened.  Despite the limited improvement achieved, 
the developed screening method could potentially be useful for screening of FrbF with other 
substrates, for the improvement of other properties of FrbF, or for the evolution of other N-
acetyltransferases. 
 
2.3 Conclusions and Outlook 
In this study, we biochemically characterized the N-acetyltransferase FrbF from the FR-900098 
biosynthetic cluster.  Kinetic parameters were determined with acetyl-CoA, the native acyl-
donor, and CMP-5’-3APn, a surrogate phosphonate substrate.  Additionally, we identified a 
rapid, non-enzymatic oxidation of the native hydroxylamine substrate, CMP-5’-H3APn, to its 
nitroso derivative.  Although this prevented the measurement of kinetic parameters with this 
substrate, we nevertheless demonstrated via in situ generation of CMP-5’-H3APn that this 
compound is in fact the preferred substrate for FrbF.  Further, we demonstrated that FrbF 
exhibits reasonably high substrate specificity for acetyl-CoA as its acyl-donor, as relative activity 
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levels fell significantly with increasing substrate size.  For propionyl-CoA, this was due 
predominantly to a decrease in kcat, indicating that it is likely hindrance of attack by the 
nucleophilic substrate, and not of binding, that lowers activity with novel acyl-donors.  To 
elucidate the roles of key active site residues in catalysis, we employed a site-directed 
mutagenesis approach. 
 
Using the knowledge gained here, we synthesized the propionyl derivative of FR-900098, called 
FR-900098P, both through in vitro enzymatic reactions and through in vivo transformations.  For 
the latter approach, a metabolically engineered strain was employed along with a mutasynthetic 
strategy to boost production of the desired FR-900098 analog.  To assess the antimalarial 
potential of FR-900098P, we expressed and characterized DXP reductoisomerase, its target 
enzyme from P. falciparum.  Inhibition constants were determined for fosmidomycin, FR-
900098, and FR-900098P, revealing the latter to be the superior inhibitor.  Finally, a colorimetric 
screening method was developed to identify FrbF mutants with improved activity. 
 
Moving forward, chemical modification of FR-900098P could be employed to generate a more 
potent drug candidate for in vivo testing.  Addition of ester groups to mask the phosphonic acid 
moiety, as has been demonstrated with fosmidomycin and FR-900098, would be expected to 
yield similar improvements in efficacy.  Beyond FR-900098P, the screening assay developed 
here can be employed to pursue other FR-900098 derivatives with other acyl substituents, as 
detection relies only on the formation of the free coenzyme A product.  The best FrbF mutants 
can then be integrated into the FR-900098 gene cluster to improve heterologous production.   
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Additionally, FR-900098 pathway optimization efforts are actively being pursued in the Zhao 
lab.  The current heterologous FR-900098 pathway in E. coli utilizes a strong T7 promoter for 
every pathway gene, which introduces a heavy metabolic burden on the cell.  To alleviate this 
burden, the expression levels of each gene need to be balanced.  Further metabolic engineering is 
also being investigated to increase overall flux through the FR-900098 synthetic pathway.  The 
results of both of these approaches will be readily applicable to the production of novel FR-
900098 derivatives.  Finally, characterization of FrbF, a representative of a new class of N-
acetyltransferases, may facilitate future studies of previously uncharacterized members of this 
family, which could lead to the discovery of new and interesting secondary metabolite gene 
clusters. 
 
2.4 Materials and Methods 
2.4.1 Strains, media and reagents 
The Escherichia coli cloning strain DH5α, expression strain BL21(DE3) and the expression 
vector pET28a were obtained from EMD Biosciences (San Diego, CA).  Antibiotics and 
isopropyl-β-D-1-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. 
Louis, MO).  All chemicals, including reaction buffers and the reagents samarium diiodide, 
cytidine triphosphate (CTP), 2-amino-4-phosphonobutyrate (2APn), and all acyl-CoAs, were 
purchased from Sigma-Aldrich (St. Louis, MO) except for the co-factor NADPH, which was 
purchased from Applichem (Darmstadt, Germany), and 1-deoxy-D-xylulose 5-phosphate (DXP), 
which was purchased from Echelon Biosciences (Salt Lake City, UT).  Organic solvents were 
purchased from Thermo-Fisher Scientific (Pittsburgh, PA).  All PCR reagents and restriction 
enzymes were purchased from New England Biolabs (Ipswich, MA), and DNA Miniprep and 
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Gel Purification Kits were purchased from Qiagen (Valencia, CA).  All primers were synthesized 
by Integrated DNA Technologies (Coralville, IA).  Talon Cobalt immobilized metal affinity 
chromatography (IMAC) resin was purchased from Clontech Laboratories (Mountain View, 
CA).  All other materials were purchased from Thermo-Fisher Scientific (Pittsburgh, PA). 
 
2.4.2 Protein expression and purification 
The E. coli BL21(DE3) strains containing pET28a-FrbF, pET28a-FrbG, and pET28a-FrbH were 
previously prepared via ligation of the respective ORFs between the NdeI and HindIII restriction 
sites.  The complete dxr gene from Plasmodium falciparum was codon-optimized for expression 
in E. coli by DNA 2.0 (Menlo Park, CA).  The core enzyme sequence (without nucleotides 1-
216, corresponding to the 72 amino acid leader peptide) was PCR amplified with added NdeI and 
HindIII restriction sites and cloned into the respective sites of vector pET28a, introducing an N-
terminal His6 tag to the protein.  E. coli BL21(DE3) was transformed with the resulting construct 
by electroporation.  Cells were grown in Terrific Broth (TB) media supplemented with 
kanamycin (50 μg/mL) at 37 °C to an OD600 of ~0.8, after which induction was carried out by 
addition of 0.3 mM IPTG (for frb constructs) or 0.5 mM IPTG (for dxr construct) at 25 °C.  In 
the case of FrbH, IPTG induction was accompanied by addition of 50 µg/mL pyridoxal-5’-
phosphate (PLP).  After 18 hr, the cells were harvested by centrifugation at 7500 rpm for 15 min 
and resuspended in 20 mM Tris-HCl (pH 7.65), 0.5 M NaCl, and 15 % glycerol supplemented 
with 1 mg/mL lysozyme.  After a freeze-thaw cycle at -80 °C, the cell suspension was sonicated 
to ensure sufficient lysis.  The lysate was clarified multiple times by centrifugation at 15000 rpm 
for 15 min, after which the His6-tagged proteins were purified by affinity chromatography on 
TALON Superflow Co
2+
 resin coupled to fast-performance liquid chromatography.  The eluted 
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proteins were washed three times in 50 mM HEPES (pH 7.25), concentrated, and stored in 15 % 
glycerol at -80 °C. 
 
2.4.3 Generation of mutants 
Mutants of the FrbF and PfDxr enzymes were generated by the megaprimer PCR method.  
Briefly, primers were designed at the site of interest containing the desired mutation such that a 
larger primer (a “megaprimer”) containing the mutation could be generated by PCR, using the 
regular forward or reverse primer as the second primer (whichever yielded the shortest PCR 
product).  Next, PCR amplification of the full-length mutant gene was carried out using the 
megaprimer at one end of the gene and the regular primer at the opposite end.  Finally, the full 
length gene containing the mutation was digested with NdeI and HindIII and ligated into the 
similarly digested pET28a vector backbone.  The ligation product was then used to transform the 
E. coli cloning strain DH5α.  Transformants were picked and grown in 5 mL LB + 50 µg/mL 
kanamycin.  Their plasmids were isolated and sequenced by the UIUC Core Sequencing Facility 
(Urbana, IL) or ACGT, Inc. (Wheeling, IL), and Sequencher software (Gene Codes Corporation, 
Ann Arbor, MI) was used to confirm the presence of only the desired mutation.  The correct 
plasmids were then used to transform the expression strain E. coli BL21(DE3), and frozen stocks 
of the resultant strains were stored in 15 % glycerol at -80 °C. 
 
2.4.4 Preparation of CMP-5’-3APn 
CMP-5’-3APn for kinetic and relative activity assays was synthesized enzymatically using 
purified N-His6-FrbH.  Synthesis was carried out in 50 mM HEPES buffer (pH 7.25) with 1.5 
mM CTP, 3 mM 2APn, 10 mM MgCl2, and ~10 µM FrbH at 30 °C for 4 hr.  Following removal 
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of FrbH with a 10 kDa cutoff Amicon centrifugal filter unit (Millipore, Billerica, MA), the 
product was purified by fractionation on an Agilent 1100 Series HPLC (Agilent, Palo Alto, CA) 
using an Alltech Prevail C18 reverse phase column (Grace Davison Discovery Sciences, 
Deerfield, IL) with isocratic flow of 15 mM ammonium formate buffer.  Fractions containing the 
product were pooled, lyophilized, and resuspended in double-distilled water.  The concentration 
of the purified CMP-5’-3APn product was determined by UV absorbance at 254 nm. 
 
2.4.5 CMP-5’-H3APn oxidation assays 
Enzymatic synthesis of CMP-5’-H3APn was performed using purified N-His6-FrbG.  Reactions 
were carried out in 50 mM HEPES buffer (pH 7.25) with 500 µM CMP-5’-3APn, 500 µM 
NADPH, and ~30 µM FrbG at 30 °C for 15 min.  Following removal of FrbG with a 10 kDa 
cutoff Amicon centrifugal filter unit, the product mixture was incubated at 30 °C.  Samples were 
collected at specified time points and kept on dry ice until analysis using an Agilent XCT ion-
trap MSD mass spectrometer at the Roy J. Carver Metabolomics Center (University of Illinois, 
Urbana, IL).  Chemical synthesis of CMP-5’-H3APn was performed using the oxidation product 
CMP-5’-NO3APn, which was purified from FrbG reaction mixtures via HPLC fractionation.  
Reduction of the nitroso to the hydroxylamine was performed anaerobically following the 
method of Kende and Mendoza [68].  In an anaerobic chamber, the lyophilized nitroso 
compound was resuspended in a mixture of tetrahydrofuran (THF) and methanol (95%/5% v/v).  
To this solution was added a 4-fold molar excess of samarium diiodide in THF.  Following 
agitation for 3 min at room temperature, the reaction was acidified with 0.1 % trifluoroacetic 
acid and extracted with ethyl acetate.  The product solution was then analyzed by LC-MS both 
before and after aerobic exposure. 
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2.4.6 FrbF kinetic assays 
All activity assays were performed with N-His6-tagged FrbF in 50 mM HEPES buffer (pH 7.25) 
at 30 °C.  For determination of kinetic parameters, the concentration of one substrate was 
maintained at 400 µM, while the other substrate concentration was varied from 0 – 1000 µM.  
Samples were collected over a 7 minute time course for product quantitation and determination 
of initial rate.  Reactions were initiated with the addition of 1.3 µM FrbF and quenched with 1 % 
trifluoroacetic acid.  All assays were performed in triplicate.  Kinetic parameters were fit to the 
data using nonlinear least-squares regression in OriginPro 8 (OriginLab Corporation, 
Northampton, MA).  Relative activity assays with alternate CoA substrates were performed with 
400 µM CMP-5’-3APn and 200 µM of the CoA compound.  Reactions were initiated with 15 
µM FrbF, and samples were collected over a 60 minute time course.  For substrates for which no 
activity was detected in this time, the assay time was extended up to 12 hr.  For all assays, 
products were detected by UV absorbance at 254 nm on an Agilent 1100 Series HPLC (Agilent, 
Palo Alto, CA), with retention times confirmed using an Agilent XCT ion-trap MSD mass 
spectrometer at the Roy J. Carver Metabolomics Center (University of Illinois, Urbana, IL).  For 
all LC-MS analyses with alternate CoA substrates, product identities were confirmed based on 
detection of the expected m/z parent ion with a corresponding m/z = 322
-
 (CMP) daughter ion in 
the MS/MS profile.  
 
2.4.7 FrbF relative activity assays 
Relative activity assays with purified N-His6-tagged FrbF mutants were performed with 400 µM 
CMP-5’-3APn and 200 µM acetyl-CoA over a 7 minute time course.  For those mutants that 
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exhibited significantly reduced activity, the assay time was extended up to 60 minutes.  Samples 
were collected and analyzed as described above. 
 
2.4.8 PfDxr kinetic assays 
All kinetic assays were carried out with N-His6-tagged PfDxr in 100 mM Tris-HCl buffer (pH 
7.5).  Determination of kinetic parameters was carried out in a total volume of 300 µL with 1 
mM MnCl2, 0.3 mM NADPH, and 50 nM enzyme while the DXP concentration was varied from 
0 – 250 µM.  Oxidation of NADPH was continuously monitored via absorbance at 340 nm in a 
Nanodrop 2000c spectrophotometer (Thermo Scientific, Wilmington, DE) at 37 °C for a 
maximum of 5 min.  All assays were performed in triplicate.  Michaelis-Menten kinetic 
parameters were fit to the data using OriginPro 8 software (OriginLab Corporation, 
Northampton, MA).  Due to the instability of the PfDxr enzyme, a fresh aliquot was used for 
each independent assay. 
 
2.4.9 PfDxr inhibition assays 
All inhibition assays were carried out with N-His6-tagged PfDxr in 100 mM Tris-HCl buffer (pH 
7.5).  To determine inhibition constants for fosmidomycin, FR-900098, and FR-900098P, kinetic 
assays were performed at multiple concentrations of each inhibitor ranging from 0 – 10 nM.  At 
each inhibitor concentration, Km values were determined, with reactions carried out at 37 °C in a 
total volume of 300 µL with 1 mM MnCl2, 0.3 mM NADPH, and 50 nM enzyme while the DXP 
concentration was varied from 0 – 250 µM.  From the measured Km values, Ki values were 
determined using the equation for competitive inhibition.  This procedure was repeated in 
triplicate for each inhibitor. 
110 
 
2.4.10 In vitro FR-900098P synthesis 
Synthesis of FR-900098P in vitro was carried out with the purified N-His6-tagged FrbF, FrbG, 
FrbH, and FrbI enzymes and commercially available substrates.  First, cytidine monophosphate-
5’-3-aminopropylphosphonate (CMP-5’-3APn) was synthesized in 50 mM HEPES buffer, pH 
7.25, containing 1.5 mM cytidine triphosphate (CTP), 3 mM 2-amino-4-phosphonobutyrate 
(2APn), 10 mM MgCl2, and ~10 µM FrbH with incubation at 30 °C for 4 hours, after which 
nearly complete conversion was observed.  Following removal of FrbH with a 10 kDa cutoff 
filter, CMP-5’-FR-900098P was synthesized by addition of 1.5 mM NADPH, 1.5 mM propionyl-
CoA, ~10 µM FrbF, and ~15 µM FrbG with incubation at 30 °C for 4 hours.  At this point, side 
products such as CMP-5’-2-amino-4-phosphonobutyrate (CMP-5’-2APn), CMP-5’-N-propionyl-
3-aminopropylphosphonate (CMP-5’-P3APn), CMP, CDP, and NADP+ were removed via  
fractionation on an Agilent 1100 Series HPLC using an Alltech Prevail C18 column with 
isocratic 15 mM ammonium formate elution.  The resulting CMP-5’-FR-900098P was 
lyophilized and resuspended in double-distilled H2O.  Finally, CMP cleavage was carried out in 
10 mM Tris-HCl buffer, pH 7.5, by addition of ~10 µM FrbI with incubation at 30 °C for 4 
hours.  The final product titer was estimated from the concentration of CMP-5’-FR-900098P 
(measured by UV absorbance at 254 nm) and confirmed by dry weight of the final lyophilized 
product.  Correct identity and purity of the final product was determined using an Agilent XCT 
ion-trap MSD mass spectrometer, where the anticipated m/z = 212
+
 parent ion and m/z = 138
+
 
daughter ion were observed. 
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2.4.11 In vivo FR-900098P synthesis 
Synthesis of FR-900098P in vivo was carried out in two different E. coli expression strains.  The 
first was a BL21(DE3) strain transformed with three compatible plasmids containing the entire 
FR-900098 biosynthetic pathway except for the nucleotide hydrolase FrbI.  This strain was 
previously prepared and described by Johannes and DeSieno, et al. [53].  The second FR-
900098P expression strain was prepared from the metabolically engineered BAP1 strain 
provided by Dr. Blaine Pfeifer, which has been genetically modified to block conversion of 
propionyl-CoA to succinate and pyruvate for central metabolism [66].  This strain was 
transformed with the same three-plasmid FR-900098 production system.  Successful 
transformation was confirmed by diagnostic PCR amplification of a pathway gene from each 
plasmid.  Both strains were cultured in 50 mL LB medium supplemented with kanamycin (50 
µg/mL), ampicillin (100 µg/mL), and chloramphenicol (25 µg/mL) at 37 °C to an OD600 of ~0.8.  
At this point, expression of the FR-900098 pathway enzymes was induced at 30 °C by addition 
of 0.5 mM IPTG, as well as 20 mM sodium propionate to increase propionyl-CoA synthesis.  
Samples of culture supernatant were collected at multiple time points up to 94 hr and clarified 
via centrifugation at 13,200 rpm for 10 min.  Analysis of clarified samples was carried out on an 
Agilent XCT ion-trap MSD mass spectrometer with a 100 x 4.6 mm Synergi 4µ Fusion-RP 80A 
column (Phenomenex, Torrance, CA) using 0.1 % formic acid in H2O (mobile phase A) and 
acetonitrile (mobile phase B) with the following elution program: 0 % B to 40 % B over 10 min; 
40 % B to 100 % B over 3 min; and 100 % B for an additional 5 min.  Products were identified 
in positive mode by their expected m/z values (198 for FR-900098, 212 for FR-900098P) with 
the corresponding m/z = 138 daughter ion. 
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2.4.12 FrbF saturation mutagenesis 
The FrbF crystal structure was visualized using Molecular Operating Environment software 
(Chemical Computing Group, Montreal, Canada).  Residues within 6 Å of the acetyl-CoA acyl 
group were selected as saturation mutagenesis candidates, with the exception of those identified 
as catalytically requisite.  Saturation mutagenesis was carried out using primers containing a 
randomized codon at the site of interest, and the mutant FrbF constructs were generated using the 
megaprimer PCR method described above.  Libraries of FrbF mutants were digested with the 
restriction enzymes NdeI and HindIII and ligated into the respective sites of the correspondingly 
digested pET28a vector.  Following transformation of BL21(DE3) and selection on LB plates 
containing kanamycin (50 µg/mL), plasmids were isolated from multiple colonies in each library 
and sequenced to confirm diversity at the targeted amino acid position. 
 
2.4.13 FrbF error-prone PCR 
Error-prone PCR was performed in mutagenic buffer consisting of 7 mM MgCl2, 50 mM KCl, 
10 mM Tris, and 0.01 % w/v gelatin, adjusted to pH 8.3 with HCl.  A biased nucleotide mixture 
comprised of 1 mM dCTP, 1 mM dTTP, 0.2 mM dATP, and 0.2 mM dGTP (final 
concentrations) was used in all PCR reactions, along with forward and reverse primers (0.5 µM 
each), the pET28a-frbF template (50 ng), Taq ligase (1 µL), and MnCl2 ranging from 0.05 to 
0.15 mM.  Reactions were cycled 24 times, with a 58 °C annealing step and a 2 minute extension 
time in each cycle.  The subsequent PCR product was gel-purified, digested with NdeI and 
HindIII, and ligated into vector pET28a.  Ten clones from each library were picked for 
sequencing to estimate the frequency of mutation in the frbF gene. 
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2.4.14 FrbF screening method 
Screening of FrbF mutant libraries was performed in a high-throughput microtiter plate assay.  
Using sterile toothpicks, individual colonies were picked from library transformation plates to 
the wells of a 96-well plate containing 100 µL of LB medium supplemented with kanamycin (50 
µg/mL) per well.  Following overnight growth to saturation at 37 °C, 5 µL from each well was 
used to inoculated 100 µL of fresh LB + kanamycin in a separate plate.  This plate was then 
incubated at 37 °C until an average OD600 of ~1.2 was reached, at which point 100 µL of LB + 
kanamycin supplemented with 0.6 mM IPTG was added to each well, yielding a final 
concentration of 0.3 mM IPTG.  Induced plates were incubated at 30 °C overnight to allow FrbF 
overexpression.  Afterward, the cells were pelleted by centrifugation at 4000 rpm for 10 min and 
resuspended in 100 µL of 50 mM HEPES buffer (pH 7.25) supplemented with 1 mg/mL 
lysozyme.  Following incubation at room temperature for 30 min, the lysis plate was subjected to 
a freeze-thaw cycle at -80 °C.  Immediately before the assay was performed, the plate was 
thawed and the cell lysate clarified via centrifugation at 4000 rpm for 10 min at 4 °C.  To 
perform the assay, 30 µL of lysate from each well was added to two separate 96-well plates.  To 
the first plate was added 50 µL of 10 mM DTNB and 70 µL of 50 mM HEPES buffer (pH 7.25), 
and the absorbance at 412 nm was measured immediately.  To the second plate was added 70 µL 
of the assay mixture, which contained (final concentrations): 400 µM CMP-5’-3APn, 400 µM 
NADPH, 300 µM of the alternate CoA substrate, and 4.8 µM FrbG in 50 mM HEPES buffer.  
The second plate was incubated at 30 °C for 60 min, after which 50 µL of 10 mM DTNB was 
added to each well and the absorbance at 412 nm was measured.  The difference between the two 
measured absorbance values was taken as an estimate of the total amount of product generated. 
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CHAPTER 3. Cloning and expression of polyketide synthases from 
Talaromyces marneffei 
 
3.1 Introduction 
3.1.1 Fungal secondary metabolites 
Fungal secondary metabolites are well-known for their diversity of bioactive properties, making 
them particularly attractive leads for drug development.  Following the fortuitous discovery of 
penicillin from Penicillium chrysogenum as a potent antibiotic, research interest in fungal natural 
products has remained strong for several decades [1].  Many fungal natural products have had 
profound impacts in the human health sector, including the aforementioned penicillin and the 
related cephalosporin antibiotics; cyclosporine, widely used as an immunosuppressant as well as 
a treatment for dry eye syndrome; and lovastatin, a blockbuster cholesterol-lowering drug [2] 
(Figure 3.1).  At the other end of the spectrum, fungal natural products can also have severe 
adverse health effects, such as the carcinogenic aflatoxins [3] and the nephrotoxic citrinin [4].  
Thus, current research on fungal natural products focuses on understanding their biosynthesis 
and activity as both curative and causative agents. 
 
Fungal natural products belong to diverse classes, including non-ribosomal peptides, assembled 
from amino acids by nonribosomal peptide synthetases (NRPSs); terpenes, assembled from 
activated isoprene precursors; and polyketides, assembled from acyl-Coenzyme A building 
blocks by polyketide synthases (PKSs) [1].  Although their structures vary widely, conserved 
motifs in some of the key enzymes involved in fungal natural product biosynthesis enable rapid 
identification of putative gene clusters from genome sequence data.  NRPS and PKS 
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megasynthases, for example, feature well conserved adenylation domains and ketosynthase 
domains, respectively, while indole alkaloid clusters feature distinct dimethylallyltryptophan 
synthases (DMATSs) [5].  As a result, bioinformatics tools for the in silico analysis of natural 
product gene clusters are plentiful [6]. 
 
Figure 3.1: Representative fungal natural products with therapeutic properties. 
 
3.1.2 Fungal genome mining 
A key finding of genome mining efforts in fungi has been the great abundance of gene clusters, 
far in excess of any expectations based on previously isolated compounds from fungal strains.  
This is particularly true in certain fungal genera, such as the Aspergilli.  Aspergillus nidulans [7], 
Aspergillus oryzae and Aspergillus terreus [5], for example, each feature more than 50 putative 
secondary metabolite gene clusters.  Of note, the prediction of gene cluster boundaries by 
bioinformatics alone is difficult given the unknown functions of most genes in a sequenced 
genome.  Recently, it has been demonstrated that microarray profiling of gene expression can 
greatly aid this process, as genes in the same pathway tend to exhibit similar expression patterns 
[8]. 
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Regardless of the exact number of gene clusters in a given genome, the large numbers of genes 
encoding key synthetic enzymes suggests a great diversity of natural products.  In A. nidulans 
alone, a total of 83 secondary metabolites have been discovered to date [7], with the vast 
majority discovered after the 2005 publication of the A. nidulans genome sequence [9].  Notably, 
many gene clusters produce several analogs of the same compound via differential decoration of 
a core scaffold, increasing the diversity of natural products synthesized even further.  As an 
example, five emericellamide analogs have been observed from one gene cluster [10].  
Nevertheless, more than 30 gene clusters in A. nidulans have still not been linked to any 
secondary metabolites, suggesting that there is still much left to uncover. 
 
Outside of the well-studied A. nidulans, knowledge of the untapped potential of fungi for natural 
product synthesis has led to the application of a variety of techniques to elicit the expression of 
silent gene clusters.  For example, epigenetic modifications of Cladosporium cladosporioides led 
to the activation of gene clusters for cladochromes, calphostin B, and oxylipins [11].  Co-culture 
with a bacterium elicited rhizoxin production from Rhizopus microspores [12].  To elicit 
production of sorbicillamines from marine fungus Penicillium sp. F23–2, culture agitation rate 
was varied [13].  Further examples in recent literature are too numerous to list. 
 
Notably, all of the results described above depend on cultivation or even genetic manipulation of 
the fungal strain containing silent pathways of interest.  However, not all fungi are as amenable 
to these approaches as, for example, the well-studied Aspergilli.  Fungi occupying very specific 
niches in their natural environments may not be suitable for laboratory cultivation.  For fungi 
exhibiting significant pathogenicity, laboratory cultivation may simply be undesirable.  Further, 
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the lack of genetic tools available for most fungal strains limits the number of techniques that can 
be applied for natural product discovery to only the most non-specific, hit-or-miss approaches.  
Reconstitution of target gene clusters in genetically tractable model organisms stands as an 
alternative to cultivation or genetic manipulation of the native host. 
 
The goal of the work presented here is to demonstrate heterologous expression in S. cerevisiae as 
a general strategy for the activation of natural product gene clusters from fungal species.  
Sequenced fungal genomes will be mined for candidate gene clusters, with a focus on those 
containing polyketide synthases.  The chosen genes will be assembled in strong S. cerevisiae 
expression cassettes, and culture extracts will be analyzed by HPLC-MS/MS for the production 
of novel compounds.  In vitro reconstitution will also be attempted for enzymes of interest. 
 
3.2 Results and Discussion 
3.2.1 Target identification and analysis 
To identify interesting fungal polyketide gene clusters for refactoring, the SMURF program was 
employed [5].  A total of 27 sequenced genomes were initially studied.  The results were first 
analyzed manually to identify clusters that had reasonably well-defined boundaries; did not 
contain too many genes, to facilitate efficient assembly; shared some similarity to characterized 
PKSs, such that product prediction would be feasible; and contained a different set of tailoring 
genes than any characterized PKS cluster, to increase the chance of discovering a novel product.  
Eventually, Talaromyces marneffei (formerly Penicillium marneffei) was chosen for more in-
depth analysis, as its genome was relatively well annotated, and it contained a marked abundance 
of putative PKS genes (25 in total) [14].  Further, at the outset of the project, only one PKS 
128 
 
product, melanin, had been reported from T. marneffei.  Thus, there exists a large potential space 
for polyketide discovery from this strain. 
 
Table 3.1: Annotation of the pks16/pks17 cluster from T. marneffei 
Gene ID Annotation, Domain Architecture Predicted Introns (NCBI) 
61670 (pks17) HR-PKS, KS-AT-DH-ER-KR-ACP 4 
61680 PKS  fragment, ACP-TE only -- 
61690 O-methyltransferase 2 
61700 Dithiol-disulfide isomerase/DSBA-like thioredoxin -- 
61710 FMO hydroxylase 6 
61720 (pks16) NR-PKS, KS-AT-ACP-TE 3 
61730  Trp-halogenase 4 
61740 Zn2C6 transcription factor -- 
61750 MFS transporter -- 
61760 Zn2C6 transcription factor -- 
 
Among all the PKS gene clusters in the sequenced genome, the cluster containing genes pks16 
and pks17 was first chosen for full-cluster refactoring.  The putative gene cluster (Table 3.1) 
contains two polyketide synthases, one non-reducing (NR) and one highly-reducing (HR), 
expected to synthesize a resorcylic acid lactone (RAL) scaffold.  In characterized gene clusters 
of this nature, the HR-PKS accepts standard CoA substrates (e.g., malonyl-CoA) to synthesize a 
reduced product that is subsequently passed to the NR-PKS for further elaboration and 
cyclization [15].  The majority of the characterized PKSs in this class produce benzenediol 
lactone (BDL) compounds, which feature a benzenediol moiety fused to a macrocycle of 12- to 
14-members [16].  Among these, the RALs have been studied in the most detail [17], although 
dihydroxyphenylacetic acid lactones (DALs) have also been the subject of investigation [18].  
RALs have garnered significant interest due to the diversity of bioactivities observed by the 
compounds sharing their unique pharmacophore (Figure 3.2). 
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Figure 3.2: Structure and bioactivity of several known resorcylic acid lactones, adapted from ref. 17. 
 
Bioinformatic analysis of the T. marneffei pks16/pks17 cluster revealed relatively high homology 
(47 % amino acid identity, 64 % similarity) of PKS17 with the highly-reducing PKS of the 
radicicol gene cluster in Chaetomium chiversii [19].  Other characterized PKSs from RAL 
clusters occupied high positions in the BLAST results, all at ~ 40 % amino acid identity.  Similar 
observations were made for the non-reducing PKS16. 
 
Among the other genes in the cluster are three putative tailoring enzymes.  PMAA_061690 was 
predicted to encode an O-methyltransferase.  Although an analogous function is found in the 
hypothemycin gene cluster of Hypomyces subiculosis [20], similarity between the two encoded 
proteins was found to be low (23 % amino acid identity over 63 % query coverage).  Gene 
PMAA_061710 was predicted to encode a flavin-dependent monooxygenase, while 
PMAA_061730 was predicted to encode a halogenase.  Here, significant similarity (64 % at the 
amino acid level) was found between the putative halogenase and those of the characterized C. 
chiversii and M. chlamydosporia radicicol clusters [19,20].  Based on this analysis, the product 
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of the target cluster is anticipated to be a RAL similar to radicicol or hypothemycin.  However, 
the particular set of tailoring genes identified here does not match those of the characterized 
RAL compounds, suggesting a new member of this class. 
 
Also included in the cluster is PMAA_061680, which encodes only a phosphopantetheine-
binding domain and a thioesterase.  However, as PKS16 also includes a thioesterase domain, it is 
unclear as to whether PMAA_061680 would be necessary for product release.  Gene 
PMAA_061700 encodes a putative dithiol-disulfide isomerase.  Similar genes have been found 
in multiple actinomycete gene clusters and the Aspergillus clavatus cytochalasin gene cluster, 
and are thought to be involved in redox sensing [21-23].  However, their exact role in 
biosynthesis is unknown.  Finally, two putative transcription factors are encoded in the gene 
cluster, along with a putative major facilitator superfamily transporter. 
 
3.2.2 Refactoring the pks16/pks17 putative resorcylic acid lactone cluster 
3.2.2.1 Assembly and initial analysis 
To refactor the putative RAL cluster from T. marneffei for expression in Saccharomyces 
cerevisiae, an assembly scheme was devised (Figure 3.3).  First, individual open reading frames 
(including both introns and exons) were amplified from the genomic DNA of T. marneffei.  Next, 
individual exons were amplified for assembly into single-gene expression cassettes with strong 
S. cerevisiae promoters [24] on a series of helper plasmids.  For the PKS genes, assembly of the 
exons was carried out with the linearized helper plasmid via in vivo homologous recombination 
in yeast.  For the tailoring genes, exons were first spliced by overlap-extension PCR, followed by 
assembly of the coding sequence with the linearized helper plasmid in yeast.  Helper plasmids 
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were designed such that each expression cassette was immediately preceded by the terminator of 
the previous cassette.  Thus, by PCR amplification of the terminator-promoter-gene-terminator 
cassettes from the five assembled helper plasmids, five linear fragments were generated with 
long overlaps for yeast in vivo assembly of the full five-gene cluster. 
 
 
Figure 3.3: Cluster assembly scheme.  Exons are amplified from genomic DNA, spliced into complete coding 
sequences, and assembled into helper plasmids.  Single-gene cassettes are then amplified from helper plasmids and 
assembled into a full cluster plasmid. 
 
Following cluster assembly and confirmation by restriction digestion and diagnostic PCR (data 
not shown), the full cluster was transformed into S. cerevisiae strain HZ848 along with the 
Aspergillus nidulans phosphopantetheinyl transferase gene npgA on plasmid pRS416.  A 
negative control strain was also prepared with empty plasmid pRS414 and pRS416-npgA.  
Transformants were grown in both SC and YPAD medium.  Culture extracts were analyzed by 
HPLC-MS for the presence of new UV peaks that eluted around the expected time for a RAL 
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compound (as assessed by similar analysis of commercially available RAL standards), including 
one that showed up in both media at 19.5min (Figure 3.4). 
 
 
Figure 3.4: UV traces from samples grown in YPAD (left) and SC (right). 
 
Isolation of the 19.5 min peak led to determination of a mass of 399.2 (398.2 in negative node, 
400.2 in positive mode) and a chemical formula of C24H34O4N.  Notably, the predicted formula 
did not include an anticipated halogen atom, and instead included an unexpected nitrogen atom.  
However, although production of the peak of interest was observed in initial replicate cultures of 
the two-plasmid strain, subsequent replicates no longer showed production.  After several 
troubleshooting measures, including reassembly of the cluster, retransformation of the plasmids, 
and transfer of the plasmid to a new S. cerevisiae host with integrated chromosomally integrated 
npgA (strain BJ5464-NpgA), the new peak could not be recovered.  Addition of a sixth gene to 
the refactored cluster, PMAA_061680 (encoding a thioesterase) also did not lead to reproducible 
production of a new peak in the UV trace. 
 
3.2.2.2 Confirmation at the transcriptional and translational levels 
As a means of confirming the functionality of the refactored plasmid, diagnostic checks were 
employed at the transcriptional and translational levels.  At the transcript level, reverse 
transcriptase PCR (RT-PCR) was first carried out to qualitatively assess the transcription of each 
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gene in the cluster, yielding positive results (data not shown).  To provide a qualitative 
assessment, quantitative PCR (qPCR) was next employed at three time points in both the HZ848 
and BJ5464-NpgA hosts.  Transcription of all five genes was seen in both hosts (Figure 3.5), 
albeit at relatively low levels comparable to the alg9 standard. 
 
 
Figure 3.5: Transcript levels of the refactored gene cluster in (a) HZ848 and (b) BJ5464-NpgA. 
 
As transcription of each gene in the cluster was observed by qPCR, protein-level detection was 
attempted next.  For this study, each gene was tagged with an N-terminal His6 tag in its 
corresponding helper plasmid and assessed individually.  However, both Coomassie staining and 
anti-His Western blotting failed to identify expression.  Next, affinity purification of the His-
tagged proteins from BJ5464-NpgA lysate was attempted.  Following concentration of the 
collected fractions, the target protein could be observed for both the O-methyltransferase and the 
FMO (Figure 3.6).  However, expression of the halogenase and the two PKSs could not be 
observed, even when switched to a multi-copy plasmid.  Notably, the BJ5464-NpgA strain 
produces two other proteins that appear on an anti-His Western blot.  Activity assays with the 
partially purified O-methyltransferase protein were attempted using a zearalenone substrate, but 
no activity was detected. 
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Figure 3.6: Anti-His6 Western blotting results following expression from single-copy helper plasmids with 
constitutive promoters and Ni-NTA purification. 
 
Given the poor protein expression results with our panel of constitutive promoters, expression 
was also tested using the ADH2 promoter.  This promoter is repressed in the presence of glucose, 
but strongly active in its absence, and has previously been used to over-express PKSs in S. 
cerevisiae [15].  As a positive control, we used this promoter to over-express Hpm8 from the 
hypothemycin cluster, and a band of the correct size was observed by SDS-PAGE and Western 
blot (data not shown).  However, when paired with pks16 or pks17 on single or multi-copy 
plasmids, expression of the target proteins was still not observed. 
 
A disadvantage of Western blotting with large proteins, such as PKSs, is that with only one tag 
per protein, sensitivity on a mass basis becomes relatively poor as protein size increases.  Thus, 
to increase the sensitivity of detection, the His6-tags in the ADH2p PKS expression plasmids 
were replaced with 3xFLAG tags, purported to be 100-fold more sensitive.  With this addition, 
expression of PKS16 was detected in cell lysate (Figure 3.7).  However, PKS17 still could not be 
observed.  Thus, it was concluded that pks17 was not amenable to expression in S. cerevisiae. 
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Figure 3.7: Anti-FLAG Western blotting reveals expression of PKS16 only. 
 
3.2.2.3 In vitro assays 
At this point, soluble expression in S. cerevisiae was found to be the significant obstacle to 
product formation from this cluster.  As an alternative means to demonstrate production, 
expression of the enzymes in E. coli was attempted.  Notably, the two PKSs in the hypothemycin 
gene cluster have been reconstituted in vitro, suggesting the viability of this approach [15].  All 
five of the genes were individually cloned into the pET28a expression vector.  While each of the 
three tailoring proteins could be expressed and purified, the PKS proteins, showed no detectable 
expression either in the soluble or insoluble protein fractions. 
 
Even though the PKSs could not be expressed in E. coli or S. cerevisiae, in vitro assays were 
attempted with the purified tailoring enzymes.  Here, the commercially available zearalenone or 
radicicol were used as surrogate substrates, as they are expected to be structurally similar to the 
product of PKS16 and PKS17.  To assist the halogenase, the flavin reductase SsuE from E. coli 
was also cloned and purified.  Interestingly, though no activity was observed for the O-
methyltransferase or the FMO, formation of a product with absorbance at 280 nm was observed 
when zearalenone was incubated with the halogenase (Figure 3.8).  The new peak exhibited an 
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m/z of 351.4 in negative mode, consistent with the addition of chlorine.  Further, the isotope 
distribution is consistent with that of a chlorinated product.  No activity was observed when the 
halogenase was incubated with zearalenone in the presence of other halogen salts, or when 
incubated with tryptophan (the substrate of other characterized halogenases RebH [25] and PrnA 
[26]).  Thus, this activity provides some evidence that the true substrate is in fact a zearalenone-
like macrolactone.  Nevertheless, as other halogenases with this function, significantly higher 
activity, and broader substrate scope have already been characterized [27,28], this particular 
halogenase was not investigated further. 
 
 
 
Figure 3.8: 280 nm UV traces show formation of a chloro-zearalenone product (m/z = 351), confirmed by LC-MS. 
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3.2.3 Expression of a panel of non-reducing PKSs 
Given the significant time and labor invested in the single pks16/pks17 gene cluster without 
detection of a novel product, subsequent studies focused on multiple clusters in parallel.  Rather 
than attempting full cluster refactoring from the outset, expression of only the PKS gene in each 
cluster was evaluated first.  For this study, only the non-reducing PKSs were considered, as they 
are expected to produce compounds with UV absorbance detectable by HPLC.  In total, eleven 
NR-PKSs were considered, including PKS1, PKS3, PKS4, PKS10, PKS11, PKS12, PKS14, 
PKS15, PKS18, PKS20, and PKS22 [14].  Additionally, PKS21 was included in the evaluation, 
as it is located in the neighborhood of PKS20 and is expected to cooperate with PKS20.  
Notably, PKS4 has previously been shown to be involved in melanin biosynthesis in T. 
marneffei, where knockdown experiments demonstrated loss of pigmentation [14].  Thus, PKS4 
can be expected to catalyze the synthesis of YWA1, the precursor of melanin in the fungal 
melanin pathway, and serves as a positive control. 
 
To evaluate protein expression, the pYAAFH helper plasmid was designed and constructed 
(Figure 3.9).  This plasmid features ADH2p and ADH2t for strong transcription, and N-terminal 
3xFLAG tag for protein detection, and a C-terminal His6 tag for affinity enrichment/purification.  
A unique AgeI recognition site was included between the two tags for assembly of the pks coding 
sequences at this position.  A 2µ replication origin was also included to boost copy number. 
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Figure 3.9: The pYAAFH plasmid for PKS expression. 
 
To assemble the PKS expression plasmids, each gene was first amplified from the genomic DNA 
of T. marneffei.  Next, the individual exons were amplified from the purified gene.  Finally, the 
purified exons were transformed with the linearized pYAAFH backbone into S. cerevisiae 
HZ848 for assembly.  All expression plasmids except for PKS11 could be successfully 
assembled in this manner, and were subsequently transformed into S. cerevisiae expression strain 
BJ5464-NpgA. 
 
Expression of the PKS proteins from BJ5464-NpgA was evaluated from small cultures by both 
Coomassie staining and anti-FLAG Western blotting of the cell lysate.  Interestingly, although 
no unique bands were observed for any of the expression strains by Coomassie staining (Figure 
3.10a), every strain was found to produce a unique band by Western blot (Figure 3.10b).  
Although the lack of apparent bands on the SDS-PAGE gels suggested very low expression 
levels for every PKS evaluated, it was suspected that expression might nevertheless be high 
enough for activity to be observed.  Detection of novel compounds from the PKS expression 
strains was attempted via HLPC-MS.  Each strain, however, was found to produce a nearly 
pYAAFH
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AgeI site 6xHis Tag + stop
URA3
AmpR
ADH2t
ADH2p
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identical UV profile (data not shown).  MS profiles were also analyzed, but also did not yield 
obvious new peaks. 
 
 
Figure 3.10: (a) Evaluation of PKS20 by Coomassie stain and anti-FLAG Western blot.  (b) Representative anti-
FLAG Western blot for three additional PKSs. 
 
3.2.4 Characterization and evaluation of PCK1p 
3.2.4.1 Characterization of strong S. cerevisiae promoters 
As the ADH2p promoter did not yield high expression levels for any of the PKSs evaluated, it 
was hypothesized that different promoters with strong expression profiles could help to increase 
protein levels.  In collaboration with Jonathan Ning, three such promoters (PCK1p, SIP18p, and 
SPG4p) were identified from the literature for further analysis [29].  To test protein expression 
driven by these promoters, each promoter was used to drive the catechol dioxygenase gene xylE 
from a multi-copy plasmid, and turnover of catechol was measured in cell lysate.  Two known 
promoters (ADH2p and TEF1p) were included in this assay for comparison.  As expected, the 
constitutive TEF1p control was found to exhibit the greatest XylE activity at the first time point 
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(24 hr).  However, at all subsequent time points PCK1p yielded the highest XylE activity (Figure 
3.11). 
 
 
Figure 3.11: XylE activity assay of promoter strength. 
 
3.2.4.2 Expression of pks4 under PCK1p 
Given the superior XylE activity observed under the PCK1p promoter, PCK1p was chosen to 
evaluate its capacity to drive PKS expression.  PKS4 was chosen for initial analysis, as it is 
expected to catalyze the synthesis of the known YWA1 product.  Replacement of ADH2p with 
PCK1p in the YAAFH-pks4 plasmid led to strong pigmentation in the BJ5464-NpgA production 
strain (Figure 3.12a).  The same phenotype was observed under SPG4p or SIP18p, but not 
observed in the empty plasmid control or with the ADH2p construct.  Interestingly, HPLC 
analysis of the extracted culture led to the identification of not one, but two significant new 
peaks in the UV profile eluting at 10.2 min and 11.2 min (Figure 3.12b). 
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Figure 3.12: (a) PKS4 expression leads to dark pigmentation in S. cerevisiae cultures and cell pellets.  (b) UV 
absorbance profiles (254 nm) reveal two new peaks in duplicate PKS4 expression strains (indicated with red 
arrows). 
 
Notably, PKS4 is a homolog of the PKS encoded by wA from Aspergillus nidulans (61 % amino 
acid identity).  This enzyme was originally thought to catalyze synthesis of citreoisocoumarin, 
evidenced by heterologous expression in Aspergillus oryzae [30].  However, a year later it was 
discovered that a single nucleotide had mistakenly been omitted from the originally published 
wA sequence [31], leading to inadvertent truncation of the TE domain in the subsequent cloning 
and heterologous expression.  When the full-length gene was re-cloned and expressed, it was 
found to in fact synthesize the YWA1 product [32], whereas citreoisocoumarin was a product of 
incorrect cyclization.  MS analysis of the PKS4 extract revealed masses consistent with both 
YWA1 and citreoisocoumarin coeluting with the new peaks in the UV profile.  These peaks were 
isolated by HPLC fractionation and analyzed by high-resolution MS, where the most probable 
chemical formulas were predicted to be C14H12O6 for the 10.2 min peak (matching YWA1) and 
C14H14O6 for the 11.2 min peak (matching citreoisocoumarin).  As the biosynthesis of these 
compounds is well studied, and the heterologous production of YWA1 has recently been 
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demonstrated in S. cerevisiae [33], further analysis of PKS4 and its corresponding gene cluster 
were not pursued. 
 
3.2.4.3 Assembly of additional non-reducing pks constructs 
Having successfully reconstituted PKS4 in S. cerevisiae, PCK1p expression plasmids were 
constructed for the other non-reducing PKSs from T. marneffei.  In these cases, however, no 
obvious new pigments were produced, and no new peaks were apparent in the HPLC-MS 
profiles.  Prediction of the products of these enzymes based on bioinformatic analysis provided 
limited insight; however, for PKS3, similarity with a recently characterized PKS from Monascus 
purpureus suggested a possible product structure (Figure 3.13) [34].  The predicted structure was 
proposed to be synthesized using one crotonyl-CoA, a metabolite not natively produced in S. 
cerevisiae.  Reconstitution of a crotonyl-CoA pathway has previously been demonstrated en 
route to n-butanol biosynthesis in S. cerevisiae [35]. 
 
The crotonyl-CoA pathway, converting acetyl-CoA to crotonyl-CoA via acetoacetyl-CoA and β-
hydroxybutyryl-CoA, was integrated to the genome of BJ5464-NpgA. Also integrated to the 
genome was a heterologous matB malonyl-CoA synthetase from Rhizobium trifolii in an effort to 
boost malonyl-CoA levels [36].  To confirm expression of all four integrated genes in the 
resulting strain (named S. cerevisiae BJ5464-THCM), qPCR was conducted (Figure 3.14).  
While expression levels were low compared to an alg9 standard, all four gene products were 
detected.  However, expression of PKS3 in this strain did not yield the predicted product. 
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Figure 3.13: (a) The crotonyl-CoA biosynthetic pathway from Clostridium.  (b) Malonyl-CoA synthesis by MatB 
from Rhizobium trifolii.  (c) Proposed synthesis of an azaphilone precursor by MpPKS5.  (d) Domain comparison 
between PKS3 of T. marneffei and MpPKS5. 
 
 
 
Figure 3.14: Gene expression profiles in S. cerevisiae BJ5464-THCM. 
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In a very recent publication, PKS3 has been shown to be involved in the synthesis of pigments 
monascorubrin and ankaflavin, as well as citrinin, through gene knockdown experiments in T. 
marneffei [37].  Given this new lead, HPLC-MS data was reanalyzed for the corresponding 
masses of citrinin and compound 1, both putative products of PKS3.  While citrinin was not 
observed, a unique peak was observed in PKS3 extracts corresponding to the mass of compound 
1 (Figure 3.15a).  The peak was observed in both pellet and supernatant extracts, and eluted with 
a very small UV peak (Figure 3.15b).  Notably, this peak was not observed in the ADH2p 
expression strain. 
 
 
Figure 3.15: (a) MS analysis of all PKS expression strains shows a peak with m/z = 233
+
 at 13 min only in the 
presence of PKS3 (black arrow).  (b) UV traces at 254 nm, zoomed in on the region shown in a black box in (a). 
 
3.3 Conclusions and Outlook 
In the study presented here, the polyketide synthases of T. marneffei were explored in S. 
cerevisiae.  A general helper plasmid was constructed for the expression, detection, and 
purification of PKSs in S. cerevisiae.  A set of 14 single PKS expression plasmids were 
constructed, leading to detectable expression of the encoded proteins by Western blot.  However, 
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polyketide products were not detected.  Three strong endogenous promoters from S. cerevisiae 
were characterized and shown to out-perform the commonly used ADH2p to drive expression of 
PKS4 for production of both YWA1 and citreoisocoumarin.  Additionally, the full pks16/pks17 
cluster was refactored on a single expression plasmid.  Although the expected RAL product was 
not observed, a halogenase active on a RAL substrate was discovered.  Finally, an S. cerevisiae 
expression host was designed to provide the crotonyl-CoA precursor for polyketide synthesis. 
 
Given our detection of soluble protein expression in all cases tested, it is likely that there is some 
small amount of accompanying activity for at least some of the PKSs.  However, this production 
is likely to be too low to yield an obvious signal in a UV or MS trace.  Without knowledge of the 
exact product of the heterologous gene or cluster, then, the manual detection of novel products 
amid an extracted metabolome becomes a painstaking, needle-in-a-haystack type of task.  More 
comprehensive analytical tools for metabolic profiling, recently exemplified by the Dorrestein 
group [38], are needed to supplant manual peak-by-peak analysis. 
 
Here, inherent limitations in the expression of these PKSs in S. cerevisiae seem to underlie their 
low expression levels (and correspondingly, the undetectable product synthesis).  Such issues 
could stem from unfavorable codon bias, incorrect prediction of introns, or other metabolic 
differences between the native T. marneffei strain and S. cerevisiae.  Notably, this is not a 
universal result; there is a literature precedent for the expression of PKSs in yeast [39], and 
during the course of this study a similar effort was undertaken by the Watanabe group with 
significantly greater success [40].  In our study, however, a valid next step would be to try 
different fungal hosts for heterologous expression.  For example, Aspergillus nidulans has 
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recently been demonstrated as a suitable host for heterologous expression of fungal PKSs [41].  
As closer relatives of T. marneffei and as native polyketide producers, Aspergillus species may 
provide natural metabolic advantages for heterologous polyketide production. 
 
3.4 Materials and Methods 
3.4.1 Strains, media and reagents 
The Escherichia coli expression strain BL21(DE3) and the expression vector pET28a were 
obtained from EMD Biosciences (San Diego, CA).  E. coli cloning strain BW25141 was a gift 
from Prof. William Metcalf (University of Illinois at Urbana-Champaign).  S. cerevisiae HZ848 
(MATα, ade2-1, ade3Δ22, Δura3, his3-11,15, trp1-1, leu2-3,112 and can1-100) was used for 
plasmid assembly and protein expression.  S. cerevisiae BJ5464-NpgA (MATα, ura3-52, his3-
Δ200, leu2-Δ1, trp1, pep4::HIS3, prb1, Δ1.6R, can1, GAL) and plasmid pZH126, containing 
hpm8 under the ADH2p promoter, were gifts from Prof. Yi Tang (University of California, Los 
Angeles).  Talaromyces marneffei genomic DNA was purchased from the American Type 
Culture Collection (Manassas, VA).  E. coli strains were grown in LB medium supplemented 
with the appropriate antibiotic (50 µg/mL kanamycin or 100 µg/mL ampicillin).  Yeast strains 
were grown in appropriate SC dropout media (for plasmid assembly and seed cultures) or YPAD 
medium (for protein expression cultures).  All media components, organic solvents, and 
consumables were purchased from Thermo-Fisher Scientific (Pittsburgh, PA).  Antibiotics and 
isopropyl-β-D-1-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. 
Louis, MO).  XAD-1180 resin and resorcylic acid lactone standards were purchased from Sigma-
Aldrich (St. Louis, MO).  PCR primers were synthesized by Integrated DNA Technologies 
(Coralville, IA), and PCR reactions were performed in FailSafe PCR PreMix G (Epicentre 
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Biotechnologies, Madison, WI) with Q5 DNA polymerase (New England Biolabs, Ipswich, 
MA).  All PCR products were purified using the DNA Clean & Concentrator or Zymoclean Gel 
DNA Recovery Kit (Zymo Research, Irvine, CA).  Plasmids were recovered using the QIAprep 
Spin Miniprep Kit (Qiagen, Valencia, CA).  Restriction enzymes and T4 ligase were purchased 
from New England Biolabs (Ipswich, MA). Talon Cobalt immobilized metal affinity 
chromatography (IMAC) resin was purchased from Clontech Laboratories (Mountain View, 
CA).  Total RNA was isolated with the RNeasy Mini Kit (Qiagen) and treated with TURBO 
DNA-free DNase (Life Technologies, Carlsbad, CA).  Complimentary DNA was synthesized 
with the ProtoScript II First Strand cDNA Synthesis Kit (NEB). 
 
3.4.2 Plasmid construction 
All single-gene helper plasmids (including pks16/pks17 pathway gene plasmids, pYAAFH 
expression plasmids, and xylE expression plasmids) were assembled via yeast homologous 
recombination in S. cerevisiae HZ848 following previously established protocol [42].  Exons of 
small genes (< 2 kb) were spliced by overlap-extension PCR [43] prior to yeast assembly, while 
PKS exons were assembled directly in yeast.  Plasmids recovered from yeast assemblies were 
electroporated into E. coli BW25141 for confirmation by diagnostic restriction digestion and 
sequencing.  Multi-gene plasmids were assembled in yeast from the single-gene expression 
cassettes, PCR amplified from the corresponding helper plasmids with primers annealing to the 
upstream and downstream terminators.  To replace the ADH2p promoter in each pYAAFH 
expression plasmid with PCK1p, three fragments for each construct were prepared by PCR: the 
backbone (without promoter), the pks gene, and the PCK1p promoter.  The three fragments were 
transformed into S. cerevisiae HZ848 for assembly via homologous recombination.  Plasmid 
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pRS405-THCM, for chromosomal integration of thI, hbd, crt, and matB to BJ5464-NpgA at the 
leu2 locus, was constructed via Gibson isothermal assembly following literature precedent [44].  
Single gene expression plasmids for E. coli were assembled via ligation of the PCR-amplified 
gene into the NdeI/HindIII sites of pET28a (for genes < 2 kb) or Gibson assembly into the 
NdeI/HindIII-linearized pET28a backbone (for PKS genes) following literature precedent. 
 
3.4.3 Transformation 
E. coli strains BW25141 and BL21(DE3) were transformed by electroporation.  S. cerevisiae 
strain HZ848 was transformed by electroporation for all plasmid assemblies, following the 
procedure reported elsewhere [42]. For transformation of S. cerevisiae HZ848 and BJ5464-
NpgA with circular plasmids, the LiAc/ssDNA method was employed, as described elsewhere 
[45].  Chromosomal integration to BJ5464-NpgA was accomplished via electroporation of the 
BstEII-linearized suicide plasmid. 
 
3.4.4 S. cerevisiae culture, extraction, and analysis 
Individual colonies of yeast expression strains were picked to 3 mL of the appropriate SC 
dropout medium in 14 mL tubes and grown at 30 °C, 250 rpm for 1 day.  Seed cultures were 
diluted 100-fold into fresh YPAD medium for protein expression and grown at 30 °C, 250 rpm 
for 3 days.  Culture supernatants were collected by centrifugation and extracted with either 
XAD-1180 resin (20 g/L) or a 3:1 volume of ethyl acetate.  XAD-1180 resin was washed with 
water and eluted with methanol.  Extracts were concentrated to dryness by rotavap, and 
resuspended in methanol (1 % of the original culture volume).  Samples were then analyzed by 
HPLC-MS/MS at the Roy J. Carver Metabolomics Center, University of Illinois, Urbana-
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Champaign, on an Agilent 1100 Series HPLC (Agilent, Palo Alto, CA) coupled to an Agilent 
XCT ion-trap MSD mass spectrometer with ESI source.  Compounds were separated with a 
Kinetex C18 column (Phenomenex, Torrance, CA) on a 0 – 100 % gradient of 0.1 % aqueous 
formic acid (solvent A) to acetonitrile (solvent B) over 25 minutes.  High-resolution MS analysis 
was performed by the School of Chemical Sciences Mass Spectrometry Facility, University of 
Illinois, Urbana-Champaign. 
 
3.4.5 Quantitative PCR 
Total RNA was isolated from 1 mL samples taken from 50 mL YPAD cultures at the specified 
times.  The corresponding cDNA was synthesized and used as template for quantitative PCR.  
Each qPCR reaction contained 10 µL Power SYBR Master Mix (Life Technologies), 0.1 µM of 
each primer, 6 µL of DNA template (diluted 100-fold from the cDNA synthesis reaction), and 
water to 20 µL.  Serial dilutions of the assembled plasmids were used as templates for standard 
curves.  Reactions were performed on a LightCycler 480 System (Roche, Basel, Switzerland). 
 
3.4.6 Protein expression and purification 
E. coli BL21(DE3) pET28a expression strains were grown in Terrific Broth (TB) media 
supplemented with kanamycin (50 μg/mL) at 37 °C to an OD600 of ~0.8, after which induction 
was carried out by addition of 0.3 mM IPTG  at 20 °C.  After 18 – 24 hr, the cells were harvested 
by centrifugation at 7500 rpm for 15 min and resuspended in 20 mM Tris-HCl (pH 7.65), 0.5 M 
NaCl, and 15 % glycerol supplemented with 1 mg/mL lysozyme.  After a freeze-thaw cycle at -
80 °C, the cell suspension was sonicated to ensure sufficient lysis.  The lysate was clarified 
multiple times by centrifugation at 15000 rpm for 15 min, after which the His6-tagged proteins 
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were purified by affinity chromatography on TALON Superflow Co
2+
 resin coupled to fast-
performance liquid chromatography.  The eluted proteins were washed three times in 50 mM 
HEPES (pH 7.25), concentrated, and stored in 15 % glycerol at -80 °C. 
 
3.4.7 SDS-PAGE and Western blotting 
S. cerevisiae strains were grown in YPAD medium for all protein expression studies.  Cells were 
pelleted by centrifugation and resuspended in lysis buffer (50 mM NaH2PO4, pH 8.0, 0.15 M 
NaCl, 10 mM imidazole) (20 mL per L of culture) [15].  Cells were lysed via sonication on ice in 
5 second pulses with 10 second intervals for a total of 30 minutes.  Lysates were clarified by 
centrifugation at 15,000 rpm and analyzed on 4-20% Min-PROTEAN TGX precast 
polyacrylamide gels (Bio-Rad, Hercules, CA) stained with SimplyBlue SafeStain (Life 
Technologies, Carlsbad, CA).  For enrichment of His6-tagged proteins, Ni-NTA agarose 
(Qiagen) was added to clarified lysate, which was then incubated at 4 °C for 2 hr with gentle 
agitation.  Resin was washed with lysis buffer and eluted with increasing concentrations of 
imidazole.  Western blotting was performed with His-probe primary antibody sc-8036 (Santa 
Cruz Biotechnology, Dallas, TX) or anti-FLAG primary antibody F3165 (Sigma-Aldrich) and 
goat anti-mouse–alkaline phosphatase secondary antibody A5153 (Sigma-Aldrich), and 
visualized with Western Blue stabilized substrate for alkaline phosphatase (Promega, Madison, 
WI). 
 
3.4.8 In vitro enzyme assays 
PMAA_061690 O-methyltransferase assays were performed in 200 µL of 50 mM HEPES buffer, 
pH 7.25, with 10 mM MgSO4, 250 µM zearalenone or radicicol, 400 µM SAM, and ca. 10 µg of 
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enzyme.    PMAA_061710 monooxygenase assays were performed in 200 µL of 50 mM HEPES 
buffer, pH 7.25, with 500 µM zearalenone, 1 mM NAD(P)H, and ca. 10 µg of enzyme.  
PMAA_061730 halogenase assays were performed in 100 mM Tris-HCl buffer, pH 7.5, with 50 
mM NaCl, 1 mM NADPH, 100 µM FAD, 500 µM zearalenone, and up to 50 µM enzyme.  
Assays with alternate halogen salts were carried out 100 mM KH2PO4, pH 7.5.  All samples were 
incubated at 30 °C for 1 – 16 hr before HPLC-MS analysis. 
 
3.4.9 XylE activity assay 
For each promoter, three biological replicates and one empty plasmid negative control were 
grown in 5mL YPAD.  Samples (500 µL) were collected at 24, 48, 72, and 96 hr and lysed with 
YPER according to the manufacturer’s suggested protocol.  Reactions were performed at 30 °C 
in a microtiter plate containing 200 µL 1X phosphate buffered saline (Lonza, Walkersville, MD) 
and 2 mM catechol, initiated with the addition of 1 µL of lysate.  Absorbance was monitored at 
375 nm for 5 min.  Activity was normalized by total protein content, measured by Bradford 
assay. 
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CHAPTER 4. Activation of a cryptic phosphonic acid gene cluster 
from Streptomyces sp. WM6378 
 
4.1 Introduction 
4.1.1 Cryptic natural products: the silent majority 
Natural products have historically served as the predominant source of leads for the development 
of human therapeutics [1].  Despite this fact, since the 1990s major pharmaceutical companies 
have either largely scaled down or completely abandoned their natural product discovery efforts 
[2].  Many natural products are produced at relatively low levels in their native hosts, making 
isolation and characterization difficult.  Further, even if a compound with desirable properties is 
discovered, producing organisms are not always cultivable outside of their native environment, 
and repeated environmental sampling often does not provide a robust supply of the desired 
product.  Producing strains can even lose their productivity over time [3].  Perhaps most 
significantly, rediscovery of known compounds is a common occurrence, complicating activity-
based screening. 
 
Synthetic chemical libraries, in contrast, provide large numbers of structurally defined 
compounds in sufficient quantities for high-throughput screening.  Nevertheless, it is important 
to note that quantity is not equivalent to quality.  In contrast to natural product libraries, synthetic 
chemical libraries are comprised primarily of low molecular weight, mostly planar compounds of 
limited stereochemical complexity [4].  For small molecules drugs to access a greater variety of 
biological targets, there still exists a need to access the structural diversity afforded only by 
natural products. 
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Supply of new natural products to meet this need, then, will require adoption of a new discovery 
paradigm beyond the classical approach of environmental sampling coupled with activity-guided 
screening.  Thankfully, genome sequencing efforts have revealed that even among the most well-
studied, laboratory-friendly microorganisms, a “silent” majority of natural products remains to 
be discovered.  Thus, techniques that allow researchers to “look harder” at previously studied 
strains can provide new avenues for the discovery of novel natural products [5].  By mining 
sequenced genomes for key genes in natural product pathways (polyketide synthases, non-
ribosomal peptide synthetases, etc.) with bioinformatic tools such as the Secondary Metabolite 
Unique Regions Finder (SMURF) [6] and the antibiotics & Secondary Metabolite Analysis Shell 
(antiSMASH) [7], new natural product gene clusters can be identified.  A variety of techniques 
can then be employed in the native host or in a heterologous host to elicit expression of the 
identified genes and production of the corresponding product [8], as outlined in Chapter 1.  In 
particular, heterologous expression in a tractable host offers the distinct advantage of liberating 
the genes from native regulation [9], which can be difficult to solve a priori in the native host. 
 
4.1.2 Phosphonic acids as drug candidates 
One class of natural products underexploited for use as human therapeutics is the phosphonic 
acids.  These compounds are characterized by the presence of a highly stable carbon-phosphorus 
(C-P) bond, which can withstand enzymatic hydrolysis and harsh treatment with strong acid or 
base.  Of note, these compounds are capable of mimicking phosphate esters and carboxylic acids, 
two of the most ubiquitous chemical moieties in biologically relevant molecules.  As a result, 
phosphonic acids can serve as analogs of these compounds, and thus as potent inhibitors of a 
great number of enzymes [10].   
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In nature, phosphonic acids are found both as small molecules and as constituents of larger 
macromolecules, including proteins, lipids, and polysaccharides.  Once viewed as “niche” 
natural products produced by only a handful of organisms, more recent analysis has revealed that 
phosphonic acid biosynthetic gene clusters are in fact relatively common in nature [11].  
Although the biosynthesis of phosphonic acid macromolecules remains largely uncharacterized, 
several small molecule phosphonate pathways have been studied in detail.  With only one known 
exception [10], all phosphonic acid biosyntheses begin with installation of the C-P bond via the 
conversion of phosphoenol pyruvate (PEP) to phosphonopyruvate (PnPy).  The equilibrium of 
this reversible reaction lies significantly on the side of PEP; thus, a thermodynamically favorable 
second-step is typically employed to drive the synthesis forward.  From this point forward, 
phosphonic acid biosyntheses diverge significantly.  Some pathways employ steps analogous to 
primary metabolism.  The FR-900098 pathway, for example, features three steps analogous to 
the tri-carboxylic acid (TCA) cycle, while the PTT pathway features two steps analogous to the 
Embden-Meyerhof-Parnas (EMP) glycolytic pathway.  In contrast, other steps feature unique 
chemical transformations not seen elsewhere [12].  The result is a great diversity of phosphonic 
acid compounds. 
 
Multiple phosphonic acid (and phosphinic acid, containing a C-P-C bond) natural products with 
interesting bioactivities have been discovered and characterized (Figure 4.1).  Phosphinothricin 
tripeptide (PTT, also known as bialaphos), for example, is an herbicide produced by multiple 
strains [13,14].  Fosfomycin, originally called phosphonomycin, was first identified from 
multiple Streptomyces species and later found to be produced by Pseudomonas syringae [15,16].  
Heterologous expression in Streptomyces lividans enabled identification of the minimal gene 
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cluster from Streptomyces fradiae [17].  Currently, fosfomycin is a clinically-approved antibiotic 
for urinary tract infections and has also been found to be effective against resistant strains of 
Staphylococcus aureus.  Another phosphonate antibiotic is dehydrophos, first identified in 1984 
[18].  This compound demonstrates broad-spectrum activity, and its biosynthetic cluster has been 
heterologously expressed and characterized.  Other examples of biologically active phosphonic 
acids include the rhizocticins [19], which have antifungal properties, and FR-900098 and 
fosmidomycin, which have undergone clinical trials as antimalarials [20]. 
 
 
Figure 4.1: Representative bioactive phosphonic/phosphinic acid compounds. 
 
A common property of bioactive phosphonic acid natural products is the pairing of the 
phosphonate moiety with another biologically relevant feature.  For example, fosfomycin 
employs an epoxide to covalently modify its target enzyme, MurA, leading to irreversible 
inactivation [10].  FR-900098 and fosmidomycin feature hydroxamic acid moieties to enable 
chelation of the active site metal in their target enzyme, 1-deoxy-D-xylulose-5-phosphate 
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reductoisomerase (Dxr), to enhance binding affinity.  Finally, a number of phosphonic acids, 
including PTT, rhizocticin, plumbemycin [21], and fosfazinomycin [22], feature conjugation of 
the phosphonic acid to a short peptide.  This allows the compound to easily pass through the 
membranes of competitor microbes via peptide uptake transporters, at which point the toxic 
phosphonic acid payload is hydrolytically released [23]. 
 
4.1.3 Phosphonic acid discovery 
The discovery of phosphonic acids is aided by the presence of two unique handles.  On the 
genetic level, the necessity of a pepM gene allows identification of phosphonic acid gene clusters 
from both sequenced genomes (via bioinformatic analysis) and genomic DNA libraries (via 
PCR-based screening) [10].  On the molecular level, phosphonates exhibit chemical shifts far 
downfield of phosphates in a 
31
P-NMR spectrum.  This signature allows rapid confirmation of 
phosphonic acid production, in contrast with bioactivity- or HPLC/MS-based screening methods 
that can be easily confounded by unrelated molecules. 
 
Previous work in the Metcalf lab at the University of Illinois, Urbana-Champaign, has led to the 
discovery of hundreds of bacterial strains with phosphonic acid biosynthetic potential, as 
determined via the detection of pepM homologs in their genomes.  Included in this collection are 
two nearly identical Streptomyces strains (based on 16S ribosomal DNA identity) named 
Streptomyces spp. WM6378 and WM6391.  Both strains possess a putative 15-gene phosphonic 
acid gene cluster that was identified and sequenced from a fosmid library.  However, cultivation 
of the native strains under various conditions did not yield detectable production of phosphonic 
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acid compounds, as assessed by 
31
P-NMR.  Further studies of the intact cluster in a heterologous 
S. lividans host turned up similar results. 
 
The goal of the work presented here is to apply synthetic biology techniques to decouple the 
cryptic phosphonic acid cluster from Streptomyces sp. WM6378 from native regulation for the 
purpose of discovering novel phosphonic acid compounds.  First, complementation studies with 
the FR-900098 pathway will be employed to assess the functionality of the three frb homolog 
genes.  Next, a refactoring strategy will be employed to replace all of the endogenous promoters 
in the gene cluster with strong, characterized promoters for heterologous expression in S. 
lividans.  1D and 2D NMR experiments will then be used to identify phosphonic acid 
compounds in culture extracts based on their characteristic downfield chemical shifts, and 
potentially interesting compounds will be isolated for further characterization. 
 
4.2 Results and Discussion 
4.2.1 Native strain analyses 
4.2.1.1 Bioinformatic analysis 
To facilitate prediction of the function of each gene in the cryptic phosphonic acid gene cluster, 
each gene was annotated by querying the NCBI database via BLAST (Figure 4.2).  Three genes 
were found to have very high sequence similarity (> 70 % identity) with frbD, frbC, and frbA 
from Streptomyces rubellomurinus, which encode the first three transformations of FR-900098 
biosynthesis from phosphoenolpyruvate (PEP) to 3-phosphonomethyl malate [24].  Thus, 
analogous transformations are anticipated in the new pathway.  However, no other genes in the 
cluster share significant sequence similarity with genes from the frb cluster, suggesting that the 
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two pathways diverge at this point.  Also found in this cluster are two genes encoding putative 
members of the ATP-grasp superfamily, sharing weak homology (e-value > 10
-20
) with rhiC of 
the rhizocticin biosynthetic pathway.  These genes suggest the possibility of amino acid 
conjugation to the phosphonic acid core molecule, a common strategy observed in several 
phosphonic acid pathways to facilitate cellular uptake. 
 
Additional genes in the cluster are proposed (based on conserved domain analysis) to encode a 
SAM-dependent methyltransferase, an acetyltransferase, a nitrilotriacetate (NTA) 
monooxygenase (NTA-Mo) homolog, and a flavin reductase.  The remaining four putative 
biosynthetic genes contain no detectable conserved domains, making functional prediction more 
difficult.  Of these four hypothetical proteins, one of these shares weak homology with some 
putative acetyltransferases; for the others, no putative functions can be assigned.  Also encoded 
in the cryptic cluster is a transporter of the major facilitator superfamily and putative regulators 
of the LuxR, RedD and anti-sigma factor antagonist families.  Outside of the putative borders of 
the cluster are cheB/cheR homlogs related to chemotaxis, and several homologs of kdp genes 
related to potassium transport.  Of note, all of the genes in the putative cluster (between the 
CheB homolog the LuxR family regulator) are transcribed in the same direction.  Further, 
intergenic sequences between the genes encoding the flavin reductase and FrbD homolog, as 
well as between the genes encoding the NTA-Mo homolog, SAM-dependent methyltransferase, 
acetyltransferase, ATP-grasp protein 1, and ATP-grasp protein 2, are all less than 10 bp in 
length, suggesting operonic transcription patterns for these genes. 
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Name Abbreviation Conserved Domains Top Blast Hits 
hypothetical 3 hyp3 none 
conserved hypothetical protein [Streptomyces 
sviceus ATCC 29083], 2e-63, 58%ID 
hypothetical 2 hyp2 none 
hypothetical protein SCAB_52611 [Streptomyces 
scabiei 87.22], 9e-53, 75%ID 
hypothetical 1 hyp1 none 
hypothetical protein SEPMUDRAFT_148397 
[Sphaerulina musiva SO2202], 0.084, 48%ID 
FrbC homolog frbC DRE_TIM_metallolyase FrbC [Streptomyces rubellomurinus], 0.0, 85%ID 
FrbA homolog frbA aconitase FrbA [Streptomyces rubellomurinus], 0.0, 71%ID 
flavin reductase FR FMN_red 
NADPH-dependent FMN reductase family protein 
[Saccharopolyspora spinosa NRRL 18395], 9e-49, 
56%ID 
FrbD homolog frbD ICL_PEPM FrbD [Streptomyces rubellomurinus], 3e-139, 75%ID 
nitrilotriacetate 
monooxygenase 
homolog FMO Nitrilotriacetate_monoxygenase 
xenobiotic compound monooxygenase YxeK 
[Pantoea ananatis PA13]; 2e-178, 55%ID 
SAM-depn Me-
transferase MT AdoMeT_Mtase 
SAM-dependent methyltransferase [Hahella 
chejuensis KCTC 2396], 2e-81, 51%ID  
acetyltransferase AT NAT_SF 
hypothetical protein plu1872 [Photorhabdus 
luminescens subsp. laumondii TTO1], 2e-29, 40%ID 
ATP-grasp protein 1 Nik1 PRK02186 (arginosuccinate lyase) 
hypothetical protein [Streptomyces nanchangensis], 
3e-118, 47%ID; Carbamoyl-phosphate synthase 
large chain [Erwinia amylovora ATCC  
BAA-2158], 2e-87 
ATP-grasp protein 2 Nik2 PRK02186 (arginosuccinate lyase) 
hypothetical protein plu1874 [Photorhabdus 
luminescens subsp. laumondii TTO1], 9e-83, 42%ID 
hypothetical 4 hyp4 none 
hypothetical protein plu1876 [Photorhabdus 
luminescens subsp. laumondii TTO1], 4e-71, 38%ID 
Figure 4.2: The annotated cryptic phosphonic acid cluster from Streptomyces sp. WM6378. 
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4.2.1.2 Cultivation and RT-PCR 
To confirm previous observations from the Metcalf lab, initial experiments were conducted with 
the native Streptomyces sp. WM6378 host.  Cultivation of this strain on MYG medium did not 
yield any peaks in the phosphonic acid range of a 
31
P-NMR trace, as expected.  Further, HPLC-
MS/MS analysis did not reveal any significant signal corresponding to 2-phosphonomethyl malic 
acid or 3-phosphonomethyl malic acid, pathway intermediates expected to be formed by the 
FrbD, FrbC, and FrbA homologs.  To check for pathway expression at the transcript level, 
reverse-transcriptase PCR (RT-PCR) was performed.  Complementary DNA (cDNA) was 
synthesized from mRNA collected at two time points (2 days and 5 days post-inoculation), and 
used as template for diagnostic PCR reactions (Table 4.1).  Some transcripts were detected only 
at one time point or the other, while others were not detected at all.  Interestingly, transcription of 
the three frb homologs was detected at both time points.  Nevertheless, inability to detect the 
corresponding FR-900098 pathway intermediates called into question the activity of the encoded 
enzymes, a property that cannot be evaluated at the transcript level. 
 
Table 4.1: RT-PCR detection of transcription in Streptomyces sp. WM6378 
Gene 2 days 5 days 
Anti-sigma factor antagonist + + 
FrbC + + 
FrbA + + 
Flavin reductase – + 
FrbD + + 
Monooxygenase – + 
Methyltransferase – – 
Acetyltransferase – – 
ATP-grasp protein 1 + – 
ATP-grasp protein 2 + – 
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4.2.2 FR-900098 complementation 
In principle, there are three main reasons for a gene cluster to be cryptic.  First, the cluster could 
be completely silenced at the genetic level through inactivating mutation(s).  Second, the cluster 
could be silenced at the transcriptional or translational levels through any number of regulatory 
pathways.  Third, the cluster could in fact be productive, but at a level that falls short of the limit 
of detectability.  To evaluate the possibility of this first means of crypticity, a complementation 
strategy was devised.  Most of the genes in the cluster encode enzymes for which the native 
substrate cannot be predicted; however, the high similarity of the frbD, frbC, and frbA homologs 
to their S. rubellomurinus counterparts allows for more confident prediction of their probable 
functions.  Thus, by first knocking out individual genes in the FR-900098 pathway and then 
introducing the corresponding homolog from the WM6378 pathway, production of FR-900098 
can serve as an indicator of functional expression of the complemented gene. 
 
Previously, the FR-900098 pathway was reconstituted in E. coli on three compatible plasmids 
bearing frbABCD, frbFGH, and frbE/dxrB, respectively [25].  Due to ease of manipulation and 
cultivation, this system was utilized for the complementation experiments.  Each target gene was 
replaced on the pETDuet-frbABCD plasmid and reintroduced to the expression strain along with 
the other two FR-900098 pathway plasmids.  HPLC-MS/MS screening revealed restored 
production of FR-900098 in both the frbD homolog and frbC homolog complementation strains 
(Figure 4.3).  Interestingly, only a very small peak above background was observed for frbA 
homolog complementation.  While this could be a sign of reduced activity, it could also be an 
artifact of expression in the non-native E. coli host, or evidence that the frbA homolog actually 
catalyzes a different reaction than anticipated.  Nevertheless, these studies provided the first 
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evidence of biosynthetic potential from this gene cluster, inspiring a total cluster refactoring 
approach. 
 
 
Figure 4.3: Complementation the FR-900098 pathway in E. coli with frb homologs.  EIC traces show m/z = 
198138 fragmentation characteristic of FR-900098. 
 
4.2.3 Refactored plasmid design and assembly 
4.2.3.1 Design 
Having ruled out inactivating mutation of the frb homologs as an explanation for the observed 
silence of the WM6378 phosphonic acid gene cluster, it was presumed that the cluster was likely 
rendered silent either by intrinsic repression in the native host or by undetectably low production 
levels.  Either of these problems can be addressed through a full cluster refactoring strategy, in 
which the cluster is simultaneously removed from native regulation via transfer to a heterologous 
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host and up-regulated via replacement of native promoters with strong promoters.  Due to its 
high genetic tractability and lack of intrinsic phosphonic acid biosynthetic pathways, S. lividans 
66 was chosen as the heterologous host.   
 
Initially, all of the structural genes, with the exception of putative regulators and the MFS 
transporter, were included in the refactored cluster design.  In total, assembly of this construct 
required 29 components: 13 structural genes, 13 promoters, and three helper fragments for 
plasmid maintenance in Saccharomyces cerevisiae, E. coli, and S. lividans, respectively.  Of the 
panel of actinomycete promoters available [26], the three strongest promoters were paired with 
the frb homolog genes with the goal of pulling flux into the pathway.  The next strongest 
promoters were paired with the two ATP-grasp proteins, the methyltransferase, the 
monooxygenase, and the acetyltransferase, which seem likely to participate in biosynthesis.  
Finally, the remaining promoters were paired with the four hypothetical proteins, which may not 
have an actual function in biosynthesis. 
 
4.2.3.2 Assembly 
To reduce the number of fragments necessary for assembly, each gene was first concatenated 
with its corresponding promoter, reducing the overall number of parts to 16.  Assembly of these 
parts was attempted in one step via yeast homologous recombination.  Although numerous 
plasmids could be recovered, diagnostic digestion repeatedly revealed that many fragments had 
been left out of the assembled construct.  Suspecting the large number of parts as the main reason 
for failure, a hierarchical assembly strategy was then designed and implemented.   
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In this strategy, the pathway was divided into two intermediate plasmids containing five and 
eight gene cassettes, respectively, along with helper fragments for S. cerevisiae and E. coli 
(Figure 4.4).  One helper fragment in each plasmid was flanked with unique restriction sites to 
facilitate linearization and assembly into the full-cluster plasmid via a bridging “master” helper 
fragment in the second assembly step.  This strategy proved to be far more successful than the 
one-step method.  For both of the intermediate plasmids, > 70 % assembly fidelity was achieved, 
as confirmed by diagnostic restriction digestion.  Assembly of the final plasmid was also 
successfully achieved, albeit with significantly lower fidelity. 
 
 
Figure 4.4: Two-step scheme for assembly of the full refactored WM6378 gene cluster.  Dashed lines indicate 
unique restriction sites. 
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4.2.4 Identification of phosphonic acid products 
4.2.4.1 Initial NMR analyses 
Following assembly of the full refactored 13-gene cluster, it was integrated to the chromosome 
of S. lividans 66 at the ΦC31 phage attachment site via conjugation from an E. coli donor.   The 
resulting strain, named S. lividans 3p2.1, was grown in liquid culture to detect the production of 
phosphonic acids.  Following six days of growth, both the dried culture supernatant and cell 
pellet were extracted with methanol, dried, and resuspended in D2O.  Analysis by 
31
P-NMR 
revealed the presence of multiple peaks in the downfield region characteristic of phosphonic 
acids (Figure 4.5).  Analogous cultivation of the native strain, as well as the heterologous S. 
lividans host without the integrated cluster, confirmed no phosphonic acid production in either of 
these strains. 
 
As further confirmation, a negative control plasmid was assembled in which a single nonsense 
mutation was introduced into the frbD homolog gene (the PEP phosphonomutase) to eliminate 
the first step of the heterologous pathway.  Assembly of this plasmid was analogous to that of the 
full-cluster plasmid in that an intermediate plasmid bearing the desired mutation was generated 
first, followed by a three-piece assembly of the final plasmid.  The resulting integrated strain, 
named S. lividans 3p2.1-Da, was found not to produce any phosphonic acids, as anticipated 
(Figure 4.5). 
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Figure 4.5: 
31
P-NMR analysis of the full-cluster integrated strain S. lividans 3p2.1 with negative controls. 
 
Having observed phosphonate production in the presence of the full refactored cluster, a time-
course study was next undertaken to see if any clues could be obtained about the order of the 
compounds observed in the context of the pathway. Collecting samples every 24 hours over a 
course of 12 days revealed that the peak at ~17.5 ppm appeared earliest, followed by several 
smaller peaks (Figure 4.6).  As the ~17.5 ppm peak subsequently reduced in size, the signals at 
~16.5 ppm and ~18.2 ppm became the dominant peaks in the spectrum, suggesting that these 
compounds could be closer to the final product of the cluster.  Alternatively, such peaks could 
also correspond to shunt products that accumulate gradually due to off-pathway activities. 
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Figure 4.6: 
31
P-NMR time-course analysis of S. lividans 3p2.1. 
 
4.2.4.2 Gene disruption experiments 
In a parallel set of experiments, a series of single-gene disruption plasmids was prepared to see if 
the pathway could be stalled at different intermediate compounds.  In each case, an amber stop 
codon was introduced early in the target gene to silence it at the translational level while 
minimally perturbing transcription dynamics.  Surprisingly, most of the disruptions introduced 
did not reproducibly affect the phosphonic acid profile, with the only exceptions being of the 
frbC and frbA disruption constructs (Figure 4.7).  In the frbA disruption strain, a peak at ~15.5 
ppm was observed, presumably corresponding to the anticipated 2-phosphonomethyl malic acid 
product.  
1
H-
31
P HMBC revealed coupling of this peak to two proton signals at ~1.9 ppm, as 
would be expected for this compound (data not shown).  Further, another strain expressing only 
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the frbD, frbC, and frbA homologs did not produce the ~15.5 ppm peak, instead yielding a peak 
at ~19 ppm. 
 
 
Figure 4.7: Disruption/deletion analysis of early-pathway genes. 
 
Another peak was observed from the frbA disruption strain and the frbDCA expression strains at 
~16.5 ppm.  Curiously, it was also seen in the frbC disruption strain.  As the frbD-catalyzed 
conversion of PEP to phosphonopyruvate is a thermodynamically disfavored process, production 
of phosphonic acids from the frbC disruption strain (presumed to be lacking the subsequent 
conversion of phosphonopyruvate to 2-phosphonomethyl malic acid) was unexpected.  
Suspecting that the peak might be due to read-through of the introduced stop codon in frbC, an 
additional strain was created in which the frbC homolog and its corresponding promoter were 
cleanly deleted from the integrated cluster.  This strain produced the same 
31
P-NMR peaks 
(Figure 4.7 above), confirming their derivation from off-pathway reactions.  For further 
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confirmation, a strain was created in which only the frbD homolog expression cassette was 
integrated to the chromosome in the absence of the other twelve genes.  Again, the same peaks 
were observed in the 
31
P-NMR spectrum, confirming them as shunt products of endogenous 
transformations. 
 
4.2.4.3 Structure elucidation 
To gain some insight into the structures of the detected products from the full-cluster strain S. 
lividans 3p2.1, 
1
H-
31
P HMBC was also employed.  As shown in Figure 4.8, the phosphorus peak 
at ~18 ppm is coupled to proton signals at 2.5 ppm and 5.8 ppm, suggesting a non-functionalized 
α-carbon and a double bond on the β-carbon, respectively.  The peak at ~16.5 ppm is coupled 
only to a proton signal at 1.8 ppm. 
 
 
Figure 4.8: 
1
H-
31
P HMBC analysis of S. lividans 3p2.1. 
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To obtain enough of the phosphonic acid products for isolation and structural characterization, 
large-scale cultivation was employed.  Through the efforts of Dr. Jiangtao Gao of the Wilfred 
van der Donk lab at the University of Illinois, Urbana-Champaign, a total of six compounds were 
isolated from a combined 50 L of culture supernatant (Figure 4.9).  The major product was found 
to be phosphonomethyl fumaric acid (compounds 1 and 6), which is presumably the product of 
only three enzymes in the pathway (the frb homologs).  Surprisingly, 3-phosphonomethyl malic 
acid, the known product of FrbD, FrbC, and FrbA in the FR-900098 pathway, was not observed.  
In the FR-900098 pathway, the aconitase-like FrbA converts 2-phosphonomethyl malic acid to 
3-phosphonomethyl malic acid in two steps.  First, the 2-phosphonomethyl malic acid substrate 
binds in the active site, undergoes dehydration, and is released in the dehydrated form.  In the 
second step, the dehydrated intermediate binds in the active site in a 180° reversed orientation, 
undergoes rehydration (at a different position, using the same catalytic residues), and is released 
as the 3-phosphonomethyl malic acid product.  Based on the products obtained here, the 
WM6378 FrbA homolog appears to bind the substrate in only one orientation, such that the 
second-step rehydration reaction cannot occur.  Although the phosphonomethyl fumaric acid 
intermediate seen here is presumed to exist in the FR-900098 pathway, its observation has not 
previously been reported in any natural product pathway. 
 
Small amounts of a 2-phosphonomethyl malic acid methyl ester (3) were observed, suggesting 
activity of the heterologous methyltransferase.  However, the other compounds produced by S. 
lividans 3p2.1 appear to be shunt products of the first or second transformations.  Of note, 
compounds 3 and 4 have also not been previously reported in natural product literature.  
Compound 5 has previously been observed in protozoans of the genus Tetrahymena, but not in a 
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bacterial system [10].  It remains unclear, however, how such a compound could appreciably 
accumulate given the thermodynamic unfavorability of the first transformation and the 
reversibility of the presumed transamination second step. 
 
 
Figure 4.9: Phosphonic acids isolated from S. lividans 3p2.1.  Isolated compounds are numbered and shown in red.  
Putative intermediates from the FR-900098 pathway are shown in black. 
 
Based on the shunt products observed from S. lividans 3p2.1, it was speculated that the peaks 
observed in the frbC deletion strain and frbD solo-expression strain (described in Section 4.2.4.2) 
could correspond to 2-aminoethyl phosphonic acid (2-AEP), phosphonoalanine, or 2-hydroxy-3-
phosphonopropanoic acid.  Spiking of the commercially available 2-AEP and phosphonoalanine 
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compounds into the extract from the frbC deletion strain confirmed the ~16.5 ppm peak to be 2-
AEP (Figure 4.10), while the small downstream peak (though unconfirmed by spiking) 
presumably corresponds to 2-hydroxy-3-phosphonopropanoic acid.  Thus, it was discovered that 
S. lividans 66 possesses the native ability to metabolize phosphonopyruvate to 2-AEP, 
presumably through ubiquitous decarboxylation and transamination.  This discovery could serve 
to inform future metabolic engineering studies to optimize phosphonic acid production in S. 
lividans. 
 
 
Figure 4.10: Spiking of known phosphonic acids into the frbC deletion strain extract.  Arrow indicates the position 
of the spiked compound. 
 
4.2.5 FMO studies and identification of 2-(hydroxy(phosphonomethyl)) fumaric acid 
4.2.5.1 E. coli expression 
The previous pathway refactoring effort left many genes without observed functions, including 
the two ATP-grasp domain proteins, the NTA-Mo homolog and flavin reductase, and two 
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putative acetyltransferases (including hypothetical protein 3).  Thus, subsequent efforts focused 
on the further analysis of these genes and their encoded proteins.  Following the structural 
elucidation of compound 1, its similarity with nitrilotriacetic acid was noted.  It was then 
hypothesized that the next step in the pathway could be a hydroxylation analogous to that 
catalyzed by NTA-Mo (Figure 4.11) [27]. 
 
 
Figure 4.11: The NTA-Mo catalyzed hydroxylation of NTA (top) with the proposed analogous hydroxylation of 1. 
 
To investigate this possibility, the NTA-Mo homolog gene and the flavin reductase presumed to 
be its partner were cloned into E. coli expression vectors for in vitro assays.  While the flavin 
reductase could be expressed and purified, it was found that the expression NTA-Mo homolog 
yielded a protein of the incorrect size, as determined by SDS-PAGE (Figure 4.12a).  Sequencing 
of the cloned gene revealed an unintended nonsense mutation, which when corrected enabled 
synthesis of the full-length protein (Figure 4.12b).  However, while oxidation of NADH (but not 
NADPH) was observed by the flavin reductase in the presence of flavin adenine dinucleotide or 
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flavin mononucleotide (data not shown), coupled in vitro assays with the NTA-Mo homolog and 
the purified compound 1 did not yield any detectable oxidation of the substrate.  Subsequently, 
the two genes were cloned into a single vector for co-expression in an E. coli strain containing 
the phnCDE phosphonate uptake transporter under inducible T7 promoters.  Feeding of 1 with 
concomitant induction of protein expression also did not yield any detectable turnover of the 
substrate. 
 
A  B  
Figure 4.12: SDS-PAGE and Western blot analysis of NTA-Mo homolog expression (a) before and (b) after 
correction of a nonsense mutation.  White arrow indicates the full-length protein (51 kDa). 
 
4.2.5.2 S. lividans expression 
Having detected a mutation in the cloned NTA-Mo homolog gene for E. coli expression, the 
sequence was also checked in the 3p2.1 strain.  When the same nonsense mutation was found to 
be present, the full-cluster plasmid was reassembled and re-integrated to S. lividans 66 to yield 
strain S. lividans 3pf.  
31
P-NMR analysis of this strain revealed the production of a new peak 
with a chemical shift at ~13.2 ppm (Figure 4.13).  
1
H-
31
P HMBC revealed two proton signals 
coupled with the phosphorus: one at 6.2 ppm, indicative of a double-bond, and one at 4.4 ppm, 
suggesting the presence of the expected hydroxyl group on the α-carbon.  Isolation of the new 
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compound confirmed the production of 2-(hydroxy(phosphonomethyl)) fumaric acid (7).  This 
structure has never been previously reported in natural product or synthetic chemistry literature. 
 
 
Figure 4.13: 
31
P-NMR (a) and 
1
H-
31
P HMBC (b) analysis after correction of the NTA-Mo homolog gene. 
 
4.2.6 Further refactoring iterations 
While repair of the NTA-Mo homolog gene resulted in the discovery of one additional 
compound, it still did not result in any observable activity for the two ATP-grasp domain 
proteins and the two putative acetyltransferases.  As a result, multiple strategies were adopted to 
try to increase expression of these genes.  First, the entire refactored 13-gene cluster was moved 
to an episomal plasmid with a pIJ101 origin, boosting the copy number from a single integrated 
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copy to 50 – 300 copies [28].  The resulting exconjugants, however, showed significantly 
reduced growth rate, perhaps owing to the metabolic burden of thirteen strong expression 
cassettes.  
31
P-NMR analysis did not reveal any phosphonic acid production (data not shown), 
again suggesting unfavorable effects on overall metabolism. 
 
In the next iteration, only the four genes with unobserved activities were cloned to a pIJ101-
based episomal plasmid (plasmid 4GS).  Their promoters were replaced with the four strongest 
promoters from the actinomycete library [26].  This plasmid was then transferred to strain 3pf.  
Although the resulting strain was able to produce phosphonic acids (data not shown), no new 
peaks were observed compared to strain 3pf, as confirmed by spiking of samples from the two 
strains.  Further, overall phosphonate production appeared to be lower in the new strain than in 
strain 3pf. 
 
In an effort to minimize the metabolic burden introduced by so many strong expression cassettes, 
a new host strain was generated in which only the six genes for which activities were observed 
(the three frb homologs, the NTA-Mo homolog and its putative flavin reductase, and the 
methyltransferase) were integrated to the chromosome.  As anticipated, the resulting strain 
(named S. lividans 6378-6g) retained the ability to produce compound 7.  Supplementation of 
this strain with individual gene expression plasmids to identify new peaks is ongoing. 
 
4.3 Conclusions and Outlook 
Through heterologous expression with complete promoter refactoring, we have successfully 
demonstrated the production of phosphonic acid compounds from an otherwise silent phosphonic 
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acid gene cluster.  Several compounds were isolated and characterized via one- and two-
dimensional NMR analyses.  Included among the identified products are two compounds, 3 and 
7, that have never been previously reported in natural product or synthetic chemistry literature.  
Additionally, we have demonstrated that Streptomyces lividans 66, a strain devoid of phosphonic 
acid biosynthetic pathways, is capable of producing multiple phosphonic acid compounds when 
supplied with only a PEP mutase gene. 
 
Notably, no activities were observed for multiple genes in the refactored cluster, even after 
evaluating multiple promoters and copy numbers.  These results highlight the inherent 
difficulties in heterologous expression, particularly with a large number of genes.  As optimal 
expression levels for every gene in the pathway are difficult to predict a priori, an over-
expression strategy is generally favored as a first-pass approach.  However, this may have 
detrimental effects on the host’s metabolism that significantly limit flux through the pathway 
[29].  On a more fundamental level, some proteins simply are not amenable to functional 
expression in a given heterologous host for reasons beyond our current level of understanding; as 
the number of genes in a pathway increases, so too does to likelihood that such a protein will be 
encountered. 
 
Moving forward, the pathway refactoring approach demonstrated here is likely to benefit 
significantly from advances in DNA synthesis, DNA assembly, and process automation.  The 
decreasing cost of DNA synthesis will facilitate refactoring not just through promoter 
replacement, but through recoding genes at the codon level.  This will help to facilitate soluble 
expression of the encoded proteins in heterologous hosts, as well as to prepare standardized parts 
184 
 
for generalizable assembly strategies.  With advances in DNA assembly protocols, different 
promoters and genes can be paired combinatorially to better explore the solution space.  Finally, 
automated assembly would allow for many pathways to be evaluated simultaneously, effectively 
mitigating the risk of an unsuccessful refactoring effort. 
 
4.4 Materials and Methods 
4.4.1 Strains, media and reagents 
The Escherichia coli expression strain BL21(DE3) and the expression vector pET28a were 
obtained from EMD Biosciences (San Diego, CA).  E. coli strains BW25141 (for general cloning 
of pir-dependent plasmids) and WM6026 (for conjugation to S. lividans), along with 
Streptomyces sp. WM6378 and the corresponding phosphonate-cluster-containing fosmid, were 
gifts from Prof. William Metcalf (University of Illinois at Urbana-Champaign).  S. lividans 66 
was obtained from the Agricultural Resource Service Culture Collection (Peoria, IL).  E. coli 
strains were grown in LB medium supplemented with the appropriate antibiotics and, for strain 
WM6026, diaminopimelic acid (19 µg/mL).  Streptomyces strains were grown on modified 
MYG medium (10 g/L malt extract broth, 4 g/L yeast extract, 4 g/L glucose) with 50 µg/mL 
apramycin or thiostrepton as needed for plasmid selection.  Medium R2 (without sucrose) was 
used for conjugation [28].  All media components and supplements were purchased from Sigma-
Aldrich (St. Louis, MO) with the exception of yeast extract (BD Biosciences, San Jose, CA) and 
LB broth (Fisher Scientific, Pittsburgh, PA).  Antibiotics and isopropyl-β-D-1-
thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. Louis, MO).  
Organic solvents and consumables were purchased from Thermo-Fisher Scientific (Pittsburgh, 
PA).  PCR primers were synthesized by Integrated DNA Technologies (Coralville, IA), and PCR 
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reactions were performed in FailSafe PCR PreMix G (Epicentre Biotechnologies, Madison, WI) 
with Q5 DNA polymerase (New England Biolabs, Ipswich, MA).  All PCR products were 
purified using the DNA Clean & Concentrator or Zymoclean Gel DNA Recovery Kit (Zymo 
Research, Irvine, CA).  Plasmids were recovered using the QIAprep Spin Miniprep Kit (Qiagen, 
Valencia, CA).  Restriction enzymes and T4 ligase were purchased from New England Biolabs 
(Ipswich, MA). Talon Cobalt immobilized metal affinity chromatography (IMAC) resin was 
purchased from Clontech Laboratories (Mountain View, CA).  Total RNA was isolated with the 
RNeasy Mini Kit (Qiagen) and treated with TURBO DNA-free DNase (Life Technologies, 
Carlsbad, CA).  Complimentary DNA was synthesized with the ProtoScript II First Strand cDNA 
Synthesis Kit (NEB). 
 
4.4.2 Plasmid construction 
Construction of FR-900098 pathway complementation plasmids was performed by restriction 
digestion and Gibson isothermal assembly.  Briefly, unique restriction sites were located 
upstream and downstream of the target gene.  The corresponding replacement gene was PCR 
amplified from the WM6378 fosmid, along with bridging fragments to fill the gaps between the 
restriction sites and the termini of the replacement gene.  Gibson isothermal assembly was 
performed according to literature precedent [30]. 
 
Plasmids 6378-3p, 6378-6g, and 4GS were assembled via yeast homologous recombination in S. 
cerevisiae HZ848 following previously established protocol [31].  Plasmids recovered from yeast 
assemblies were electroporated into E. coli BW25141 for confirmation by diagnostic restriction 
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digestion and sequencing.  Correct plasmids were then electroporated into E. coli WM6026 for 
conjugation to S. lividans. 
 
Single gene expression plasmids for S. lividans were constructed using Gibson isothermal 
assembly Master Mix (NEB) according to the manufacturer’s suggested protocol.  Single gene 
expression plasmids for E. coli were assembled via ligation of the PCR-amplified gene into the 
NdeI/HindIII sites (for the flavin reductase) or NdeI/BamHI sites (for the NTA-Mo homolog) of 
pET28a.  For the dual expression plasmid, the flavin reductase and monooxygenase were 
sequentially ligated into the NcoI/BamHI and NdeI/AvrII sites, respectively, of pRSFDuet. 
 
4.4.3 Transformation 
E. coli strains BW25141, WM6026, and BL21(DE3), as well as S. cerevisiae strain HZ848, were 
transformed by electroporation. Conjugation of plasmids into Streptomyces spores was 
performed using the modified protocol described elsewhere [17]. 
 
4.4.4 FR-900098 complementation assays 
E. coli BL21(DE3) FR-900098 complementation strains were grown in 50 mL LB medium 
supplemented with ampicillin, kanamycin, and chloramphenicol.  Cultures were grown at 37 °C, 
250 rpm to a density of 0.8, at which time the temperature was reduced to 30 °C and IPTG was 
added to a final concentration of 0.3 mM.  After 40 hr of growth, 1 mL samples were collected, 
lysed by freeze-thaw at -80 °C, and centrifuged to remove cellular debris.  The clarified sample 
was analyzed by HPLC-MS/MS as described previously [25]. 
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4.4.5 Protein expression and purification 
The E. coli BL21(DE3) pET28a expression strains were grown in Terrific Broth (TB) media 
supplemented with kanamycin (50 μg/mL) at 37 °C to an OD600 of ~0.8, after which induction 
was carried out by addition of 0.3 mM IPTG  at 20 °C.  After 18 – 24 hr, the cells were harvested 
by centrifugation at 7500 rpm for 15 min and resuspended in 20 mM Tris-HCl (pH 7.65), 0.5 M 
NaCl, and 15 % glycerol supplemented with 1 mg/mL lysozyme.  After a freeze-thaw cycle at -
80 °C, the cell suspension was sonicated to ensure sufficient lysis.  The lysate was clarified 
multiple times by centrifugation at 15000 rpm for 15 min, after which the His6-tagged proteins 
were purified by affinity chromatography on TALON Superflow Co
2+
 resin coupled to fast-
performance liquid chromatography.  The eluted proteins were washed three times in 50 mM 
HEPES (pH 7.25), concentrated, and stored in 15 % glycerol at -80 °C. 
 
4.4.6 SDS-PAGE and Western blotting 
S. lividans strains were grown in 5 mL selective MYG cultures for all protein expression studies.  
Cells were pelleted by centrifugation and resuspended in 500 µL B-PER reagent (Thermo 
Scientific, Pittsburgh, PA) for lysis following the manufacturer’s suggested protocol.  Lysates 
were analyzed on 4-20% Min-PROTEAN TGX precast polyacrylamide gels (Bio-Rad, Hercules, 
CA) stained with SimplyBlue SafeStain (Life Technologies, Carlsbad, CA).  Western blotting 
was performed with His-probe primary antibody sc-8036 (Santa Cruz Biotechnology, Dallas, 
TX) and goat anti-mouse–alkaline phosphatase secondary antibody A5153 (Sigma-Aldrich), and 
visualized with Western Blue stabilized substrate for alkaline phosphatase (Promega, Madison, 
WI). 
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4.4.7 In vitro enzyme assays 
Flavin reductase assays were performed in 800 µL of 30 mM HEPES buffer, pH 7.8, with 300 
µM NAD(P)H, 30 µM flavin cofactor (FMN/FAD), and ca. 0.5 µM flavin reductase.  Decrease 
in absorbance at 340 nm was measured for 1 – 2 minutes at room temperature following addition 
of the enzyme.  Monooxygenase assays were performed in 400 µL of 30 mM HEPES buffer, pH 
7.8, with 300 µM NAD(P)H, 30 µM flavin cofactor (FMN/FAD), 2 mM MgCl2, ca. 10 µM 
monooxygenase, and ca. 1 µM flavin reductase.  Samples were incubated at 30 °C for 4 – 18 hr 
(for aerobic reactions) or at room temperature for 18 hr (for anaerobic reactions).  For some 
trials, 10 mM glucose and 5 nM glucose dehydrogenase were added for cofactor regeneration.  
Samples were desalted with Chelex 100 resin (Bio-Rad) and spiked with 100 µL D2O for 
31
P-
NMR analysis. 
 
4.4.8 Streptomyces lividans cultivation 
Streptomyces lividans liquid seed cultures (2 mL MYG with the appropriate antibiotic) were 
inoculated from a plate or frozen stock with a sterile 200 µL pipet tip, which was left in the 14 
mL culture tube.  Seed cultures were incubated at 30 °C with 250 rpm shaking until achieving 
turbidity or high particle density (typically 2 to 3 days).  A 500 µL inoculum was then added to 
50 mL of fresh MYG medium with the appropriate antibiotic in a baffled 250 mL Erlenmeyer 
flask with ca. fifty 4 mm glass beads.  The 50 mL cultures were incubated at 30 °C with 250 rpm 
shaking for 5 to 7 days.  For large-scale cultivation, 600 mL cultures in baffled 2 L Erlenmeyer 
flasks (with beads) were inoculated with 6 mL of a 2 – 3 day old culture. 
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4.4.9 NMR analysis 
S. lividans cultures were transferred to 50 mL conical tubes via serological pipet and pelleted at 
4000 rpm in an Eppendorf 5810R centrifuge for 10 min.  The supernatants were then split into 
two 50 mL conical tubes (25 mL of supernatant in each), while the cell pellet was stored at -80 
°C.  The supernatant samples were then flash frozen in liquid nitrogen and lyophilized to 
dryness.  To each dried supernatant tube was added 25 mL of methanol, while the thawed cell 
pellet was resuspended in 10 mL methanol.  Methanol suspensions were briefly agitated by hand, 
then vortexed for 2 min, then shaken by hand for 5 to 10 min, and finally incubated at 4 °C in a 
rolling incubator for 0 to 2 hr.  Samples were then clarified via centrifugation twice at 4000 rpm 
for 10 to 15 min each time, and filtered to remove residual particulate matter (as needed).  
Methanol extracts from supernatant and pellet were then pooled, evaporated to dryness by 
rotavap, and resuspended in 700 µL deuterium oxide (added in two 350 µL aliquots).  A small 
spatula-full of Chelex 100 resin (Bio-Rad) was then added to each sample in a 1.7 mL centrifuge 
tube, which was incubated for 10 to 30 min at room temperature with 650 rpm agitation in a 
microplate shaker.  The samples were then centrifuged for 2 min at maximum speed in a 
benchtop centrifuge, and the supernatant was added to a 10 kDa or 5 µm filter to remove residual 
resin and particulates.  The filtrate was then transferred to a 5mm NMR tube for 
31
P-NMR 
analysis.  
31
P-NMR was conducted in an Agilent 600 MHz NMR machine with OneNMR probe 
at the Institute for Genomic Biology.  Samples were analyzed with an acquisition time of 0.3 
seconds for a total of 2560 transients.  Data was analyzed using MNova software (MestreLab 
Research, Escondido, CA). 
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4.4.10 Isolation of compounds 1 – 7 
To isolate compounds 1 – 6, 50 L of culture supernatant from strain 3p2.1 was dried completely 
by lyophilization.  Compound 7 was isolated from 5 L of culture supernatant from strain 3pf.  
After treatment with 90 % methanol, the supernatant was dried and applied to Sephadex G-20 
columns of different sizes to separate phosphonic acids 1 – 6; phosphonic acid 7 was found in 
the precipitate following an analogous methanol cut.  Compounds 1, 3, 6, and 7 were isolated 
individually, while compounds 2, 4, and 5 were isolated as a mixture.  Structures were confirmed 
by one- and two-dimensional NMR analyses, as well as MS analysis performed at the School of 
Chemical Sciences Mass Spectrometry Facility, University of Illinois, Urbana-Champaign. 
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CHAPTER 5. Efficient multiplex genome editing of Streptomyces 
species via an engineered CRISPR/Cas9 system 
 
5.1 Introduction 
Actinobacteria of the genus Streptomyces are among the most prolific and well-studied producers 
of diverse secondary metabolites [1,2].  Over the past several decades, Streptomyces strains have 
been found to produce a number of important bioactive natural products, such as the anticancer 
compound daunorubicin from Streptomyces peucetius [3], the herbicide phosphinothricin from 
Streptomyces hygroscopicus [4] and Streptomyces viridochromogenes [5], and the antibacterial 
daptomycin from Streptomyces roseosporus [6].  While these decades of study might suggest 
that the supply of Streptomyces natural products is nearing exhaustion, in fact genome 
sequencing efforts have revealed that the well is far from dry, even in the most comprehensively 
studied strains [7]. 
 
Access to this “silent” majority of uncharacterized natural product gene clusters would benefit 
greatly from the development of new genetic manipulation tools that leverage genomic 
information to aid natural product discovery, characterization, engineering and production.  In 
the context of a Streptomyces strain of interest, for example, facile genome manipulation would 
aid both discovery and validation of new natural products from uncharacterized gene clusters, as 
well as ensuing biochemical and mechanistic studies.  In heterologous production strains, such 
techniques would further enable genomic remodeling to direct metabolic flux toward a pathway 
of interest and eliminate competing pathways, as well as pathway engineering for product 
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diversification.  Nevertheless, the current Streptomyces genetic toolkit, though well-developed 
and widely employed, often mandates a significant investment of time and effort. 
 
Typically, for gene disruption in Streptomyces, single cross-over integration of a suicide plasmid 
can be employed, resulting in disruption of the gene of interest with a selectable marker [8].  
However, the limited number of selectable markers limits the reusability of this approach.  
Further, disruption via single-crossover can revert in the absence of selective pressure, resulting 
in undesired restoration of the wild type allele.  Inclusion of flanking recombinase target sites 
and expression of the corresponding recombinase can enable recycling of markers and improve 
mutation stability, but this mandates additional steps and leaves a scar sequence at the target site. 
 
Alternatively, clean genomic deletions can be made via double-crossover integration [8]. 
However, this multi-step process is often labor and time intensive. First, integration of the 
disruption vector at the target locus (the first single-crossover event) is identified with a 
selectable marker.  Next, loss of the disruption vector and its selectable marker (the second 
single-crossover event) is identified via non-selective culture.  Finally, colonies exhibiting loss of 
the selectable marker (upon replica plating) must be further screened to separate those that have 
lost the vector via the desired second crossover event from those that have reverted the first 
crossover event to restore the original genotype.  Counterselectable markers such as rpsL and 
glkA can facilitate identification of the second crossover event, but are limited to use only in 
particular mutant hosts [8].  To facilitate identification of double-crossover integrants in one 
step, a double-strand break (DSB) can be introduced at the genomic locus of interest, as has been 
demonstrated using a homing endonuclease [9].  However, this method is dependent upon prior 
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integration of the homing endonuclease recognition site at the target locus, as homing 
endonucleases are minimally amenable to specificity alteration [10]. 
 
Recently, DSB-mediated genome editing has been achieved via the type II Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated proteins (Cas) system of 
Streptococcus pyogenes [11].  Functioning like a bacterial immune system, CRISPR/Cas requires 
three components to realize targeted cleavage of foreign DNA: Cas9, the nuclease and scaffold 
for the recognition elements; CRISPR RNA (crRNA), short RNAs conferring target site 
specificity, encoded as spacers in a CRISPR array; and trans-activating crRNA (tracrRNA), a 
short RNA that facilitates crRNA processing and recruitment to Cas9 [12].  The 
Cas9/crRNA/tracrRNA complex can target any DNA sequence, known as a protospacer, 
provided that the requisite protospacer-adjacent motif (PAM) is present at the 3’ end (NGG in 
the case of S. pyogenes, where N represents any nucleotide) [13]. 
 
To repurpose this system for genome engineering, spacer sequences matching genomic loci of 
interest can be directly programmed into a heterologously expressed CRISPR array.  To further 
simplify the system, fusion of the crRNA and tracrRNA into a single synthetic guide RNA 
(sgRNA) transcript has been demonstrated, obviating the need for processing of the transcribed 
CRISPR array (pre-crRNA) into individual crRNA components [14].  The S. pyogenes 
CRISPR/Cas system has been successfully reconstituted in a variety of hosts across all domains 
of life, including (but not limited to) Escherichia coli [15], Saccharomyces cerevisiae [16], and 
human cell lines [17].  Compared with other tools for site-specific genome engineering, such as 
zinc-finger nucleases and transcription activator-like effector (TALE) nucleases, the engineered 
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CRISPR/Cas system offers unprecedented modularity.  Targeting any site of interest requires 
only the insertion of a short spacer into a CRISPR array/sgRNA construct, which can be 
achieved rapidly and with high throughput using modern DNA assembly techniques.  A suitable 
target site needs only to have an adjacent NGG sequence, which are notably abundant in GC-rich 
Streptomyces genomes. 
 
The goal of the work presented here is to design, construct, and evaluate an engineered 
CRISPR/Cas9 system in actinobacteria.  The system will be reconstituted in multiple 
Streptomyces species for both single-locus and multiplex targeting to introduce precise deletions 
of various lengths.  To facilitate rapid customization to any task of interest, the full 
CRISPR/Cas9 system will be contained on a single plasmid that is amenable to insertion of 
custom spacer sequences and editing templates. 
 
5.2 Results and Discussion 
5.2.1 Plasmid design 
To harness the CRISPR/Cas system for genome editing in Streptomyces species, the 
pCRISPomyces expression system was designed (Figure 5.1).  The initial design included both 
tracrRNA and CRISPR array expression cassettes along with cas9.  Previously characterized 
strong promoters [18] were selected to drive expression of the CRISPR/Cas elements, along with 
widely-used terminators from phages fd, lambda, and T7.  Analysis of the Streptococcus 
pyogenes cas9 gene revealed the presence of several rare codons. Among them were many bldA 
codons, translation-level regulators of secondary metabolism in Streptomyces species [19].  As a 
result, for the initial pCRISPomyces design (pCRISPomyces-0), a cas9 gene codon-optimized 
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for human cell lines (hSpcas9) was chosen, as it was conveniently found to be devoid of bldA 
codons.   
 
To facilitate seamless, one-step Golden Gate assembly of custom-designed spacers into the 
CRISPR array, a lacZ cassette flanked by unique BbsI restriction sites was incorporated between 
two direct repeat sequences in the empty CRISPR array.  A unique XbaI restriction site was 
included to enable linearization of the backbone for insertion of additional elements, such as 
editing template sequences for recombination-driven repair, via Gibson assembly or traditional 
ligation.  Inclusion of aac(3)-IV allows selection in both Escherichia coli and Streptomyces 
hosts, the colE1 origin enables replication in E. coli, and the RP4 origin of transfer oriT enables 
conjugative transfer of pCRISPomyces plasmids from E. coli to Streptomyces hosts.  Finally, the 
temperature-sensitive rep region from pSG5 allows rapid clearance of the pCRISPomyces 
plasmid following the desired genome editing. 
 
5.2.2 Assembly of pCRISPomyces-0 
To enable Golden Gate assembly of spacers into the pCRISPomyces backbone, all other 
recognition sequences for the Type IIS restriction enzyme of choice had to be removed.  Because 
it had the fewest sites present in the designed construct (5 total: 2 in hSpcas9, 2 in the rpsLp(XC) 
promoter, and 1 in the pSG5 rep), the Type IIS restriction enzyme BbsI was chosen for the 
pCRISPomyces system.  To perform all desired BbsI-removing mutations simultaneously, an 
assembly scheme was designed in which mutations in rpsL(XC) were introduced in a gBlock 
synthetic DNA construct and the junctions between the fragments were positioned at the 
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remaining mutation sites.  Given the number of parts this assembly scheme mandated (9 total; 
Figure 5.1), yeast homologous recombination was chosen to maximize assembly efficiency. 
 
 
Figure 5.1: Assembly scheme for pCRISPomyces-0 plasmid. 
 
Implementation of yeast in vivo assembly required addition of an extra fragment for plasmid 
maintenance and selection in yeast.  As a result, a piece of the pRS416 E. coli-yeast shuttle 
vector was also included in the assembly, bringing the total number of fragments to 9.  XbaI 
recognition sites were added to the end of this yeast helper fragment to allow its excision 
following assembly, obviating the need to remove BbsI recognition sites from this fragment and 
reducing the overall size of the final pCRISPomyces construct.  Further, the resulting unique 
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XbaI site could then be repurposed for linearization of the pCRISPomyces backbone.  Assembly 
was carried out successfully, and confirmed via diagnostic digestion and sequencing of the cas9, 
tracrRNA cassette, and CRISPR array cassette. 
 
5.2.3 Evaluation of pCRISPomyces-0 
To assess the functionality of the pCRISPomyces system, initial experiments were carried out in 
the well-studied strain Streptomyces lividans 66 [20].  Plasmids were designed and constructed to 
target either one gene (redN) or two genes (redD and redF) from the undecylprodigiosin gene 
cluster [21].  In both cases, a 20 bp sequence with the requisite NGG PAM sequence was chosen, 
with preference given to sites on the non-coding strand and those with multiple purine bases at 
the 3’ end [22].  To minimize off-target effects, sites were chosen in which the last 12 bp of the 
protospacer plus the PAM (15 bp in total) were unique [17], as confirmed by BLAST analysis 
against the published genome sequence.  Both constructs were initially assembled without an 
editing template to assess the potential for NHEJ-mediated repair. 
 
Delivery of the pCRISPomyces-0 plasmids to S. lividans was attempted via conjugation.  
However, repeated attempts failed to yield any exconjugants.  As a troubleshooting measure, a 
series of plasmids was assembled to test the different elements of the pCRISPomyces-0 plasmid.  
Conjugation of the empty pCRISPomyces-0 plasmid again failed to yield exconjugants, ruling 
out the possibility that cell death was mediated only by RNA-guided digestion at the targeted 
loci.  Replacement of the pSG5 rep origin with the pIJ101 origin also did not yield any 
exconjugants, suggesting that the toxicity of the pCRISPomyces-0 plasmid stems from the 
CRISPR/Cas machinery and not the general plasmid maintenance elements.  Removal of the full 
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hSpcas9 gene, in contrast, restored normal conjugation efficiency, suggesting a general toxicity 
associated with over-expression of the Cas9 protein.  This was further confirmed by constructing 
a plasmid containing only the hSpcas9 gene without the tracr/crRNA cassettes, which again did 
not yield any exconjugants.  Interestingly, integration of the hSpcas9 cassette to the chromosome 
via the ΦC31 integrase was well tolerated by the cell, suggesting that Cas9 toxicity was only 
apparent when the gene was present at high copy number.  Notably, however, no genome editing 
activity was observed when all elements of the CRISPR/Cas system were co-integrated to the 
chromosome, as all exconjugants with integrated redN or redD/redF targeting cassettes 
maintained the ability to produce undecylprodigiosin (evidenced by their red pigmentation). 
 
Since the cas9-integrated S. lividans exhibited normal growth characteristics, hSpcas9 expression 
at the transcriptional and translational levels was evaluated in this strain.  Quantitative PCR 
(qPCR) of the hSpcas9 transcript revealed high expression (120-fold) relative to an hrdB internal 
standard at 24 hr, followed by a significant decrease in expression at 48 hr and 72 hr (~5-fold).  
At the translational level, expression of the Cas9 protein was not seen via Coomassie staining 
(Figure 5.2).  After addition of a C-terminal 3xFLAG tag to the integrated cas9, Western blotting 
revealed only the expression of a much smaller protein than the expected 160 kDa size.  Thus, it 
was determined that the human codon-optimized hSpcas9 was not properly expressed in S. 
lividans. 
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Figure 5.2: Expression analysis of human codon-optimized Cas9 in S. lividans by SDS-PAGE and Western blot. 
 
5.2.4 Assembly and evaluation of pCRISPomyces-1 
For the next iteration of pCRISPomyces design, the sequenced genomes of Streptomyces and 
related genera were queried to identify a more favorable cas9 for S. lividans expression. While 
many strains were identified with putative CRISPR arrays and related Cas proteins, no cas9 
homologs were found.  Rather, CRISPR/Cas systems in Streptomyces appear to be exclusively of 
the Type I or Type III varieties, utilizing multi-enzyme complexes to perform functions 
analogous to those of the single-polypeptide Cas9.  To avoid the complications associated with 
coordinated expression of several Cas genes, a codon-optimized cas9 for Streptomyces 
expression (sSpcas9) was instead designed and synthesized de novo. 
 
Replacement of hSpcas9 with sSpcas9 in pCRISPomyces-0 resulted in construct 
pCRISPomyces-1.  At the same time, the sSpcas9 cassette was integrated to the S. lividans 
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chromosome for comparison with the previous hSpcas9 expression results.  For this strain, SDS-
PAGE and Western blotting revealed high-level expression of the Cas9 protein at the expected 
160 kDa size (Figure 5.3). 
 
 
Figure 5.3: Expression analysis of Streptomyces codon-optimized Cas9 in S. lividans by SDS-PAGE and Western 
blot.  Red arrows indicate the expected band (160 kDa). 
 
To evaluate targeted genome editing with the sSpCas9 protein, subsequent experiments were 
carried out with the episomal pCRISPomyces-1 plasmid.  Two genomic protospacer sequences 
were targeted using pCRISPomyces-1: one in redN, as described previously; and one in actVA-
ORF5, from the actinorhodin gene cluster [23].  Protospacer sequences were identified as 
described above.  To enable defined editing via homologous recombination, a 2 kb editing 
template was supplied on the pCRISPomyces-1 plasmid.  The editing template consisted of two 
1 kb arms homologous to the corresponding sequences upstream and downstream of the 
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protospacer, designed to introduce a short deletion (20 – 34 bp) to partially or fully eliminate the 
protospacer sequence and create a frame shift. 
 
The pCRISPomyces-1 plasmids were transferred to S. lividans via conjugation.  Although 
notably reduced conjugation efficiency was observed for both of the targeting plasmids bearing 
the sSpcas9 gene, enough exconjugants were obtained for downstream analysis.  To screen for 
the desired editing event, genotyping of multiple exconjugants was carried out by first isolating 
the genomic DNA and then PCR amplifying the target locus.  To ensure that the PCR product 
was amplified from the chromosome rather than the pCRISPomyces plasmid, primers were 
designed to anneal slightly upstream and downstream of the editing template sequence.  Each 
PCR product was sequenced with internal primers to determine if the intended deletion had been 
introduced. 
 
Using the pCRISPomyces-1 system, genome editing events were observed.  However, editing 
efficiency was found to be low (Table 5.1).  For the redN target, three out of fourteen 
exconjugants possessed the desired deletion, while the remaining eleven strains were unedited at 
the redN locus.  As a negative control, a pCRISPomyces-1 derivative plasmid bearing all 
CRISPR elements (tracrRNA, redN spacer, and redN editing template) except for sSpcas9 was 
constructed and conjugated into S. lividans.  In this case, twelve exconjugants were screened, and 
each possessed the unedited genotype.  For the actVA-ORF5 target, a similar efficiency was 
observed as the redN target, with two out of eight exconjugants displaying the edited genotype. 
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Table 5.1: pCRISPomyces-1 editing results in S. lividans 66 
Plasmid Target Deletion Size Result 
pCRISPomyces-1 w/o Cas9 redN 20 bp 0/12 
pCRISPomyces-1 redN 20 bp 3/14 
pCRISPomyces-1 actVA-ORF5 34 bp 2/8 
 
To demonstrate clearance of the pCRISPomyces-1 plasmid, one of the identified S. lividans 
strains carrying the desired redN deletion was cultured non-selectively at high temperature (37-
39 °C).  After growth to stationary phase, a fraction of the culture was plated to isolate individual 
colonies.  Multiple colonies were obtained that had regained apramycin sensitivity and did not 
produce the red undecylprodigiosin pigment, indicating successful clearance of the temperature-
sensitive plasmid.  This sequence allows the apramycin selection marker to be reused in this 
strain for future applications, such as further genome editing or introduction of heterologous 
genes. 
 
5.2.5 Evaluation of pCRISPomyces-2 
5.2.5.1 Single-locus targeting 
Since the three-component CRISPR/Cas9 system of the pCRISPomyces-1 plasmid did not 
exhibit high editing efficiency, it was speculated that employing the simpler two-component 
system could yield improvement.  To test this hypothesis, the same protospacers in the redN and 
actVA-ORF5 target genes were evaluated with the sgRNA-expressing pCRISPomyces-2 plasmid.  
Editing efficiency was again evaluated by genotyping multiple isolated exconjugants.  With the 
pCRISPomyces-2 redN-targeting construct, significantly higher editing efficiency was observed, 
as six out of six randomly selected exconjugants were revealed to possess the edited phenotype 
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(Table 5.2).  Similar results were observed for the actVA-ORF5 target, where eight out of eight 
randomly selected exconjugants were found to be correctly edited.  Taken together, these results 
show that sgRNA targeting affords higher efficiency than tracr/crRNA targeting.  A possible 
explanation could be that pre-crRNA processing by native RNase enzymes is inefficient when 
applying CRISPR/Cas in Streptomyces, in contrast to results in other hosts where native RNase 
enzymes appear sufficient [17]. 
 
Table 5.2: pCRISPomyces-2 editing results in S. lividans 66 
Plasmid Target(s) Deletion Size Result 
pCRISPomyces-2 redN 20 bp 6/6 
pCRISPomyces-2 actVA-ORF5 34 bp 8/8 
pCRISPomyces-2 redN/actVA-ORF5 20 bp and 34 bp 4/4 
pCRISPomyces-2 redD/redF 31,415 bp 4/4 
 
5.2.5.2 Multiplex targeting 
One of the key advantages of the CRISPR/Cas system compared with other targeted nucleases is 
the relative ease with which multiple sequences can be simultaneously targeted using the same 
Cas9 endonuclease.  Given the observed superiority of sgRNA over the tracrRNA/CRISPR array 
configuration for single-target genome editing, additional constructs were designed with two 
sgRNA cassettes to evaluate the potential for multiplex targeting.  In these constructs, tandem 
sgRNA cassettes were driven by two copies of the same strong promoter.  Insertion of both 
cassettes into the same pCRISPomyces-2 backbone was carried out in one step by Golden Gate 
assembly with a synthetic DNA fragment containing the first sgRNA sequence, a terminator, a 
promoter, and the second sgRNA sequence, all flanked by BbsI sites. 
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The first dual-targeting construct was designed to introduce simultaneous short deletions in both 
the redN and actVA-ORF5 loci, utilizing the same protospacer sequences and 2 kb editing 
templates previously evaluated.  Following conjugation and isolation of genomic DNA from 
multiple exconjugants, both loci of interest were sequenced.  In four out of four strains evaluated, 
the desired deletion was observed at both loci, demonstrating the potential for multiplex genome 
editing.  The ability to cut two loci in the genome simultaneously opens up the possibility for 
excision of larger chromosomal segments by introducing a DSB at both ends and bridging the 
gap with a plasmid-borne editing template (Figure 5.4a).  To test this method, a second dual-
targeting construct was designed to delete the entire 31 kb red cluster.  Protospacer sequences 
were selected within the genes at the start and end of the cluster (redD and redF, respectively), 
and a 2 kb editing template was constructed from the 1 kb sequences immediately flanking the 
cluster.  In total, four exconjugants were picked and evaluated by PCR from genomic DNA with 
primers that anneal outside of the 1 kb homology arms.  In all four cases (Table 5.2), the 2.1 kb 
band indicative of cluster deletion was observed, while no band was observed when wild type 
genomic DNA was used as template (Figure 5.4b).  Similarly, PCR amplification with a primer 
annealing within the deleted region only produced a 1.1 kb band from the wild type genomic 
DNA, but not from the strains in which the red cluster had been deleted.  Phenotypic screening 
(Figure 5.4C) confirmed loss of red pigmentation in all four edited strains. 
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Figure 5.4: Deletion of the 31 kb red cluster in S. lividans.  (a) Two sgRNA transcripts guide Cas9 to introduce 
DSBs at both ends of the cluster, while a co-delivered editing template bridges the gap via homologous 
recombination.  (b) PCR evaluation of red cluster deletion from four exconjugants (DF1 – DF4) with wild type 
control (wt).  (c) Phenotypic screening confirms loss of red pigmentation (wild type shown for comparison). 
 
5.2.6 Evaluation in multiple Streptomyces species 
Outside of S. lividans, it would be desirable to utilize the pCRISPomyces plasmids in other 
Streptomyces strains to realize targeted editing of genes of interest, such as natural product gene 
clusters, in the native producers.  To evaluate the possibility for broader applicability, two 
additional Streptomyces species were selected: S. viridochromogenes DSM 40736 and 
Streptomyces albus J1074.  In S. viridochromogenes, two genes within the phosphinothricin 
tripeptide (PTT) gene cluster [24], phpD and phpM, were chosen as individual targets.  For both 
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genes, the corresponding single-targeting pCRISPomyces-2 plasmid was constructed with an 
appropriate spacer and 2 kb editing template to introduce a short frame-shift deletion early in the 
coding sequence.  Following an analogous conjugation and genotyping protocol as described for 
S. lividans, seven out of seven exconjugants isolated with the phpD-targeting plasmid were 
confirmed to possess the intended deletion.  For phpM, a total of six exconjugants were screened, 
and four were found to exhibit the desired mutant genotype (Table 5.3).  The other two 
exconjugants possessed the unedited wild type sequence.   
 
Table 5.3: pCRISPomyces-2 editing results in other Streptomyces species 
Strain Target(s) Deletion Size Result 
S. viridochromogenes DSM 40736 phpD 23 bp 7/7 
S. viridochromogenes DSM 40736 phpM 20 bp 4/6 
S. albus J1074 sshg_05713 67 bp 6/6 
S. albus J1074 sshg_00040/sshg_00050 13,214 bp 2/3 
S. albus J1074 sshg_05699/sshg_05729 50,626 bp 2/2 
 
In S. albus, the PKS-NRPS hybrid gene sshg_05713 from a cryptic polycyclic tetramic acid 
macrolactam gene cluster [25] was chosen to evaluate single locus targeting, again to introduce a 
short frame-shift deletion using a 2 kb editing template.  Six out of six exconjugants evaluated by 
PCR amplification from genomic DNA and sequencing were confirmed to harbor the intended 
67 bp deletion (Table 5.3), confirming Cas9 functionality in this strain.  As a second trial, a dual-
targeting plasmid was constructed to delete a full 13 kb lanthipeptide cluster encoded by genes 
sshg_00040 to sshg_00050.  After conjugation with the dual-targeting plasmid containing a 2 kb 
editing template, three S. albus exconjugants were isolated and evaluated by PCR.  All three 
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were found to yield the correct PCR product indicative of full-cluster deletion (amplified with 
primers 1 and 3 in Figure 2a), and the identity of the PCR product was confirmed by sequencing.  
However, one of the three also yielded the PCR product with a primer annealing within the 
deleted region (primers 2 and 3 in Figure 2a), indicating a mix of edited and wild type cells in 
this population.   
 
As a third trial, an analogous dual-targeting plasmid was constructed to target both ends of the 
polycylic tetramic acid macrolactam gene cluster spanning genes sshg_05699 to sshg_05729 for 
deletion of the full 50 kb region.  After conjugation with the dual-targeting plasmid containing a 
2 kb editing template, two S. albus exconjugants were picked from the conjugation plate and 
restreaked to isolate individual colonies.  Three individual colonies were screened from each 
exconjugant were screened by PCR, and all were found to yield the correct PCR product 
indicative of full-cluster deletion. The identity of the PCR product was confirmed by sequencing.  
PCR amplification with a primer internal to the gene cluster did not yield the target band, as 
expected for deletion of the cluster.  Taken together, the observed efficient genome editing of S. 
viridochromogenes and S. albus without strain-specific modification of the pCRISPomyces 
backbone suggests broader applicability of this system in various Streptomyces species. 
 
5.3 Conclusions and Outlook 
In summary, we have demonstrated that the type II CRISPR/Cas system of S. pyogenes can be 
reconstituted successfully in Streptomyces hosts to realize targeted genome editing.  While the 
native tracr/crRNA configuration yielded only modest genome editing efficiency when evaluated 
in S. lividans, utilization of guide RNA boosted efficiency significantly, enabling multiplexing 
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for the introduction of short and long deletions.  Further, high-efficiency genome editing was 
realized in two additional Streptomyces strains, demonstrating broad host applicability.  To 
facilitate implementation of the CRISPR/Cas9 genome editing system for any target(s) of 
interest, we have developed pCRISPomyces plasmids amenable to insertion of custom spacers 
and editing templates via modern DNA assembly techniques.  Thus, application of the 
pCRISPomyces system could significantly reduce the time and labor needed to perform precise 
chromosomal manipulations compared to previous techniques. 
 
Moving forward, the pCRISPomyces system should facilitate a wide variety of future studies in 
Streptomyces species.  In known natural-product-producing strains, for example, pCRISPomyces 
can be used for gene deletion experiments in the elucidation of biosynthetic pathways.  Further, 
precise mutations can be introduced to facilitate in vivo mechanistic studies.  In non-producing 
strains with cryptic natural product gene clusters, promoters can rapidly be knocked-in in front of 
one or more key genes for gene cluster activation experiments.  Alternatively, putative regulators 
can be up- or down-regulated to de-repress silenced pathways. 
 
In popular heterologous hosts such as S. lividans and S. albus, implementation of CRISPR/Cas9-
mediated genome editing could be used for extensive genomic remodeling to design optimal 
hosts for heterologous expression.  This includes knocking out competing pathways, introducing 
or up-regulating pathways for precursor biosynthesis, or introducing seamless tags to evaluate 
temporal expression patterns of heterologous proteins.  The CRISPR/Cas9 system further enables 
rapid alteration of previously integrated genes, opening the door for pathway optimization 
studies to maximize production of valuable products. 
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5.4 Materials and Methods 
5.4.1 Strains, media and reagents 
E. coli strain NEB5-alpha (New England Biolabs, Ipswich, MA) was used for plasmid cloning 
and maintenance.  Yeast in vivo plasmid assembly was performed in S. cerevisiae HZ848 [26].  
S. lividans 66 was obtained from the Agricultural Resource Service Culture Collection (Peoria, 
IL), S. albus J1074 was a gift from Prof. Wenjun Zhang (University of California, Berkeley), and 
S. viridochromogenes DSM40736 and the E. coli conjugation strain WM6026 [24] were gifts 
from Prof. William Metcalf (University of Illinois at Urbana-Champaign).  E. coli strains were 
grown in LB medium supplemented with apramycin (50 µg/mL) and, for strain WM6026, 
diaminopimelic acid (19 µg/mL).  Streptomyces strains were grown on modified MYG medium 
(10 g/L malt extract broth, 4 g/L yeast extract, 4 g/L glucose) with 50 µg/mL apramycin as 
needed for plasmid selection.  Medium R2 (without sucrose) was used for conjugation [8].  All 
media components and supplements were purchased from Sigma-Aldrich (St. Louis, MO) with 
the exception of yeast extract (BD Biosciences, San Jose, CA) and LB broth (Fisher Scientific, 
Pittsburgh, PA).  PCR primers were synthesized by Integrated DNA Technologies (Coralville, 
IA), and PCR reactions were performed in FailSafe PCR PreMix G (Epicentre Biotechnologies, 
Madison, WI) with Q5 DNA polymerase (New England Biolabs, Ipswich, MA).  All PCR 
products were purified using the DNA Clean & Concentrator or Zymoclean Gel DNA Recovery 
Kit (Zymo Research, Irvine, CA).  Plasmids were recovered using the QIAprep Spin Miniprep 
Kit (Qiagen, Valencia, CA).  Restriction enzymes and T4 ligase were purchased from New 
England Biolabs (Ipswich, MA). 
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5.4.2 Plasmid construction 
Plasmid pCRISPomyces-0 was constructed via yeast homologous recombination [26] from the 
following fragments: promoter rpsLp(XC) [18], synthesized as a gBlock (Integrated DNA 
Technologies, Coralville, IA) to remove BbsI recognition sites; human codon-optimized Spcas9 
and fd terminator, split into three pieces to remove BbsI recognition sites; promoter rpsLp(CF), 
PCR amplified from a previous construct [18]; tracrRNA, oop terminator, promoter gapdhp(EL) 
[18], a lacZ expression cassette flanked by BbsI recognition sites and direct repeat sequences, 
and a T7 terminator, synthesized as a gBlock (IDT); yeast helper fragment containing URA3 and 
CEN6/ARS4 flanked by XbaI recognition sites, PCR amplified from pRS416 (Stratagene, La 
Jolla, CA); and an E. coli/Streptomyces helper fragment containing origin colE1, selection 
marker aac(3)IV, pSG5 rep origin, and origin of transfer oriT, PCR amplified in two pieces from 
plasmid pJVD52.1 [24] to remove a BbsI recognition site in pSG5 rep.  The resulting 
intermediate plasmid was then digested with XbaI to liberate the yeast helper fragment, and the 
backbone was re-ligated to yield pCRISPomyces-0.  Replacement of the pSG5 rep region with 
pIJ101 rep or attP/ΦC31 int was performed via digestion of pCRISPomyces-0 with ClaI and 
SphI and ligation of corresponding similarly digested insert.  Addition of a C-terminal 3xFLAG 
tag to hSpcas9 was performed via digestion with SspI and XbaI and Gibson assembly with 
fragments comprising the C-terminal end of hSpcas9, a 3xFLAG tag, and the remaining 
downstream elements (tracrRNA and crRNA cassettes). 
 
Plasmid pCRISPomyces-1 was assembled from pCRISPomyces-0 via digestion with FseI and 
EcoRI and ligation of a similarly-digested Streptomyces codon-optimized Spcas9 gene, 
synthesized by GenScript (Piscataway, NJ).  Plasmid pCRISPomyces-2 was constructed via 
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isothermal assembly of the EcoRI/XbaI-digested pCRISPomyces-1 backbone with two synthetic 
gBlocks (IDT) comprising a guide RNA expression cassette (with a BbsI-flanked lacZ cassette in 
place of the spacer sequence).  All targeting constructs were assembled by a combination of 
Golden Gate assembly [27] (for insertion of spacers) and traditional digestion/ligation or 
isothermal assembly [28] (for insertion of editing templates).  Single spacer inserts were 
generated by annealing two 24 nt oligonucleotides (offset by 4 nt to generate sticky ends), while 
double spacer inserts were synthesized as gBlocks (IDT).  The 1 kb left and right arms of each 
editing template were amplified from purified genomic DNA, spliced by overlap-extension PCR 
[29], and ligated into the XbaI site of the desired plasmid.  Correct plasmid assembly was 
confirmed by diagnostic digestion and sequencing (GeneWiz, South Plainfield, NJ).  Plasmid 
maps were generated with Vector NTI (Invitrogen, Carlsbad, CA). 
 
5.4.3 Transformation 
E. coli NEB5-alpha was transformed by heat shock following the manufacturer’s suggested 
protocol.  Yeast transformation was performed as described elsewhere [26].  E. coli WM6026 
was transformed by electroporation.  Conjugation of plasmids into Streptomyces spores was 
performed using the modified protocol described elsewhere [30]. 
 
5.4.4 SDS-PAGE and Western blotting 
S. lividans strains were grown in 50 mL selective MYG cultures for all protein expression 
studies.  Samples of 1 mL were collected and concentrated 5-fold in B-PER reagent (Thermo 
Scientific, Pittsburgh, PA) for lysis following the manufacturer’s suggested protocol.  Lysates 
were analyzed on 4-20% Min-PROTEAN TGX precast polyacrylamide gels (Bio-Rad, Hercules, 
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CA) stained with SimplyBlue SafeStain (Life Technologies, Carlsbad, CA).  Western blotting 
was performed with anti-FLAG primary antibody F3165 (Sigma-Aldrich, St. Louis, MO) and 
goat anti-mouse–alkaline phosphatase secondary antibody A5153 (Sigma-Aldrich), and 
visualized with Western Blue stabilized substrate for alkaline phosphatase (Promega, Madison, 
WI). 
 
5.4.5 Screening of S. lividans strains 
Following conjugation, individual exconjugants were randomly picked and restreaked on MYG 
agar plates supplemented with 50 µg/mL apramycin and grown at 30°C for 2-3 days.  Single 
colonies were then picked to liquid MYG medium for genomic DNA isolation using the Wizard 
Genomic DNA Purification Kit (Promega, Madison, WI).  The locus of interest was PCR 
amplified and sequenced using primers annealing ~300 bp upstream and downstream of the 
deletion site (GeneWiz, South Plainfield, NJ).  Clearance of the plasmid was accomplished with 
high-temperature cultivation (37-39 °C) for 2-3 days, followed by replica plating on selective 
and non-selective plates to confirm restoration of apramycin sensitivity.  For phenotypic 
screening of undecylprodigiosin-producing strains, saturated liquid cultures were streaked on 
non-selective R2 plates without sucrose and grown at 30°C for 2-3 days. 
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